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Abstract
The study o f absolution, distribution, metabolism and excretion (ADME) o f compounds 
within the body is of vital importance to health. PXR is a nuclear receptor which 
regulates the expression of a great many ADME genes and is responsible for the 
regulation o f all parts o f the ADME of many compounds. It is believed that the nuclear 
receptors, including PXR, activate genes on a ligand dependent basis, a mechanism 
which is probably regulated by the recmitment of a different battery o f co-regulator 
proteins. The ligand dependent selection of genes by recruitment of alternate co-regulator 
complexes has not yet been directly demonstrated. The co-regulator proteins of PXR are 
not well characterised although co-regulator complexes of other receptors, including the 
oestrogen receptor, growth hormone receptor and retinoic acid receptor are comparatively 
well characterised.
In order to demonstrate that different co-regulator complexes can be recruited by 
different ligands of PXR is was first necessary to identify the co-regulator complexes of 
PXR. An immunoprécipitation assay was developed and used in conjunction with an 
half GFP interaction assay as validation. The immunoprecipitated samples gave 
interesting data by mass spectrometry although it was not possible to validate these 
results using the half GFP interaction assay. This thesis contiibutes significantly to the 
effort to identify PXR co-regulator proteins although further investigation using alternate 
techniques may yield more information.
Conclusive demonstration of a differential gene expression by different ligands came in 
the form of a gene array based on primary rat hepatocytes dosed with pregnenalone- 16a- 
carbonitrile (PCN) and lithocholic acid (LCA). Appropriate dose ranges of these 
compounds were established in a separate, pilot, study and were within appropriate 
literature dose ranges. This gene array generated some 2000+ significantly altered gene 
expression profiles, as determined by statistical analysis of the data. Venn diagram 
analysis shows a clear difference between PCN and LCA with a number o f commonly 
and individually expressed genes. A number o f significantly altered genes were 
identified by princicpal components analysis as being important drivers o f difference 
between the effects of PCN and LCA. Taqman QPCR analysis o f these genes gave 
strong evidence that these two compounds are exerting different transcriptional effects.
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Introduction
1.1 General introduction)
1.1.1 Xenobiotic and endobiotic metabolism and disposition
The body is metabolises a large numbers of chemicals everyday; these include both 
endogenous chemicals including, steroid hormones, bile acids, cytokines and 
immunomodulators and exogenous chemicals such as therapeutic agents, and industrial 
or environmental toxins and pollutants. Such a broad spectmm of chemical exposures 
has led to the development o f complex metabolic machinery that is capable of processing 
these compounds, returning the body to homeostasis and preventing serious biological 
harm and damage to the tissues (Plant, 2003). Processing of chemicals occurs at all stage 
of absorption, distribution, metabolism and excretion (ADME), with each stage being 
discussed in the following sections.
Absorption
The absorption of a compoimd is defined as the movement of that compound from its site 
of exposure into the systemic blood system; hence, any compound entering the body fr om 
outside requires a mechanism of absorption into the blood. Common routes of exposure 
are oral (absorption through the intestine and stomach), inhalation (absorption through 
the lung squamous epithelium) and topical (absorption through the skin). 
Pharmaceuticals are generally administered orally, topically, or by intravenous injection, 
as these routes have high patient compliance and are eifrier convenient of have rapid 
uptake. In comparison, environmental contaminants are often inhaled as gaseous 
products, smoke or chemical sprays, but may equally be consumed as chemicals in or on 
foodstuffr or absorbed topically by contact with said chemicals. The absorption of 
molecules across cell membranes is a simple thermodynamic process depending largely 
on the chemical nature of the molecule itself. The commonest modes for chemicals to 
pass biological membranes are (Gibson, 2001, Plant, 2003),Passive Diffrrsion; the net 
movement of molecules from an area of high concentration to and area of low 
concentration along a concentration gradient.
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• Facilitated diffusion; movement o f molecules by simple diffusion through a non 
selective membrane protein channel.
• Active transport; the movement of molecules in an energy dependent manner 
often against a concentration gradient.
• Endocytosis; uptake of molecules into cells through vacuole formation
• Paracellular transport; circumvention of cellular layers through movement 
between cells. May only occur if cells are not joined by tight junctions
The nature of a molecule directly affects the way in which it is absorbed by the body. 
Lipinki’s rule of 5 gives a guideline as to chemical characteristics which make a drug 
more easily absorbed through the gut and is as follows:
• No more than 5 hydrogen bond donor functional groups, i.e. NH and OH.
• No more than 10 hydrogen bond acceptor flrnctional groups i.e. NH2 and O, 
where a lone pair is available for attack.
• A molecular size of no more than 500 daltons.
• A high lipophilicity expressed as logP greater than 5.
A molecule should not violate more that one of the above stipulations in order to be 
adequately absorbed by oral administration.
1.1.3 Distribution
Following compound absorbtion into the blood, it is the distribution of blood flow 
throughout the body that dictates the amount of dmg any one organ and tissue will 
receive; those tissues most heavily perfused, such as the liver or kidneys, receiving the 
bulk o f the dose. The liver has blood supplied ft om the circulatory system via the hepatic 
artery and from the intestines via the hepatic portal vein; compounds ingested orally will 
enter into the hepatic portal vein following absorption, and hence the liver is the first 
organ many compounds encounter. Because of this unique location, the liver represents 
the primary site of metabolism of a majority o f ingested compounds, many of which ar e 
removed or significantly altered on the first pass through the organ (Plant, 2003, Gibson, 
2001, Yamazaki et al., 1996a, Yamazaki et al., 1996b). Other major metabolic sites
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include the kidney the lungs and the intestinal mucosa, (Gibson, 2001, Plant, 2003, 
Krishna and Klotz, 1994).
As detailed above, chemicals pass across a membrane either passively if their nature is 
lipohillic, but require transport protein to facilitate this process if the chemical is more 
polar in nature. There aie two families of such transport proteins, with members from 
each family specialized to facilitate influx fi'om the hepatic blood supply and efflux fi'om 
the cell, either into the systemic blood supply or bile canaliculi. These two families are 
the solute canier family (SLC) and the ATP binding cassette family (ABC) 
(Venkataramanan et al., 2006). The transport of chemicals into the hepatocyte is mainly 
mediated through three transporter subfamilies; the organic anion family of proteins 
(OATP), which are responsible for the uptake of many stmcturally diverse compoimds 
(Faber et al., 2003, Gui et al., 2001); the sodium dependent taurocholate co-transporting 
protein (NTCP), which transports bile salts and their derivatives (Friesema et al., 1999); 
the organic cation transporters (OCTs), which are capable of moving small cationic 
molecules in either direction across the membrane depending on tire concentration 
gradient (Busch et al., 1996). The expression level of many of these transport proteins, 
and hence their capapcity to transport chemicals, falls under the transcriptional regulation 
of a nuclear receptor, with a central receptor in this process being the nuclear receptor 
PXR (Guo et al., 2002a, Guo et al., 2003, Guo et al., 2002b, Staudinger et al., 2001b, 
Staudinger et al., 2003, Anapolsky et al., 2006, Gibson et al., 2006).
1.1.4 Metabolism
Metabolic processesing of a chemical within the liver is often a complex multi stage 
reaction mediated by a number of enzymes, flom both the Phase I and Phase II class. 
Phase I is concerned with the hydroxylation o f a broad range of compounds by the 
cytochrome P450 family of enzymes (Nebert and Russell, 2002, Nelson et al., 1996). 
Phase II is concerned with the secondary conjugation of the hydroxylated compounds, 
commonly with the thiol glutathione or with glucuronic acid and is mediated by families 
of enzymes known as the glutathione-S-transferases (GSTs) and the uridinediphosphate 
glucuronosyltransferases (UGTs) (Falkner et al., 2001, Sonoda et a l, 2002, Xie et al, 
2003, Gibson, 2001).
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As seen with transport proteins, the expression of these enzymes is usually regulated by 
members of the nuclear receptor family, with PXR being perhaps the most important 
receptor in the regulation of a broad spectium of cytochrome P450s, GSTs and UGTs in a 
species dependant manner. These include CYP3A4 in humans (3A1 in rats), members of 
the CYPIA family, CYP2C9, GST «2 and p2 and the UDPGTR (Gibson et al., 2006, 
Gibson, 2001, Bodin et al., 2005, Barbier et al., 2003, Hartley et al., 2004, Xie et al., 
2003, Falkner et al., 2001).
1.1.5 Excretion and distribution
Excretion of compounds post metabolism is primarily through the bile (from the 
hepatocytes into the bile cannaliculus and hence into the intestinal tract) or urine (via 
ultrafiltration in the nephron) (Plant, 2003, Gibson, 2001, Ayrton and Morgan, 2001). 
Hepatic excretion is dependent on the activity of hepatic efflux transporters including 
members of the multidmg resistance associated proteins (MRPs, ABCCs) including 
MRPl, 2, 3 and 6 (Konig et al., 1999a, Konig et al., 1999b), P-gycoprotein, the bile salt 
export pump (BSEP) and the multidmg resistance protein 3 (Beilke et al., 2007, Eloranta 
and Kullak-Ublick, 2005, Trauner and Boyer, 2003, Fitzgerald et al., 2002, Faber et al., 
2003). Billiaiy excretion is dependent on these proteins to overcome tire huge differences 
in concentration of conjugates and compounds between the bile and the hepatocytes 
(Ayrton and Morgan, 2001). In the kidney excretion is primarily dependent on 
glomerlular filtration rate (Dresser et al., 2001).
Wliile not directly involved in the enzymatic process of metabolism, the role of the 
hepatic efflux transporters is important when considering the phamiacological nature of 
the mechanism behind the induction of the groups of compounds mentioned above. PXR 
as a receptor exerts its transcriptional effects in a dose dependent manner and therefore 
relies on a sufficiently high intracellular concentration of the compounds to maintain its 
transcription effect as demonstrated by the ability of the P-glycoprotein efflux transporter 
to limit the efficacy of the human PXR agonist rifampicin (Schuetz et al., 1996).
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1.2 The regulation of transcription by the general transcription factors and their 
interactions with nuclear receptors.
1.2.1 Chromatin and the nucleosomes
The core of the 
nucleosome consists 
of an octamer of two 
sets of histone H3 
and H4 Dimers and 
two sets of histone 
H2A and H2B 
dimers.
DNA HI histi
Core o f 8 Histone Molecutes
Histone HI acts as 
a linker molecule 
binding the DNA 
as it wraps around 
the histone core 
and anchoring the 
nucleosome 
structure.
Figure 1.2.1 the nucleosome as the basic unit of chromatin.
The nucleosome is the most basic unit of eukaryotic chromatin. Approximately 150 base pairs of 
DNA wraps around the histone core to create the nucleosome. The histone proteins are HI, H2A, 
H2B, H3 and H4 and they combine in an octamer of proteins to form the central hub of the 
nucleosome. Nucleosomes may be spaced close together in heterochromatin, the density of the 
DNA packaging, effectively suppressing transcription; or they may be spaced far apart as in 
euchromatin which is more receptive to the transcriptional machinery. Adapted from the website of 
the University of Davidson in Davidson North Carolina USA 
(http://www.bio.davidson.edu/courses/Moibio/MolStudents/spring2000/iamar/histonehI.htmy
The histone DNA binding proteins are by far the most abundant proteins within the cell 
with ^proximately 60 million of each of the histone proteins per ceil in humans (Alberts 
et al., 2002). When isolated from cells in interphase, the growth phase of the cell, the 
DNA appears as a thick filament which can be unravelled into a series of bead like 
structures when viewed under the electron microscope (Alberts et al., 2002).
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The nucleosomes are the basis of the structure of chromatin and allow for the 
condensation of the genetic material into chromosomes during cell division. During 
interphase the genetic material is in a filamentous structure of densely packed 
nucleosomes. This filament is supported by the bend of the DNA linker region caused by 
the wrapping of the DNA around the histones and the interaction of the tails of the 
histone proteins with the DNA (Alberts et al., 2002). When in this filamentous form 
there is Httle access to the genetic material and so transcription is effectively suppressed. 
When opened by the activity of chromatin remodeling complexes and histone 
modification enzymes the nucleosomes separate, moving further apart to expose more 
DNA in the linker region and enabling access forthe transcriptional machinery (Alberts et 
al., 2002).
1.2.2 Transcription as a naive and inducible process
Many signalling pathways within the cells end in the alteration of the transcriptional 
pattern of a host of effector genes. These signalling pathways recrait and activate what 
are known as specific transcription factors. The cell cycle regulating cyclin dependant 
kinases control a series o f checkpoint transcription factors that will either allow the cell to 
progress or hold it back (Alberts et al., 2002). The growth factor receptors often activate 
a Map kinase pathway, the terminal effector proteins o f which are transcription factors 
such as Jun, Ink, and NF-kB (Alberts et ah, 2002). These specific transcription factors 
are responsive to the oxidative, xenobiotic, and metabolic stresses to which the cells are 
subjected (Alberts et al., 2002). Signalling pathways, particularly those for growth or 
differentiation, require a change in gene expression usually via activation of various 
transcription factors. The nuclear receptors fall into the specific transcription factor 
family but are ligand dependant, activating a range of genes in response to a range of 
ligands (Belandia and Parker, 2003). A family of transcription factors are requiied to 
attract and internet with RNA polymerase II and as such are members of the general 
transcription fector complex. As discussed in the following sections the accumulation of 
the general transcription factors is required to allow Pol II to interact with the DNA.
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1.2.3 General transcription factors and the RNA polymerase transcriptional 
complex
Transcription is the fondation o f RNA from DNA, using the genetic code as a template 
(Alberts et al., 2002). The enzymes responsible for this are the RNA polymerases, a 
family of three enzymes each of which forms a different set of end products with distinct 
biological frmctions (tRNA, rRNA and mRNA) (Alberts et al,, 2002). RNA polymerase 
II (Pol II) is the enzyme responsible for forming mRNA, the template from which protein 
synthesis occurs at the ribosome. Experimental evidence suggests that Pol II itself is not 
sufficient for transcription to occur and requires a frmily of general transcription fiictors 
to support the process (Malik and Roeder, 2000, Davis et al., 2002, Woychik and 
Hampsey, 2002): These factors are referred to as TFIDC where X represents the letter 
assigned to each of these generic factors (Emerson, 2002, Cosma, 2002) see figure 1 for a 
generic schematic for the assembly of the transcription factors (Ogboume and Antalis, 
1998, Oiphanides et al., 1996, Emerson, 2002).
Transcription initiation is centered on the region of DNA immediately upstream (5’) to 
the point at which transcription starts (transcription start site (tss)), which is referred to as 
the proximal promoter. Eukaryotic promoter sequences contain a core promoter that 
forms the stincture required for transcription of the gene and is usually located between 
base pairs -45 and -30, relative to the tss. This is known to contain the TATA box, 
which is an 8-nucleotide sequence located within a GC rich area and has a sequence (5’- 
TATAAAA-3’), and is present in over 70% of eukaryotic proximal promoter sequences 
(Cosma, 2002, Emerson, 2002). A specific protein known as the TATA box binding 
protein (TBP) recognizes this sequence and binds to it and is the only general 
transcription factor to have a specific target within the DNA sequence, this can be seen in 
frame 2 of fig 1 (Emerson, 2002, Woychik and Hampsey, 2002).
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Transcriptome formation
P f t B O t C
1.) Bindmg of TFIID. consisting of TBP and TAFs. TAft
C tenm ul Domain
TFim
2.)Attractions oflFIIB  andpreperafion 
for Pol II binding
TFIIE
3 )Pol II com nla binding TFIIFiPol n Conçkx
TFIIH^
4.') Association of the final transcription factors
Figure 1.2 A schematic representation of the formation of the basal transcription 
preinitiation complex and the recruitment of RNA polymerase II to initate transcription.
The complex begins with the binding of the TATA binding protein and the TFIID protein 
complex (frame 1), followed by recruitment of TFIIB (Frame 2) and TFHF (Frame 3) and 
finally TFIIE and H and interaction with the RNA polymerase II complex (Frame 4). This 
figure was assembled using information from (Metivier et al., 2003) and (Orphanides et al., 
1996).
The TBP associated factors (TAFs) (Emerson, 2002, Cosma, 2002) bind to the TBP and 
form the basis of the TFIID general transcription factor. TFIID is a complex of 
approximately 10 proteins, including TBP and the TAFs (Emerson, 2002, Orphanides et 
al., 1996). The nature of this complex is variable and the exact composition is dependent 
upon the cell type and chromatin context. It contains specific transcription factors 
functions which are required on a promoter to promoter basis. It has been suggested that 
some of the TAFs structurally resemble the histone subunits, and hence may foiin a TAF 
octamer, analogous to the histone octamer which bends and opens the DNA. The crystal 
structure of TFIID shows a molecular clamping mechanism with subdomains which 
suggests that there would be stearic hindrance to the binding of the component proteins of 
TFIID to each other and the DNA (Metivier et al., 2003).
Once TFIIB has fully bound TFIIA complexes with TFIID it allows a confonnational 
change to occur that promotes binding of the other general transcription factom, starting 
with TFIIB (Malik and Roeder, 2000).
TFIIB is required for the successful binding of the Pol II complex and binds after the 
initial DNA preconditioning by TFIID and TBP as shown in figure 1.2. Unlike TFIID, 
TFIIB is a single polypeptide with an N teiminal zinc DNA binding domain, and a core 
domain that stretches to the C teiminal two thirds of the peptide chain. Human TFIIB 
contains a helix turn helix DNA binding domain which binds to a TFIIB response 
element (BRE) and is a sequence commonly seen in promoters immediately adjacent to 
the TATA box. (Malik and Roeder, 2000, Woychik and Hampsey, 2002, Orphanides et 
al., 1996).
These events lead to the binding of the Pol II complex as a large complex with TFHF. 
TFHF is required for efficient binding of the non-phosphorylated Pol II and for the 
assembly of the other general transcription factors. TFHF is a heterotetramer consisting 
of two subunits, the larger TFHFa and RAP74 heterodimer and the smaller TFHFj3 and 
Rap30 heterodimer.
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Once Pol n  and TFHF have bound the way is opened for the binding of TFIIE; TFIIE is 
a heterotetramer of two larger TFIIEa and two smaller TFHEP subunits. TFIIE is one of 
two final general transcription factors that bind and is partly responsible for completion 
of the initiation complex. TFIIE regulates the ATP dependent fonnation of the initial 
phosphosphdiester bonds between the first RNA bases. TFHF, along with tiie final 
transcription factor TFHH, has an important role in reducing the number of false starts 
that occur due to promoter stalling of Pol II and are essential for efficient elongation of 
the RNA product.
TFHH is considered to be the final general transcription factor, and by far the largest 
complex, to integrate into the transcriptome. The TFHH complex consists of 9 subunits 
and the spatial arrangement and size of the polypeptides means the TFHH forms a ring 
structure which completely encases the DNA double strand (Woychik and Hampsey,
2002). The two cores o f TFHH have separate activities containing two DNA helicases 
which have opposing polarities and a cyclin-dependant kinase (cyclin H dependant) 
activity. The most important step(s) in the initiation of transcription are termed “melting” 
of the DNA, a process requiring ATP, and the eventual refonning of the double helix. 
The DNA helicase subunits of the core of TFHH are primarily responsible for the melting 
step during initiation. The first helicase unwinds the DNA helix effectively straightening 
the molecule and allows progression of the transcriptome. The other helicase has 
opposite gyrase activity and reanneals the DNA back into a double helix behind the 
transcription “bubble”. This pai ticulai' general transcription factor has been implicated in 
transcription (Cosma, 2002).
1.2.4 Recruitment of the transcriptional complex is ordered and timely
The activity of chromatin remodeling complexes and the specific sequence of recruitment 
of the general transcription factors means that the order and timing of gene transcription 
is both transcription factor and gene promoter dependent. The role of nuclear receptors 
has been best studied by the role of ER in the timing o f gene transcription (Cosma, 2002). 
When treated with oestiadiol the oestrogen receptor transcription complex is recmited to 
the promoter in a cyclical fashion, with the complex forming to initiate transcription and 
dissociating as transcription is initiated. It has been shown that fifteen minutes after
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activation with oestradiol co-activatore such as p300/CBP have been recmited to ERa 
and the receptor has bound to the DNA. The histone acetylase activity of p300/CBP 
increases the attraction of the promoter to the Pol II complex and enables preferential 
binding to increase expression of the selected gene(Cosma, 2002). Approximately forty- 
five minutes after induction other co-activators such as PCAF are recmited, and this is 
followed by binding of Pol II and the initiation of transcription. The initiation of 
transcription leads to dissociation of the ER complex from the promoter (Cosma, 2002).
1.2.5 The interaction between nuclear receptors and the general transcription 
factors
The human thyroid receptor associated protein (TRAP) /mediator complex is a large 
multi subunit protein complex consisting of approximately 25 proteins of vaiying sizes 
(Ito et al., 1999, Malik and Roeder, 2000, Ito and Roeder, 2001). Mediator complexes 
have been identified in sachromyces, D. melanogaster and C. elegans, witli each complex 
exhibiting unique biology and the human mediator complex being very different to that 
of lower species (Malik and Roeder, 2000). The human TRAP/mediator complex is 
known to interact with nuclear receptors via the co-activators that are recmited to the 
activated receptor (Ito et al., 1999, Malik and Roeder, 2000). TRAP /mediator does not 
contain any co-activator activity that is shared with the rest of the co-activator complex 
(for instance it has no HAT activity) but it is known to interact with nuclear receptors and 
with RNA polymerase II (Ito et al., 1999, Malik and Roeder, 2000, Ito and Roeder,
2001).
hi the sequential accumulation of co-activators by nuclear receptors and of the general 
transcription factors which make up the pre-initiation complex with RNA polymerase II. 
The binding of TRAP/mediator is an end stage process occumng after chromatin 
modification and decompression by the ATP dependent remodelling complexes (Ito and 
Roeder, 2001). One member of the TRAP complex in particular responsible for 
interacting with nuclear receptors is TRAP 220; it has been shown to interact with several 
nuclear receptors including TR, VDR, RAR, RXR, PPAR a and y, ERa, and GR (Yuan 
et al., 1998, Hittelman et al., 1999, Zhu et al., 1997). In addition, its -overexpression in 
cells leads to an enhancement of TR, VDR and PPARy dependent transcription (Zhu et
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al., 1997, Yuan et al., 1998, Hittelman et al., 1999, Rachez et al., 2000, Rachez and 
Freedman, 2001, Llopis et al., 2000). The TRAP 220 protein contains two LXXLL 
motifs, which are usually found in co-activator proteins and bind to the corresponding 
LXXLL motifs within the ligand dependent AF2 domain (Glass and Rosenfeld, 2000). 
The two LXXLL mofis of TRAP 220 have been shown to have varying affinities for 
different nuclear receptors with TR, VDR and PPARa binding to the second motif in the 
peptide sequence, with RXR binding to the first motif in the sequence (Yuan et al., 1998, 
Rachez et al., 2000, Ren et al., 2000). It is possibe therefore that TRAP 220 binds to both 
the activated receptor and its obligate binding partner (Ito and Roeder, 2001). A second 
protein TRAP 170 has been shown to interact in a ligand independent manner to the AFl 
domain of GR (Hittelman et al., 1999) which facilitates TRAP binding and fimction by 
serving as a supplemental bridge between the nuclear receptor, mediator and general 
transcription factor complex (Ito and Roeder, 2001).
AR and RAR have been shown to interact directly with members of the general 
transcription factor complex (Heinlein and Chang, 2002, Rochette-Egly et al., 1997, 
Schulman et al., 1995), interacting directly via the n terminus with the TFIIH complex 
presumably via the LED (Svejstrup et al., 1996). TFIIH interaction via the ligand 
dependent helix 12 with ERa strengthens the ligand dependent nature of this interaction 
(Chen et al., 2000). TFIIB has also been shown to interact with several nuclear receptors 
including TR, VDR and HNF4a (Ahmed et al., 2000, Anzick et al., 1997, Hiort et al.,
2000). The direct interaction with the general transcription factors and AR leads to an 
increase in the efficiency o f transcription by RNA polymerase II.
Further investigation into the complexes of the ‘orphan’ nuclear receptors such as PXR 
and FXR will reveal which of these two mechanisms of interaction with RNA 
polymerase II they employ to transmit signal to the basal transcription machineiy.
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U  Nuclear receptors
Nuclear receptors are classified into a large superfamily of transcription factors, which 
regulate biological processes including basic biological roles such as embryonic and 
organ development, as well as more pathophysiological processes such as tumorigenesis 
and proliferation (Mohan and Heyman, 2003, Bonet et al., 2003, Freemantle et al., 2003)
U . l  General structure
DBD
Hinge AF2
Figure 1.3 The general protein structure of the nuclear receptor superfamily adapted 
from (Giguere, 1999).
Nuclear receptors all contain 5 conserved domains which may differ somewhat in structure 
but which are of conserved function. As demarcated in red is the activation 1 domain at the N 
terminus, this domain is responsible for the ligand independent transcriptional activities of the 
receptors. In white can be seen the DNA binding domain which is the most conserved of all 
the nuclear receptor domains and always contains two zinc finger structures. In orange is the 
hinge region which is of varying length between receptors and allows for greater or lesser 
flexibility in the stmcture of the receptor, and may be responsible for altering the DNA 
binding orientation of the receptors wiüi regards its obligate binding partner. In pink is the 
ligand binding domain, arguably the most distinctive area of difference between receptors, 
this region is of varying lengths and secondary structures in receptors, which confer upon the 
receptor the ligand binding selectivity and variability. The activation function 2 domain, 
shown in green is the region of the receptor which is most mobile and reveals a co-activator 
binding site on ligand binding.
U .1.1 DNA binding domain and response elements
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Nuclear Receptors share several domains, the most conserved being the DNA binding 
domain (DBD). The DBD consists of two finger like, cysteine rich protein loops known 
as zinc fingers (Freedman et al., 1988). These Zinc fingere enable the non-covalent 
association of the receptor with the major groove of the DNA (Luisi et al., 1991). Each 
receptor has a preferred sequence of nucleotides to which it will bind, although there 
appear to be considerable promiscuity in this, as will be discussed later (Freedman et al., 
1988). Mutation of key residues within the DBD revealed the presence of two regions 
critical to DNA bindmg, known as the P box and the DR box (Umesono and Evans, 1989, 
Hsieh et al., 1995). The P-box and DR-box are regions of the first Zinc finger which 
confer the nucleotide sequence specificity to the receptor, the sequence of amino acids 
within these regions dictating the binding preference (Luisi et al., 1991). The binding 
preference leads to a categorization of the NR superfamily based on the preferred 
response element within the DNA sequence (See below).
NRs bind to specific nucleotide motifs within the DNA sequence which are known as 
response elements. P box amino acids specify which response element the receptor will 
recognize. The NRs can be grouped into ‘subfamilies’ based upon the preferred response 
element (Umesono and Evans, 1989, Bonet et al., 2003). The GR-box group includes tlie 
glucocorticoid receptor (GR), mineralocorticoid receptor (MR), progesterone receptor 
(PR) and andosterone receptor (AR) which all bind to the sequence AGAACA. The ER 
groups consists of the retinoic acid receptor (RAR), retinoid X receptor (RXR), vitamin 
D receptor (VDR), thyi'oid hoimone receptor (TR) and estrogen receptor (ER). These 
receptors have a two amino acid difference in the P Box area in comparison to the GR 
group, which enables them to recognize the nucleotide sequence AGGTCA (Hsieh et al., 
1995, Zilliacus et al., 1994). Seveml receptors of this group bind to the DNA as 
obligate heterodimers with RXR (Umesono and Evans, 1989). Each receptor pair leaves 
a footprint on the DNA which is determined by the orientation of the receptor and its 
DBD stmcture. These footprints may be direct repeats, in which both receptor response 
elements mn 5’-3’ on the DNA chain, inverted repeats, in which the receptor response 
elements mirror image each other with the two ends adjacent, or everted repeats, in which 
the receptor response elements miiTor image each other with the two beginnings adjacent. 
These response elements are separated fi*om each other by a unique distance determined
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by the size of the bound proteins and hence their zinc finger DBD’s. This unique 
distance confers the ability of the receptors to activate only specific genes (Forman and 
Samuels, 1990, Perlmann et ah, 1993). The DR box lies between the second and third 
cystine residues of the first zinc finger the sequence of which has been shown to be 
critical in determining the DNA binding characteristics of the receptor (Perlmann et al., 
1993).
Zinc finger motifs of 
cystine chelating to 
the zinc atom. 
These structures are 
integral to the DNA- 
receptor interaction
Zinc finger module 1
P and D boxes 
determine the 
receptor binding 
affinity for the 
various response 
elements.
P box
Zinc finger module 2
D box
COOH I ___
102
CTE
1.4 The Zinc finger DNA binding domain of the nuclear receptor adapted from (Giguere, 
1999).
The two zinc fingers intercalate with the minor groove of the DNA allowing the receptor to bind. 
The sequences shown as the P and D boxes, highlighted above, determine the affinity of the 
receptor for the response element sequences. The zinc atom is vital for the structure of the 
fingers, and the co-ordination of the four cysteine residues holds the structure of the finger. 
Highlighted in bold are residues which make direct contact with the DNA; those residues which 
have open or closed circles are important in the receptor dimerization upon activation of the 
receptor. The C teiminal extension region (CTE) has been shown to be involved in assisting both 
DNA binding and receptor dimérisation.
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A third region has been identified and is known as the D box. Mutation of this sequence 
has been shown to dismpt the DNA binding of the receptor making it less specific for its 
preferred response element thus increasing its promiscuity for DNA binding. A mutation 
of an alanine to a threonine within this region was found to ablate the DNA binding 
capacity of GR and it has been found that TR and RAR depend on the function of this 
domain for DNA binding.
1.3.1.3 Hinge region
The hinge region of a nuclear receptor is an area of the protein separating the DBD and 
the ligand binding domain (LED). This region provides flexibility within the structure of 
the protein and contains several functional motifs. The N terminal area of the hinge 
region contains a T box that is involved in the dimerization of the receptor and an A box 
which is involved in half site recognition and the DNA binding (Claessens et al., 2001, 
Heinzel et al., 1997). The C terminal section of the hinge region regulates protein-protein 
interaction between the receptors, the co-regulator proteins and the transcription factors 
which enable interaction with the transcriptional machineiy (Heinzel et al., 1997, 
Ceraline et al., 2004).
1.3.1.4 Ligand binding domain
This region shows the lowest amount of conservation across the nuclear receptors family, 
which is perhaps not surprising given its role in the specific interaction of ligand and its 
cognate receptor; despite this a structural analysis shows a conserved tertiaiy structure in 
this region across almost all nuclear receptors (Wagner et al., 1995, Wurtz et al., 1996b, 
Wurtz et al., 1996a). The LDB is a globular structure consisting o f 11-12 a helices 
arranged in a 3 tiered structure with p pleated sheets intermingled (Wurtz et al., 1996a).
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The globular structure leads to the formation o f an hydrophobic pocket within which the 
ligand can bind (Bourguet et al., 2000). Binding of the ligand within the LBD leads to a 
conformational change which stabilizes the shape of the protein in an active 
configuration(Bomgraeber et al., 2003).
The C teiminal portion of a nuclear receptor contains an activation fimction 2 (AF2) 
motif which is found within the twelve and final a  helix and has been shown to be vital 
for transcriptional activation (Berkenstam et al., 1992). When a ligand is bound to the 
LBD the confoimational change alters the position of the 12“' helix switching it fiom an 
inactive to an active position (Voegel et al., 1996, Renaud and Moras, 2000, Shiau et al., 
2002).
The natme of the ligand dependent change in position of helix 12 is complex; evidence 
suggests that the change is not only dependant on the presence of a ligand but also on the 
exact nature of the ligand (Westin et al., 1998, Darimont et al., 1998). The traditional 
idea of agonists having affinity and efficacy and antagonists having only affinity is not 
applicable in this case (Darimont et al., 1998). Whereas agonists bind and cause a 
confoimational change which could be considered to positively activate the receptor, 
antagonists can cause a conformational change which moves helix 12 in a negative 
maimer, preventing transcriptional activation by the receptor (Shiau et al., 1998).
While an agonist is bound to the receptor the confoimational change in helix 12 is such 
that helices 3, 11 and 12 localise to foim an hydrophobic ‘surface’(Westin et al., 1998, 
Darimont et al., 1998). Many co-activator proteins contain leucine rich LXXLL motifs, 
which are reciprocated on the surface formed by these helices (Shiau et al., 1998). The 
LXXLL motifs form mini helices, which can entwine enabling the receptor and co­
activators to bind. In the presence of an antagonist or partial agonist, it is thought that 
helix 12 changes position such that it blocks the binding of co-activator proteins (Nettles 
and Greene, 2003, Needham et al., 2000).
1.3.1.5 Activation factor 1 domain
The AFl domain confers ligand independent transactivation function to tlie receptor 
(Dahlman-Wright et al., 1995). Found at the N terminus of the protein this region can co­
operate with the AF2 domain to bring about transcription (Kumar et a l, 1987). This 
region varies between receptors and its efficacy and importance in receptor function 
differs depending on structure and functional motifs elsewhere in the protein (Wammark 
et a l, 2001). There is an hypothesis that some co-regulators when binding to this site can 
induce a structural change within the protein which can stabilize the N terminal region of 
the polypeptide and lead to a somewhat weaker transcriptional activity (Onate et a l, 
1998). It is highly likely that neither of the AFl and AF2 domains can function alone and 
that receptors require both regions to achieve maximal transcription (Benecke et al, 
2000, Be van et a l, 1999).
1.3.2 Activation and mechanism of action
Nuclear receptor activation is not solely dependent on ligand binding but it is the key to 
getting maximum receptor activation. The mechanism by which nuclear receptors 
regulate target genes can be either DNA dependent (Cis regulation), or DNA independent 
(trans regulation) (Flick et al, 2002). Cis regulatory receptors can bind DNA, either 
repressing or activating the gene by binding to the response element within the promoter 
region of the target (Pearce et a l, 1998). By constrast, tians regulation generally 
represses transcriptional activity at the promoter and involves the binding of the receptor 
to other DNA binding proteins (Almawi and Melemedjian, 2002). Ligand binding is not 
required for trans regulation to occur and many receptors are shown to exhibit this type of 
behavior in the inactive state, effectively enabling them to inteixupt the activity of other 
classes of nuclear receptor (Bruna et a l, 2003).
1.4 The impact of co-regulator proteins on nuclear receptor function
1.4.1 The role of chromatin remodelling, factors in the modulation of nuclear 
receptor activity.
Chromatin is the combination of DNA with protein cores called histones. Chromatin can 
be separated into loosely packaged more transcriptionally active or inducible 
euchromatin, or into tightly packaged transcriptionally silent or inactive heterochromatin. 
The conversion from heterochromatin to euchromatin and visa-versa is regulated by the 
density of histone packaging (Hom and Peterson, 2006). Within euchromatin
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transcription may still be inhibited as even the loose packaging of the histones can 
prevent access of RNA polymerase II and its transcription factors to the DNA (Felsenfeld 
and Groudine, 2003, Kinyamii and Ar cher, 2004). The remodeling of these chromatin 
and nucleosome stmctures plays a cmcial role in induced transcription as seen through 
activation of nuclear receptors.
1.4.2 Chromatin remodeling complexes.
There are two main classes of enzyme responsible for altering the density of chromatin 
increasing the access for the transcriptional machinery. The ATP dependent chromatin 
remodeling complexes use the energy from ATP to alter the conformation of the histone 
proteins (Berger, 2002, Vignali et al., 2000). The histone modification enzymes catalyze 
the post-translational modifications of the histone proteins including, acétylation, 
méthylation, phosphorylation, ubiquitination and sumoiylation (Neely and Workman, 
2002, Wade, 2001, Zhang, 2003, Trotter and Archer, 2004).
The ATP dependent chromatin remodeling complexes alter the position or stability of the 
nucleosomes within the chromatin in a non covalent manner and have been implicated as 
essential parts of complexes enabling transcription, replication, DNA repair and 
recombination (Trotter and Archer, 2004). The complexes themselves are based arormd a 
central core catalytic subunit containing an ATPase function. The type æid nature of the 
catalytic subunit is what identifies the families of ATP dependent chromatin remodeling 
complexes. The ATPase unit may include the SWESNF, ISWI, Mi-2/NuRD complex or 
INO80 (Eberharter and Becker, 2004). The SWI/SNF complexes are perhaps the best 
characterized (Trotter and Archer, 2004) and most abundantly expressed complexes with 
many combinations of protein subunits constituting the variation seen across the family 
(Nie et al., 2000).
Human SWI/SNF is a large multiprotein complex which contain either BRGl or hBrm as 
the central ATPase subunit, also consisting of several other BRG associated factors
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(BAFs) (Xue et al., 2000, Wang et al., 1996b). Human SWISNF complexes bave been 
shown to consist of a mixture of the BAF proteins with complexes that have been 
purified containing BAF170, BAF155, BAF60, BAF57, BAF53 and BAF47 (Wang et al., 
1996a). The function of the complex has been shown to rely only on the presence of the 
central core units, with BRGl and hBrm proving sufficient to remodel the nucleosomes. 
The activity of these enzymes increases with the addition of the BAF proteins, nearing 
optimal the more BAFs which are added (Phelmr et al., 1999, DiRenzo et al., 2000). The 
human SWI/SNF complex may be subdivided further by the identification of 2 distinct 
groups of complexes containing either BAF250 or BAF200 and BAFl 80. Complexes 
containing BAF250 are known as the BAF complex (hSWI/SNFa) whereas those 
containing BAF200 and BAF 180 are the PBAF complexes (hSWI/SNFb) (Nie et al., 
2000, Lemon et al., 2001, Yan et al., 2005).
The SWI/SNF complex has been shown to associate with several other proteins/protein 
complexes known to actively alter transcriptional activity including the histone 
deacetylases HD AC 1&2, protein arginine methyltransferases, co-activator associated 
arginine methyltrasnferases (CARMl), with the nucleosomes méthylation activation 
complex (NuMAC), with the transcriptional co-repressor Sin3A and with the tumour 
suppressor BRCAl (Sif, 2004, Trotter and Archer, 2004).
1.4.3 The role of chromatin remodeling factors in nuclear receptor regulation
Perhaps the best method cuiTently used to identify the activity of chromatin remodeling 
factors involves the use of the mouse mammaiy tumour vims promoter. This promoter 
region can be stably incorporated into the genome of cell lines and when in this format 
forms a highly organized system of 6 nucleosomes. Within the DNA sequence lie several 
response elements, most notably for the glucocorticoid receptor (GR) but also for other 
nuclear receptors and non ligand dependent transcription fectors. Using this model it is 
possible to test for the efficacy of the interaction between these transcription factors and 
the chromosome remodeling factors which are recmited (Fryer and Aicher, 1998, Archer 
et al., 1992). The interaction between the ATP remodeling complexes and nuclear 
receptors was first identified for GR (Muchardt and Yaniv, 1993, Fryer and Archer,
1998). Since then a number of others have been studied identifying interaction between
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several other receptors and transcription factors, among them the estrogen receptor (ER) 
(Acevedo and Kraus, 2004, Kraus and Wong, 2002, Kinyamu and Archer, 2004, Ichinose 
et ah, 1997).
The studies performed on GR activation and its transcriptional activity show a 
dependency on the recruitment of the SWI/SNF BRGl/hBrm containing complexes 
(Acevedo and Kiaus, 2004, Trotter and Archer, 2004). Experiments performed in SW13 
BRGl/Brm null mice showed that while the other chromatin remodelling complexes 
were intact and operational (Mi-2 containing and ISWI) they were not sufficient to enable 
GR transcriptional activity (Trotter and Archer, 2004). The interaction of the SWI/SNF 
complex with specific promoters has been shown to correspond to the locahzation of 
nuclear receptors and members of other transcription factor families. The attraction is 
mediated through interactions with the acetylated tails of histone proteins and is 
dependent on BRGl/hBrm, BAF 250, BAF 60a mid BAF57 (Belandia et al., 2002, Inoue 
et al., 2002, Garcia-Pedrero et al., 2006). BAF 260 and BAF60a have been shown to 
bind to GR in a ligand independent manner but they are required for ligand dependent 
activity (Hsiao et al., 2003). BAF 250 is shown to bind to GR in a ligand dependent 
manner (Nie et al., 2000). GR also interacts with BAF 180 in cells expressing PBAF 
demonstrating that GR does not discriminate between the BAF and PBAF complexes 
(Inoue et al., 2002, Fryer et al., 2000).
Other receptors including the progesterone receptor (PR), androgen receptor (AR) and 
ERa have been shown to depend on BRGl binding for their transcriptional activities 
(Fryer and Archer, 1998, Huang et al., 2003, Chiba et al., 1994, Muchardt and Yaniv, 
1993, Hsiao et al., 2003, Koszewski et a l, 2003).
1.4.4 The role of histone modification in nuclear receptor coactivation.
1.4.4.1 Histone acétylation and acetylases
Accompanying the recruitment of chromatin remodelling complexes nuclear receptors 
recruit other, multi-protein, complexes which alter the chromatin stmcture by covalently 
modifying the histone proteins (Kinyamu and Archer, 2004, Fischle et a l, 2003, S trahi 
and Allis, 2000). The most studied and most commonly employed histone modification
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is the acétylation of lysine residues in the amino terminal of the histone proteins. The 
enzymes which are recmited for this fimction are known as this histone acetyl 
transferases (HATs) and are opposed by the activity of the histone deacetylase proteins 
(HD AC) (Kinyamu and Archer, 2004). The regulation of transcription via the variation 
in the level of histone acétylation has been long known (Kinyamu and Archer, 2004), 
with increases in tlie levels of acétylation conelating to an increase in the transcriptional 
activity of that gene (Fischle et al., 2003, Kurdistani and Gmnstein, 2003). Acétylation 
of the histone proteins is thought to decrease the affinity of the histones for DNA which 
weakens their interaction and which opens the nucleosomes up for transcription factors 
and RNA polymerase II (Gmnstein, 1997, Brower-Toland et al., 2002). It is possible that 
the combination of covalent modifications present on the histones at any one time acts as 
a code responsible for recmiting different accessoiy proteins and transcription factors, 
giving rise to differential patterns of gene expression (Fischle et al., 2003, Jenuwein and 
Allis, 2001).
Generally speaking, it is known that some identified co-activators recmited by nuclear 
receptors have HAT activity while some identified co-repressor s exliibit HDAC activity 
(Kinyamu and Aicher, 2004). Co-activator proteins recmited by nuclear receptors which 
have HAT activity include PCAF/GCN5, p300/CBP, TAF250, SRCl and ACTR 
(Brownell et al., 1996, Schiltz and Nakatani, 2000, Bannister et al., 2000, Mizzen et al., 
1996, Ogryzko et al., 1996, Spencer et al., 1997, Chen et al., 1997). There is some 
evidence o f crosstalk between the chromatin remodelling factors and the histone 
modification complexes and it has been demonstrated that GR dependent transcription of 
some genes requires the recmitment o f both the SWI/SNF and HAT complexes (Logie et 
al., 1999, Fry and Peterson, 2001).
The effect of acétylation on tlie activity o f nuclear receptors has been extensively studied 
for GR activity at the MMTV promoter. The inhibition of HDAC activity by the use of 
trichostatin A (TCA) or sodium butyiate leads to a hyperacelylation o f the histones which 
actually reduced the activity of GR suggesting that overactivation of the histone proteins 
can suppress transcriptional activity (Bresnick et al., 1991, Bartsch et al., 1996, Wilson et 
al., 2002). GR is known to interact with the HAT complexes p200/CBP and SAGA
(Fryer and Archer, 1998, Fiyer et al., 2000, Wallberg et al., 1999). The exact nature of 
the interaction between the receptor and the HAT complexes is unknown although it has 
been shown that PR recruits SRCl and p300/CB and GR recruits SRCl/GRIP 1 and 
PCAF, both events leading to the acétylation of histones H3 and H4. This suggests that 
SRCl acts as a bridging protein (Wilson et al., 2002, Sheldon et al., 2001), in a similar 
fashion to demonstrated bridging proteins such as the transactivation/transformation 
domain associated protein (TRRAP), This is a protein involved in the SAGA hat 
complex and of complexes containing the HAT proteins PCAF and TIP60 while not 
being a HAT itself (Yanagisawa et a l, 2002, Brand et a l, 1999, Amati et a l, 2001). 
TRRAP has been shown to be associated with ERa and its presence is required for ER 
activation (Yanagisawa et a l, 2002).
1.4.4.2 Histone deacetylases
As mentioned before HDAC complexes are generally known to be antagonistic to the 
activation of nuclear receptors and are integral parts of the co-repressor protein 
complexes (Kinyamu and Archer, 2004). It is suggested that both HAT proteins and 
HDAC complexes are contained within tire same protein complexes, enabling the rapid 
regulation of gene expression by changing cellular environments (Kinyamu and Archer, 
2004). The co-repiessor complexes NCoR and SMRT are requiied for the suppression 
of gene expression by nuclear receptors (Baniahmad et a l, 1995) and both of these 
complexes are known to contain both class I and class II HDACs (Underhill et al, 2000, 
Yoon et a l, 2003, Wen et a l, 2000).
1.4.4.3 Histone Phosphorylation
Protein phosphorylation is an extremely common method of altering protein function by 
covalently modifying lysine and serine residues within a protein sequence, and all 5 
histone proteins are subject to phosphorylation (Kinyamu and Archer, 2004).
The most studied phosphorylation event is that of histone HI (Bradbury, 1992, Roth and 
Allis, 1992). Histone HI is a linker protein which is involved in the stabilization of the
nucleosomes, and hence chromatin, stmcture and is capable of preventing the access of 
transcription factors and the initiation complexes (Hill, 2001, Cheung et al., 2002). GR 
modulated expression of the MMTV promoter involves the phosphorylation of the HI 
molecule and has been shown to lead to the dispersal of the protein from the nucleosomes 
(Lee and Archer, 1998, Bresnick et al., 1991). Excessive activation of GR has been 
shown to inactivate the promoter via HI déphosphorylation leading to a condensation of 
the nucleosomes and increased resistance to GR activation (Lee and Archer, 1998). 
Inactivation of GR Ikeads to reformation of the promoter stmcture and rephosphorylation 
of HI (Banks et al., 2001). The importance of the phosphorylation o f the HI isoforms is 
seen as vital to the survival of cells, with mouse embryos aborting upon inactivation of 
the phosphorylation mechanism (Banks et a l, 2001, Gunjan et a l, 1999).
The phosphorylation of serine 10 of histone H3 has also been shown to increase the 
transcriptional activity of the promoter, loosening the chromatin packaging and has also 
been shown to be involved in GR mediated transcription (Bradbury, 1992, Cheung et al, 
2002, Cheung et a l, 2000, Li et a l, 2003).
1.4.4.4 Histone méthylation
Histone méthylation occurs on specific lysine and arginine residues of both histones H3 
and H4 (Fischle et a l, 2003, Kouzarides, 2002). Méthylation of histone proteins can 
have mixed effects on chromatin stmcture; the overall effect of which being determined 
by the residue which has been modified and the level of méthylation (mono, di or tri 
méthylation) (Kinyamu and Archer, 2004). The dimethylation of lysine 9 of H3 and the 
tri méthylation of lysine 27 of H3 are associated with gene suppression and 
monomethylation of lysines 4, 36 and 39 of H3 is associated with an increase in 
transcriptional activity (Fischle et a l, 2003, Kouzarides, 2002, Strahi et a l, 2002).
The histone metliyltransferases (HMTs) are chromatin bound enzymes with méthylation 
as an irreversible and stable covalent modification of the histone whereas 
phosphorylation and acétylation are revei'sible (Bannister et a l, 2002). The HMTs that 
are currently identified are:
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Siiv39Hl methylating H3 at lysine 9 with the subsequent recmitment of accessoiy 
proteins (Lachner et al., 2001, Tachibana et al., 2001),
G9A methylates lysines 9 and 27 of H3 (Tachibana et a l, 2001) and ESET (Yang et al,
2002).
Setl is an HMT that methylates lysine 4 and is associated with transcriptional activation 
of GR (Kinyamu and Aicher, 2004) as the hypo méthylation of lysine 9 of H3 is 
associated with with GR activation (Li et a l, 2003).
The méthylation of arginine residues within the histone sequence occurs on arginine 
residues 2, 17 and 26 of H3 and 3 of H4, This is mediated by the protein arginine 
methyltransferases (PRMTs), which are known as PRMTl and PRMT 4/C ARM 1 
(Kinyamu and Aicher, 2004); PRMTl modifies H4 at arginine 3 and CARMl modifies 
H3 at arginines 2, 17 and 26. Both o f these proteins have been identified as associating 
with the pl60 co-activators and p300 (Chen et a l, 1999, Wang et a l, 2001, Koh et al,
2001). Méthylation of H3 arginine 17 has been shown to be important in the activation 
of transcription by both GR and ERa, via the binding of CARMl in the co-regulator 
complex (Ma et a l, 2001, Bauer et a l, 2002).
1.4.5 AFl interacting co-activators
The AFl domain of nuclear receptors is the aiea showing the least level o f conseivation 
between the receptors, presumably due to the fact that it acts as a second transcriptional 
activation domain and is involved in mediating nuclear receptor responses which are cell 
type and promoter specific (hnakado et a l, 1991, Mcinemey and Katzenellenbogen,
1996). The AFl domain functions as a ligand independent transcriptional activator and 
in this state is capable of eliciting a low, but biologically functional level of 
transcriptional activity. In co-operation with the ligand dependent AF2 domain the AFl 
domain is capable of raising the receptor to its most active (Edwards, 2000). In yeast it 
has been shown that the AFl domain of GR is capable of interacting with a series of 
acetyltransferase proteins which are known as SAGA (SPt, Ada, Gcn5 acetyltiansferases)
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while in mammalian cells it has been shown to interact with the human analogue o f Ada2 
and enliance the activity of the receptor by binding to AFl (Henriksson et al., 1997, 
Wallberg et al., 1999). The AFl domain of ERa has been shown to interact with p68 
RNA helicase in vitro and in vivo but tliis has not held true for other receptors studied, 
including AR, MR, RAR or ER(3. This interaction has been shown to enhance the 
AFl mediated receptor activation not the AF2 mediated activation (Endoh et al., 1999).
1.4.6 Other nuclear receptor interacting proteins
The vitamin D receptor interacting protein (DRIP) and the thyroid receptors associated 
protein (TRAP) are multi protein complexes found to associate with their namesake 
receptors (Rachez et al., 2000, Pineda Torra et al., 2004). It has been shown that 
TRAP/DRIP interact with other nuclear receptors and it is thought that these complexes 
foim a bridge between the nuclear receptor, its co-regulators and the basal tianscription 
machinery (Ito et al., 1999, Rachez et al., 2000). ARA 70 is a 70 kDa protein which 
interacts with the ligand binding domain of human AR and enhances its tianscriptional 
activity (Alen et al., 1999) and binds poly glutamine repeats within the ligand binding 
domain (Hsiao and Chang, 1999). ARA70 has a somewhat different function from other 
nuclear receptor co-activators in that it seems to specifically enhance the weak AF2 
activity of the AR receptor (Gao et al., 1999). The high mobility group proteins HMG 1 
and HMG 2 are proteins which have been shown to interact between the nuclear receptor 
and its target DNA sequences, increasing the specificity of the receptor for its target 
sequences for PR, AR, GR and ER (Xu et al., 1999, Boonyaratanakomkit et a l, 1998, 
Melvin and Edwards, 1999). The HMG proteins aie minor groove DNA binding proteins 
which do not interact specifically with the nuclear receptor response elements but which 
are actively recmited to the receptor DNA complex and reinforce the receptor binding by 
forming extra protein-protein and protein-DNA bridges (Edwards, 2000). The activity of 
these proteins seems restricted to the steroid hormone type 1 receptors and is not shown 
to affect any type II oiphan receptors such as VDR, PXR, RXR (Edwards, 1999, 
Boonyaratanakomkit et a l, 1998, Melvin and Edwards, 1999).
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1.5 Co-repressor complexes
1.5.1 Known co-repressor complexes and their functions
Co-repressor complexes play a vital role in regulation of nuclear receptor biology as they 
represent a mechanism to prevent the transcription of target genes when the receptor is 
naive or bound to an antagonist (Jepsen and Rosenfeld, 2002). There are several distinct 
mechanisms by which these repressor complexes function. Competition for co-activator 
binding sites and/or sequestration of the co-activator complexes into inaccessible areas of 
the chromatin/cell will reduce the activity of the receptors. Direct interaction wiüi core 
transcriptional machinery by increased histone méthylation or increased histone 
deacetylation also reduces the ability of genes to interact with receptors and 
transcriptional complexes (Jepsen and Rosenfeld, 2002, Chen and Evans, 1995, Horiein 
et al., 1995, Ordentlich et a l, 1999, Park et a l, 1999).
It was observed that the thyroid hormone (TR) and retinoic acid receptor (RAR) were 
able to actively repress the transcription of their target genes in the absence of a ligand 
(Baniahmad et a l, 1992). NCoR and SMRT were identified as the proteins that bound to 
these receptors when they were in their repressive state; both NCoR and SMRT are large 
protein complexes shown to bind specifically to receptors and maintain them in an 
inactive/repressive state (Horiein et a l, 1995, Chen and Evans, 1995, Ordentlich et al, 
1999, Park et al, 1999). The proteins NCoR and SMRT both contain a conserved 
nuclear receptor interacting domain (NRID) (Li et a l, 1997a, Seol et a l, 1996, Zamir et 
a l, 1996) which consists of a specific amino acid repeat of Lxxxixxxl/L (Hu and Lazar, 
1999, Nagy et a l, 1999, Perissi et a l, 1999, Heery et a l, 1997), which forms an a helix 
similar to that of the LxxLL motif of co-activator proteins but is one helical turn longer 
than that of the co-activator motif (Heery et a l, 1997, Mcinemey et a l, 1998). 
Within the associated protein complexes of NCoR and SMRT are two secondary 
proteins, being Rpd3p/histone deacetylase 1 and Sin3 (Heinzel et a l, 1997, Nagy et a l,
1999). The acétylation of lysine residues on histone proteins is linked to an increase in 
transcriptional activity and the formation of euchromatin. The denser and 
transcriptionally repressed areas of heterochromatin are found to be acetylated less than 
euchromatin (Gmnstein, 1990, Turner, 1993). The histone deacetylase complexes
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(HDACs) were first identified in yeast and consisted of one of two core proteins which 
are either histone deacteylase Ip (Hda Ip) or the previously mentioned Rpd3p (Rundlett 
et ah, 1996). Investigations into the role of histone deacetylase complexes have revealed 
that HDAC 1 is capable of mediating deacetylation and repressing transcription when 
active on chromatin but not when active on naked DNA suggesting that the histone 
proteins are required for the mechanism by which deacteylation represses transcription 
(Huang and Kadonaga, 2001).
HDAC 1 and 2 have been identified as interacting partners of the co-repressor complexs 
of Sin associated proteins (SAP) and the nucleosome remodeling and histone 
deacetylation complex (NURD) (Zhang et a l, 1997, Zhang et a l, 1998c, Zhang et al, 
1998b, Zhang et a l, 1999b, Tong et a l, 1998, Xue et a l, 1998). The NURD complex 
has an ATP dependent chromatin remodelling function (Knoepfler and Eisenman, 1999). 
When co-repiessor complexes are purified using either anti HDAC 1 or anti HDAC 2 
they usually contain components of the NURD complex including the Mi-2 ATP 
dependent chromatin remodelling subimit (Humphrey et a l, 2001). This suggests that the 
HDAC components are acting as a central core upon which the other complexes foim 
(Humphrey et a l, 2001, Jepsen and Rosenfeld, 2002). The HDACs 1 and 2 have been 
found in both SMRT and NCoR complexes (Guenther et a l, 2000, Jones et a l, 2001, Li 
et a l, 2000, Underhill et a l, 2000) which contain the SAP complex and Sin3 (Zhang et 
a l, 1997, Zhang et al, 1998c).
Other proteins found associated with NCoR and SMRT have been identified, although 
their functions as part o f co-repressor complexes are not well understood. Transducin 
beta like protein 1 (TBLl) was identified as being a binding partner o f NCoR and SMRT 
and contains a motif known as the WD40 repeat which is a protein binding motif 
associated with co-repressor proteins known to bind to non ligand dependent 
transcription factors Tupl and groucho (Bassi et a l, 1999, Dong et a l, 1999). 
Furtheimore, the Krab associated protein 1 (KAPl) is a trichostatin A (TSA) sensitive co­
repressor which interacts with heterochiomatin protein 1 and is a known member of 
SWI/SNF ATP remodelling complexes (Underhill et a l, 2000). DNA méthylation is 
associated with gene suppression and the methylated dinucleotide binding protein
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MeCpG2 has been shown to interact with HDACs, with the Sin complexes (Jones et al., 
1998, Nan et al., 1998) and has been shown to be part of the NCoR complex (Kokura et 
al., 2001), possibly leading to another mechanism of gene repression.
1.5,2 Regulation of co-repressor complexes
The nature of the regulation of nuclear’ receptors means that the repressor complexes are 
required to disassemble and make way for activator complexes in a shoi*t space of time. 
To achieve this there are three primary mechanisms of regulation of repressor complex 
activity and cellular location (Jepsen and Rosenfeld, 2002). The NCoR and SMRT 
complexes have been identified as binding to a protein known as mSiah2 (Zhang et al., 
1998a) which is a protein known to lead to proteosomal degradation of its binding 
partners (Hu et al., 1997). Co-transfection of NCoR and mSiah2 showed a sharp decrease 
in NCoR which is not seen with a proteosome inhibitor (Zhang et al., 1998a). 
Phosphorylation of serine threonine residues in the protein chain is a common mechanism 
of protein post-translational regulation. The protein kinase A (PKA) stimulator forskolin, 
or the mitogen activated protein kinase (MAP kinase) and protein kinase C (PKC) 
stimulator epidermal growth factor (EGF), are shown to decrease the tamoxifen- 
dependent association of NCoR with ERa (Lavinsky et al., 1998). Activation of MAP 
kinase with L throxine also lead to dissociation of SMRT fiom the thyroid hor*mone 
receptor (TR) (Davis et al., 2000).
1.6 NR1I2; the Pregnane X Receptor (PXR)
1.6.1Tissue Distribution and subcellular localization
PXR was originally detected by northern blot analysis in the liver, colon, and small 
intestine (Lehmann et al., 1998); subsequent RT-PCR studies have shown expression of 
the mRNA in stomach, bone manow, spinal chord , heart, thalamus, adrenal gland, pons 
and medulla (Lamba et al., 2004). PXR has also been shown to be expressed in certain 
tumour cells including breast cancers and their surrounding healthy tissue and in
endometrial cancer cell lines (Dotzlaw et al., 1999, Masuyama et al., 2003). The 
expression of PXR in cancer cells may suggest a mechanism behind the dmg resistance 
of certain tumours (Masuyama et al., 2003, Masuyama et al., 2005, Carnahan and 
Redinbo, 2005).
There is some conflicting evidence regarding the localisation of PXR within tlie cell with 
some groups using GFP tagged human PXR and immunochemistry methods finding PXR 
sequestered within the nucleus regardless o f the presence or absence of ligand (Sueyoshi 
and Negishi, 2001, Koyano et al., 2004). PXR has also been shown to localise to tlie 
nucleus with ligand binding in the liver of PCN treated mice. PXR has been found in 
complexes with the molecular chaperone heat shock protein 90 kDa (hsp90) and the 
constituitive adrostane receptors (CAR) retention protein. It was suggested that both 
proteins assist in chaperoning PXR to the nucleus but are not transfeiTed across the 
nuclear membrane (Squires et al., 2004).
1.6.2 DNA Binding
PXR forms an obligate heterodimer with the retinoid X receptor (RXR) on DNA binding 
(MangeIsdoif and Evans, 1995, Lehmann et al., 1998, Kast et al., 2002) and binds to 
repeats of the sequence AG(G/T)TCA in the promoter regions of the target genes. 
Specifically PXR RXR binds to direct repeats (DR) (both sequences running 5’-3’) with 
three to five nucleotides separating the repeats known as DR3, DR4 and DR5, and also to 
the everted repeats (the beginning of each repeat sequence adjacent to each other) with 
six or eight nucleotides separating the repeats known as ER6 and ER8 (Lehmann et al., 
1998, Blumberg et al., 1998, Kast et al., 2002). The variation in these response elements 
suggests that the heterodimeric PXR-RXR complex is able to alter its conformation 
depending on the nature of the response element. This is supported by the fact that the 
heterodimer can recmit different co-regulators depending on the nature of the ligand and 
the co-regulator (Carnahan and Redinbo, 2005).
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1.6.3 Structural considerations
In general PXR follows the generic structure of the nuclear receptors, containing an AFl, 
DBD, hinge region, LBD and AF2 domains (Carnahan and Redinbo, 2005). The AFl 
domain of PXR is shorter than that of other receptors and would normally be concerned 
with the ligand independent activity of the receptors, the flmctional significance of this 
modification is uncleai* (Carnahan and Redinbo, 2005). As with all other nuclear 
receptors tlie DBD of PXR consists of two zinc finger groups structured fiom the amino 
acid chain allowing ligand dependent binding to the DNA response elements when in 
combination with the obligate binding partner RXR. The DBD of PXR contains a 
nuclear localisation signal which allows for tiaffickiug of the protein across the nuclear 
membrane (Camahan and Redinbo, 2005, Kawana et al., 2003). As with all other 
nuclear receptors the DBD and LBD of PXR are separated by the hinge region (amino 
acids 107-141), which allows flexibility within the protein structure; PXR contains a 
shorter hinge region than many other nuclear receptors although the functional 
significance of this is also unclear (Camahan and Redinbo, 2005).
The LBD (amino acids 141-434) of PXR consists of both a veiy large ligand binding 
pocket and the AF2 domain (Gampe et al., 2000). Ligand binding the LBD leads to tlie 
foimation of a strong protein-protein interaction with the LBD of RXR. The presence of 
the ligand initiates a series o f confonnational changes altering the position of several 
charged amino acids that are necessary for this interaction, which is also important in 
recruiting co-activators of the p i 60/SRC family (Renaud et al., 1995, Xu et al., 2002, 
Nolte et al., 1998).
Phosphorylation of nuclear receptors is a known mechanism employed to alter their 
biological activity including tlie DNA binding capability, ligand binding specificity, 
recruitment of co-activatora and dimeric partners (Camahan and Redinbo, 2005). The 
ability of PXR to dissociate fi-om the co-repressor complex NCoR and to recmit the co­
activator SRCl is diminished by activation of the protein kinase C pathway, whereas
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activation of the protein kinase A pathway has been shown to increase the transcriptional 
activity of PXR by phosphorylation of sites within both tlie DBD and LBD (Ding and 
Staiidinger, 2005).
The ciystal stincture of PXR has been resolved both in the ligand-free state and in 
combination with xenobiotics and bound to the co-activator SRCl; its stmtcutre has been 
shown to follow the general pattern of tliree layers of a helicies forming the ligand 
binding cavity (Chrencik et al., 2005, Watkins et al., 2003a, Watkins et al., 2003b, 
Watkins et al., 2001). Most other nuclear receptors have a two or three stranded p sheet 
whereas PXR has an extended five stranded p sheet formed from a 60 amino acid 
extension (aa 175-235) of the LBD which is unique to PXR (Kliewer et al., 1998). While 
most nuclear receptors have a LBD with limited flexibility the insert provides PXR with 
enormous flexibility, through the increased size of this region. A 13 amino acid stretch 
of the inserted amino acids is unstmctured appealing to be too flexible for visualisation 
by X  ray ciystallography (Camahan and Redinbo, 2005). The remaining 47 amino acids 
fonn an a helix and two fiirther p sheet strands. The additional a helix lies towards the 
bottom of the LBD and is shown to be more mobile than the other helices which make up 
the LBD stmcture. The mobility of this helix confers the ability to bind a range of ligand 
stmctures and sizes which is imique to PXR (Camahan and Redinbo, 2005, Chrencik et 
al., 2005, Watkins et al., 2003a, Watkins et al., 2003b, Watkins et al., 2001). The 60 
amino acid extension of the LBD as discussed above enables the foraiation of a ligand 
binding pocket which can range in size fiom around 1200 angstroms to over 1600 
angstroms (Camalian and Redinbo, 2005). The ligand binding pocket is adapted to bind 
the ligands of PXR in that it contains few polar amino acid residues, contaiuing only 8 
distributed throughout the LBD (Watkins et al., 2001). The majority of the amino acid 
residues o f the LBD remain in constant orientation whether bound to ligand or not. The 
side chains of histidine 407 and leucine 209 have been shown to rotate on ligand binding 
and have also been shown to be required for ligand binding (Watkins et al., 2003a, 
Watkins et al., 2003b, Chrencik et al., 2005).
The ligands of PXR are typically lipophilic with few hydrophilic modifications or side 
chains (Lipinski et al., 2001). As said before PXR is somewhat different in the nucleai*
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receptor family as regards the range of ligands which are capable of eliciting a 
transcriptional response. Ligand binding to PXR has been modelled for both large and 
small ligands. The compound SR12813 is a 503 dalton molecule and has been shown to 
enter the LBD in a range of orientations which only become more limited when the 
LxxLL domains of the AF2 helix and SRCl combine (Watkins et al., 2001).
1.6.4 Co-regulator binding of PXR
The co-regulator complexes for PXR are poorly understood when compared to those of 
ER, GR and others (Camahan and Redinbo, 2005). Co-immunoprecipitation studies for 
PXR found that the co-activator SRCl bound to the receptor. Yeast two hybrid screens 
have shown that PXR binds to SRCl and receptor interacting protein 140 (RIP 140) in the 
presence of phthalic acid; in addition, when complexed with progesterone, 
dexamethasone or pregnenalone PXR binds SRCl, RIP 140 and the suppressor of gal 
l(SUGI) (Kliewer et al., 1998, Masuyama et a l, 2000, Masuyama et a l, 2001). Studies 
of the PXR LBD fused to a second transcriptional protein also showed an interaction with 
SRCl(Synold et a l, 2001, Takeshita et a l, 2002, Takeshita et al, 2001, Wentworth et al,
2000), Synold et al also proposed interactions with GRIPl, ACTR and DRIP205 (Synold 
et a l, 2001).
The binding of co-repressors to PXR is somewhat less well understood (Camahan and 
Redinbo, 2005). Common co-repressor complexes SMRT and NCoR have been tested in 
vitro and both complexes were shown to bind to PXR to gieater or lesser extents in a 
ligand dependent manner (Synold et a l, 2001). Other work has been done using the 
repression of CYP3A4 as a model for suppression of PXR activity by SMRT and NCoR 
although the results are not clear and in some instances are contradictory (Takeshita et al, 
2002, Zhou et a l, 2004, Camahan and Redinbo, 2005).
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1.6.5 Co-ordinated regulation of Xeno- and Endo-biotic metabolism by the nuclear 
receptor PXR (NR1I2)
The detoxification of compounds in the liver, which is the best characterized fimction of 
PXR, is a multistage process. As discussed previously, compounds must enter the 
hepatocyte across the plasma membrane before metabolism may begin. Metabolism 
itself is a multistep process often requiring rounds of hydroxylation by a series of 
cytochrome P450 enzymes with differing substrate specificities, followed by the addition 
of large hydrophihc groups such as the tripeptide glutathione or a glucuronic acid. Post 
hydroxylation/conjugation, the compound is removed fi*om the hepatocytes into the 
billiary cannaliculus or into the blood for removal by glomemlar filtration. All of these 
processes are regulated in some part by the transcriptional activities of PXR and are 
discussed in more detail below (Gibson, 2001, Plant, 2003).
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ADME genes known to be
Phase I: regulated by PXR within the Phase II:
CYP3A(4, 1, II) Hepatocyte UGTlAl,
CYP2C9,CYP2B6, GST m2, GSTo2,
CYP7A1 SULT2A1
L
Hepatocyte
Influx Transporters: 
OATPlBl,OATPlB3,
EffluxTransporters : 
ABCB1,ABCC2, 
ABCC3,ABCC4, 
BSEP
Figure 1.5: The ADME genes known to be regulated by PXR within the Hepatocyte.
A Cartoon representation of the hepatocyte and the known influx, metabolism and efflux 
proteins which are regulated at the transcriptional level by PXR. A compound would enter 
through the influx transporter seen to the left highlighted in blue, metabolism via phase I 
enzymes shown in light blue often proceeds to phase II conjugation shown in brown and 
finally efflux into the blood or bile via the transporters to the right hand side shown in red. 
Information was assembled from the references in the text following this diagram.
The initiation of ADME starts with the uptake of compounds by transporters. OATPIBI 
and 1B3 are expressed in hepatocytes and are located basolaterally (Jigorel et al., 2006). 
They regulate the sodium dependent uptake of organic anions into the cell. OATPIBI 
has a very broad substrate specificity being responsible for the sodium independent 
uptake of conjugated and naive bile acids, bilirubin and its metabolites, prostagaldins, 
thromboxanes and leukotrienes (Jigorel et al., 2006, Kullak-Ublick et al., 2004, Guo et
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al., 2002b). OATP 1B3 has a greater substrate specificity being responsible for sodium 
independent uptake of conjugated bile acids, billimbin and some hormones such as 
estradiol conjugates and tliyi'oid hoimone (Kullak-Ublick et al., 2004, Jigorel et al., 2006, 
Guo et al., 2002b). Using the agonists PCN and atoivastatin PXR has been shown to 
regulate the expression o f these proteins in several studies (Jigorel et al., 2006, Guo et al., 
2002b).
Phase I metabolism is involves the hydroxylation of compounds by the cytochrome P450 
enzymes (CYPs); CYP3A4 is the most abundant CYP in the human liver and is of 
particular importance as it has a wide substrate specificity metabolizing up to 50% of 
prescribed phamiaceuticals (Cholerton et al., 1992, Wrighton et al., 1996). The 
expression of CYP3A4 is heavily regulated by PXR (Bertilsson et al., 1998, Lehmann et 
al., 1998) which is demonstrated by transcriptional up-regulation in the presence of 
rifampicin and hyperforin (Luo et al., 2002, Pascussi et al., 2005); there us also 
correlation between the expression of CYP3A4 and PXR (Westlind-Johnsson et al.,
2003).
CYP2C9 is the second most highly expressed CYP in human liver, and like PXR contains 
a wide substrate specificity, being estimated to be responsible for the metabolism of 16% 
of prescribed compounds (Miners and Birkett, 1998, Chen et al., 2004). PXR has been 
shown to be one of the major regulating transcription factors (Gerbal-Chaloin et al.,
2001) with expression being mediated by many compounds including rifampicin and 
hyperforin (Gerbal-Chaloin et al., 2001, Yeh et al., 2006). CYP2B6 is expressed in the 
liver, kidney, brain, lung and small intestine (Gervot et al., 1999). As an enzyme it is 
responsible for metabolizing the hydroxylation of a range o f compound including 
cyclosporine and efavirenz (Urquhart et al., 2007). PXR was shown to directly increase 
the expression of CYP2B6 (Chang et al., 2003), being induced by rifampicin and 
hyperforin (Wang et al., 2003). CYP7A1 is the primary rate limiting enzyme in the 
neutral synthesis pathway of cholic and chenodeoxycholic acids (CA and CDCA 
respectively) fiom cholesterol (Goodwin et al., 2000, Chiang, 1998). CYP7A1 is found 
in the liver attached to the endoplasmic reticulum of the hepatocytes (Schwarz et al.,
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1997). PCN and many other PXR ligands have been shown to repress transcription of 
CYP7A1 in a PXR dependent manner (Li et al., 1990, Staudinger et al., 2001b).
Phase 11 metabolism is concerned with the post hydroxylation addition of a more 
hydrophilic chemical moieties, namely glutathione, glucuronic acid and sulphate groups. 
The UDP gycosyltrasnferuses (UGT) ar e a family of enzymes catalyzing the addition of a 
glucuronic acid group to an hydroxyl group thus increasing the overall hydrophillicity of 
the compound and making urinary and billiary excretion easier (Urquhart et al., 2007). 
UGTlAl is found in the liver, small intestine, colon, stomach and bile duct (Tukey and 
Strassburg, 2000) and is responsible for the glircuronidation of a range of compounds 
including heme, billimbin, steroids and steroid homones (Urquhart et al., 2007). The 
expression level of UGTlAl has been shown to be regulated by PXR as demonstrated by 
the induction of this gene by treatment with rifampicin (Gardner-Stephen et a l, 2004, 
Chen et a l, 2003). The glutathione S transferases are a family o f enzymes which mediate 
the addition of a molecule of the tripeptide (Glu-Cys-Gly) glutathione to an hydroxyl 
group (Urquhart et a l, 2007). The GSTs are divided into subfamilies depending on the 
amino acid sequence, these are a, p, co, t z  (Urquhart et al, 2007). PXR has been shown 
to upregulate GSTs of the a and p families, in particular o2 and p2 (Falkner et a l, 2001, 
Gong et a l, 2006, Hartley et a l, 2004, Slatter et a l, 2006a, Guzelian et a l, 2006). The 
sulphotransferases (SULTs) catalyse the addition of sulphate groups to a range of 
compounds, some of which are already glucuronidated or glutafliiolated (Urquhart et al, 
2007). PXR has been shown to regulate the expression of SULT2A1 
(dehydroepiadrosterone sulphotransferase) when treated witli rifamicin (Duanmu et al, 
2002, Sonoda et a l, 2002).
The end result of metabolism is a need to remove the altered chemical stmctures from the 
cell. The transporter ABCCl (MRPl) is expressed widely in the body, chenington et al 
demonstrated that PXR and CAR ligands induce the expression of this transporter in rats 
(Albermann et al, 2005, Cherrington et a l, 2002). . ABCC2 (MRP2) is known to be 
expressed at the apical surface of the hepatocytes and in several other tissues (Albermann 
et a l, 2005, Cherrington et a l, 2002). It is responsible for the ATP dependent transport
of conjugated bile acids and conjugated xenobiotics. The expression of MRP2 was found 
to be modulated by both PCN and rifampicin in different systems (Kast et al., 2002), 
ABCC3 is expressed basolaterally in hepatocytes and is responsible for the efflux of 
conjugated and naive bile acids and conjugated xenobiotics from the cell (Albemiann et 
al., 2005, Jigorel et al., 2006). The expression o f ABCC3 was shown to be regulated by 
PXR in cultured human hepatocytes and in the hepatoma cell lines Huh? and HepG2, and 
was regulated in rats by administration of the PXR ligand PCN (Rius et al, 2003, 
Eloranta and Kullak-Ublick, 2005, Staudinger et a l, 2003). ABCC4 is located on the 
basolateral surface of hepatocytes and is capable o f effluxing a host o f compounds 
including cyclic nucleotides and sulphated bile conjugates (Rius et a l, 2003). The bile 
salt export polypeptide (BSEP) is located on the apical surface of hepatocytes and is 
responsible for exporting primary bile salts into the cannaliculus. Expression of this 
protein was shown to be via PXR in mice in response to PCN administration (Schiietz et 
a l, 2001).
Overall PXR is responsible, in some part, for regulating tire metabolism of a gr eat many 
xeno- and endo- biotics and in some cases, such as for lithocholic acid where PXR 
directly regulates all stages of its uptake, metabolism and disposition (Bock and Kohle,
2004)
1.7 NR1H4; The Farnesoid X receptor (FXR)
1.7.1 Tissue distribution, expression and ligand specificity
FXR is found abundantly in flie liver, gut and kidney, showing a distribution strongly 
correlating to those tissues exposed to bile acids. Inducement of cholestasis is a common 
side effect of compormds not entering the drug market and is a chief cause of premature 
withdrawal of a test compoimd. It can also be induced by several endogenous 
compounds such as oestrogen and tliis can be can be reversed by FXR specific ligands 
such as 6-ECDCA and GW4064 (Liu et a l, 2003).
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There are four FXR isoforms created from differential splicing of the mRNA. These 
differ in their ligand specificity and ability to activate the genes commonly known to be 
regulated by FXR. This is characterized by expression of fibrinogen by FXR. When 
activated by bile acids over-expressed FXR a2 and a4, which lack a 4 amino acid insert, 
activated expression of fibrinogen mRNA whereas FXR a l and a3 over-expression had 
no effect on fibrinogen expression (Anisfeld et al., 2005).
The farnesoid X receptor (FXR) shows affinity and efficacy for many endogenous bile 
acids, the most potent being CDCA followed by DCA, CA and UDCA. While LCA is a 
weak agonist at this receptor, its presence at significant concenfrations can strongly 
antagonize the effects of CDCA and DCA (Makishima et al., 1999, Redinger, 2003, 
Eloranta and Kullak-Ublick, 2005, Lew et al., 2004, Yu et al., 2002).
1.7.2 FXR Co-regulators
Knowledge o f the protein co-regulators of FXR, like PXR, is limited. In vitro, ligand 
stimulated binding of FXR to SRCl has been shown, but in vivo studies isolating the 
protein co-regulators have yet to produce results.
DRIP205, a member of the vitamin D receptor and thyroid receptor associated protein co­
activator complexes have been shown to activate FXR in a ligand dependant manner 
causing binding to a FXR response element in reporter gene constracts. Inconclusive in 
itself this information requires further study before a definitive interaction can be shown 
(Wu et al., 2002, Rachez and Freedman, 2001, Pineda Toira et al., 2004).
The peroxisome prolifeatror-activated receptor-y co-activator-1 (PGC-1) has been shown, 
in different studies, to interact in a ligand-independent and ligand dependant manner. 
Whereas some reports have shown PGC-1 to interact in a ligand-independent manner 
with the DNA binding domain of FXR, it has also been shown to be a ligand recruited co­
activator of this receptor; further experimentation is required to clarify this issue. The 
evidence for both is inconclusive and further proteomics information would be required 
from in-vivo co-activator complexes before this can be resolved (Kanaya et al., 2004, Wu 
et al., 2002, Zhang et al., 2004b).
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BafôOc is a subunit of the SWI/SNF transcription complex, and has been shown to 
interact with FXR. It is speculated, although not concluded, that it is through interaction 
with this protein that FXR recmits the chromatin remodelling complex to the genes that it 
regulates (Debril et al., 2004).
CARMl is a co-regulator that has been demonstrated to be activated by CDCA activation 
of FXR, the méthylation of lysine 9 of histone H3 enables higher binding rates of FXR to 
the promoter sequence of the DNA in the expression of BSEP (Ananthanarayanan et al., 
2004).
Ligand activation of FXR has also indicated the binding or SRCl, a member of the pl60 
family o f co-regulators (Lew et al., 2004, Makishima et al., 1999).
SHP or the Small Heterodimeric Partner (NR0B2)is a nuclear receptor that does not 
possess DBD and negatively regulates the expression of many genes in concert with the 
activation of FXR, and to some smaller extent PXR, as these increase the expression level 
of this protein. SHP acts to prevent DNA binding of the target nuclear receptors and 
downregulating their expressed genes. It is described as an FXR co-regulator protein 
although many of its actions are through binding to other nuclear receptors such as 
HNF4a (Hepatocyte nuclear factor 4a), which then impact upon FXR action (Guo et al., 
2003, Ourlin et al., 2003, Bae et al., 2004, Eloranta and Kullak-Ublick, 2005).
1.7.3 FXR gene regulation
The activities of FXR are only well understood as regards the genes concerning the 
regulation of bile flow and to some extent bile and xenobiotic metabolism (Lee et al.,
2006), FXR is known to regulate the expression o f up to 50 genes in the various tissues in 
which it is expressed (Lee et al., 2006). FXR activates transcription as an obligate 
heterodimer with RXR in all cases bar one, the activation of the uridine 5 ’-diphosphate- 
glucuronyltransferase 2B4 (UGT2B4) gene. The preferred DNA binding motif for the 
FXR-RXR dimer is an IRl element (an inverted repeat of AGGTCA), although binding 
has been shown to DR3 and DR4 motifs (Huber et al., 2002).
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Wlien activated by bile acids, FXR can activate transcription of BSEP (ABCBll) an 
ABC (ATP binding cassette) transmembrane transport protein. In this way increased bile 
acid accumulation in the hepatocyte leads to its own excretion into bile, reducing the 
intracellular hepatocyte concentration (Sinai et al., 2000, Redinger, 2003, 
Ananthanarayanan et al., 2001, Plass et al., 2002).
MDR3 (ABCB4) is another ABC membrane transport protein, specializing in the 
transport of phospholipids and cholesterol, namely phosphatidylcholine. This transporter 
is expressed basolaterally and is used to negate the cytotoxic effects of the detergent bile 
acids by binding them in micelles o f cholesterol and phospholipids (Fitzgerald et al., 
2002).
The Illeal bile acid binding protein (I-BABP) has been shown to be upregulated by FXR 
when activated by bile acids and is a small protein which is expressed in the cytosol of 
enterocytes, binding to absoibed bile acids with a veiy high affinity. Once bound to bile 
acids I-BABP aids in the routing of these bile acids through to the basolateral membrane 
of the enterocyte, where they aie removed by export proteins into the portal blood 
system. I-BABP may be part of a system which may have evolved to make the 
enterohepatic recirculation of bile acids more efficient (Sinai et al., 2000, Redinger, 
2003).
UGT2B4 is the enzyme that detoxifies the hydrophobic primary bile acids into more 
hydrophilic glucuronyl adducts. The activation o f this gene is the only known case in 
which FXR binds as a monomer to DNA (Barbier et al., 2003).
Bat and Bacs (Bile acid-CoA Synthetase and Bile acid-CoA:amino acids n- 
acetyltransferase respectively) are two enzymes up-regulated by bile acid-activated FXR; 
like UGT2B4 these enzymes modify the lipophillic bile acids, reducing their toxicity 
(Redinger, 2003, Makishima et al., 1999, Goodwin and Kliewer, 2002). These enzymes 
convert the primary bile acids into taurine and glycine conjugates, which in human bile 
represent the majority of bile acids present (Makishima et al., 1999). This conjugation 
plays an important role in dietary lipid absorption with an increase in conjuageted bile 
acids giving a greater rate of clearance of absorbed fats. An increase in the level of
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conjugation of the total bile pool within a cell leads to an increase in the rate of removal 
of bile salts through BSEP as this transporter is specific for conjugated bile salts (Byrne 
et al., 2002). High levels of LCA have been shown to down-regulate the e?qpression of 
BSEP by a ligand-dependant and FXR-mediated mechanism (Yu et al., 2002, Rizzo et al., 
2005, Beilke et al., 2007). This is through antagonism of FXR when LCA is at 
concentrations high enough to compete for the FXR ligand binding site (Yu et al., 2002, 
Rizzo et al., 2005, Beilke et al., 2007). It has been shown that the binding of LCA does 
not lead to co-regulator binding, and indeed actively prevents co-activator binding. 
These findings are somewhat counter-intuitive given that FXR is generally considered a 
hepatoprotective nuclear receptor, and hence its expected role would be to eliminate toxic 
bile acids fiom the cell, and more works needs to be undertake to examine this 
phenomenon (Yu et al., 2002).
OATPIB3 is an organic anion transport protein shown to be up-regulated by 
FXR(Urquhart et al., 2007, Kullak-Ublick et al., 2004). 0AT1B3 is a basolaterally 
expressed membrane protein, transporting a range xenobiotics and peptides, including 
bile acids into the cell, although the comparative contribution of bile acid uptake by this 
channel is less than other members of its family (Urquhart et al., 2007, Kullak-Ublick et 
al., 2004). OATPIBI, a channel with high affinity for bile acids is suppressed by FXR 
activation, and perhaps the expression of OATP1B3 is to partially maintain hepatic 
clearance of xenobiotics in times of raised bile acid concentration (Urquhart et al., 2007, 
Kullak-Ublick et al., 2004).
NTCP (Sodium taurocholate cotranspoiting polypeptide) is involved in the transport of 
80% of the conjugated bile acids that are subject to enterohepatic circulation across the 
basolateral membrane of the hepatocyte. Models of choleostasis have found that the 
mRNA levels of this protein are suppressed by bile acids, but not through direct 
interaction of FXR (Goodwin and Kliewer, 2002, Kullak-Ublick et al., 2004). When 
activated by bile acids, FXR up-regulates SHP, which is capable of interfering with the 
binding of many nuclear receptors, including the RAR-RXR heterodimer responsible for 
regulating expression of NTCP (Goodwin et al., 2000). Whereas this mechanism is not 
conserved between rodents and humans there is evidence that HNF4a homodimer
association with the NTCP promoter in humans is dismpted by SHP binding, supporting 
the role o f SHP in influencing NTCP expression (Kullak-Ublick et al., 2004, Goodwin 
and Kliewer, 2002).
1.8 N R lIl; the Vitamin D receptor (VDR)
1.8.1 Tissue distribution, expression and ligand selectivity
Expression patterns of VDR have been characterised in several species and are generally 
found in cell lines including the breast cell line T74D, and the intestinal tumour line 
ATCC 407 and HL60 (Baker et al., 1988). VDR expression has been found in pre 
adipocytes, in the skin kératinocytes (Li et al., 1999, Li et al., 1997b), in osteocytes, 
osteoblasts and osteoclatsts (Cao et al., 1993, Medhora et al., 1993), and in dental tissues 
(Davideau et al., 1996).
There are three splice variants of VDR originating flom the alternative splicing of exons 
found at the 5’ portion of the gene generating three N terminal variants (Crofts et al., 
1998) in humans. Within the cell GFP tagged VDR was seen largely in the nucleus but 
with a significant cytosolic presence, which was diminished on addition of agonist 
(Michigami et al., 1999)
As with other receptors the binding of ligand alters the structure of the LBD to reposition 
helix 12 containing the AF2 functional domain, the repositioning o f helix 12 allows 
several things. Initially the AF2 domain mediates the interaction between the VDR and 
microtubules, with some evidence that this leads to binding of the motor protein dynein 
which manages retrograde transport along the microtubules, leading to the nuclear 
translocation of the receptor by moving towards the nucleus (Barsony and McKoy, 1992).
1.8.2 Structural considerations
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The crystal stmcture of VDR has proved difficult to elucidate in its entirety; however, the 
stmcture of the ligand binding domain has been resolved (Rochel et al., 2000). The LBD 
of VDR contains a peptide loop (residues 165 to 215) that has no known function, or 
similarity to otlier nuclear receptor domains, and it is speculated that it is the variability in 
this area which makes the entire crystal stmcture of VDR difficult to obtain. As with 
most other nuclear receptors the LBD of VDR is located in the C terminus of the 
proteins, and binds it cognate ligand, 1,25 diliydroxy vitamin D3, with a Kd of 10"^ ° M 
and 24-25 dihydroxy vitamin D3 with approximately 100 times less specificity 
(Bmmbaugh and Haussier, 1974, Mellon and DeLuca, 1979). It is important to note that 
ligand specificity of VDR is not the sole predictor of transcriptional response to ligand 
presence as there are intracellular proteins which bind vitamin D and its metabolites and 
regulate their; hence the free concentration of ligand may be substantially less than the 
absolute concentration. For example, the intracellular vitamin D binding protein 
modulates the movement of vitamin D through the cell and its availability to its receptor 
(Nykjaer et al., 1999, Koike et al., 1998).
The VDR DBD consists of two zinc finger motifs, as for all receptors, and ligand 
activation leads to binding to the VDR response elements the most common of which is 
the DR3 response element of the bases AGGTCA (Haussier et al., 1998), a secondaiy 
response element in the fonn of the inverted palindrome 9 (IP9) is also found occupied 
by VDR (Schrader et al., 1997), although the usage of this element is not fully 
understood. On binding to the DNA the VDR RXR heterodimer twists the DNA by 55° 
and it is suggested that this helps to facilitate access by the general transcription factors 
and the initiation complex to the DNA (Strugnell and Deluca, 1997). The binding of 
VDR to its response elements appears to alter its binding orientation and repress or 
induce expression of the gene. To repress the expression of the target gene the VDR 
binds to the 5 ’ response element half site and RXR to the 3 ’ half site, whereas to induce 
the target gene the VDR must bind to the 3 ’ half site and RXR to the 5’ (Haussier et al.,
1998). It is also possible for VDR to bind to DNA as a homodimer at a DR3 response 
element o f sequence GGTTCA, as seen for the osteopontin gene (Freedman and Towers, 
1991).
1.8.3 Interactions with co-regulators
The interactions of the VDR with co-activator complexes are not well understood but it 
has been shown that the site of interaction involves contributions from the LBD of both 
VDR and RXR. Mutation of the site of interaction at residue 246 of VDR has been 
shown to reduce tlie capacity of the receptor to bind to its co-regulators (Carlberg, 2004). 
The AF2 domain, located in the very C tenninal portion of the LBD and in helix 12, 
undergoes a conformational change allowing the binding of the co-activator complexes 
and subsequent recruitment of the general transcription factors and the preinitiation 
complex (Dusso et al., 2005).
It has been shown that VDR interacts with the co-activators SCRl and with the 
DRIP/TRAP complex. Drip205 interacts directly with the VDR ligand binding domain. 
The DRIP/TRAP complex is thought to bridge the receptor and co-activator complex and 
the basal transcription factors (Jumtka et al., 2001, Rachez and Freedman, 2000). 
VDR has also been shown to bind to the histone deacetylase co-repressor which leads to 
a condensation of the chromatin and a decrease in the accessibility to Pol II (Jurutka et 
al., 2001, Rachez and Freedman, 2000). VDR recruits a co-modulator protein known as 
NCoA62/Skip which is referred to as a co-modulator as it can botii suppress and repress 
DNA binding of the receptor (Leong et al., 2004), both the co-activator protein 
p300/CBP and the co-repressor s NCoR and SMRT have been shown to bind to the N 
terminus of NCoA62/Skip (Leong et al., 2004). The binding choice of NCoA62/Skip for 
the CO-activator or co-repressor complex seems dependent on the relative availability of 
the complexes in the cell this suggests that NCoA62/Skip does not have a binding 
preference for either co-repressor or co-activator (Leong et al., 2004). It has also been 
shown that the NCoA62/Skip complex mediates a linkage between the receptor and 
members of the spliceasome complex, responsible for the splicing of immature pre 
mRNA providing a physical link between the two complexes (Zhang et al., 2003).
VDR has been shown to interact with several basal transcription factors including TFIIB 
and the TBP associated factor TAFn55 (Gill et al., 1998, Lavigne et al., 1999). In
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separate studies the binding of VDR to the common co-activating proteins SRCl and 
TIF2 were shown to be recruited in a ligand dependent manner (Gill et al., 1998, Castillo 
et al., 1999, Lavigne et al., 1999). The binding of SRCl to VDR enables an interaction 
with Smad 3 which is a member of the transforming growth factor (TFG) p signalling 
cascade, its binding to the VDR complex acts as a co-activator of VDR and a point of 
cross talk between the signalling pathways. The direct interaction between VDR and the 
co-repressor s NCoR and SMRT are weak,which correlates with evidence suggesting that 
VDR exhibits only a weak repressive effect when in the apo (naive) form (Tagami et al., 
1998).
1.8.5 VDR gene activation
VDR has very broad transcriptional effects, with the exact tianscriptome response being 
determined by the tissue environment that is being activated, hi the intestines VDR 
enhances the efficiency of the absorption of dietary calcium and phosphate (Li et al.,
1998). To achieve this it increases the expression of the calcium channels TRPV6 and 
TRPV5 and the intracellular calcium transport protein calbindin D (Bouillon et al., 2003). 
In the bone, VDR regulates the size and function o f osteoclatsts, the cells responsible for 
the resorption of bone to increase the serum calcium concentration, and VDR knockouts 
have been shown to have reduced size and hmctionality in these cells (Takeda et al.,
1999). hr the parathyroid gland VDR has been shown to directly up-regulate the 
expression of the parathyroid hormone gene (Dusso et al., 2005). In the kidney VDR has 
been shown to decrease the expression of the calcium channel TRVP5 and hence the 
excretion of calcium by the kidney (Hoenderop et al., 2001), VDR has also been shown 
to have activity in arresting cell growth and in cancerous cells prevents growth in the GO- 
G1 transition by indicating expression of the cyclin dependent kinase inhibitors p21 (liu 
1996) and p27 (li 2004). On a more general level activation of VDR has been shown to 
lead to the sequestration of vitamin D in the early endosomes for degredation (Cordero et 
al., 2002) and also the expression of the intracellular transport protein calbindin 
(Christakos et al., 1979), together these result in a self limiting effect for vitamin D 
concentration within the cell (Dusso et al., 2005).
1.9 NR1I3; the constituitive androstane receptor (CAR)
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1.9.1 Tissue distribution, expression and ligand selectivity
CAR was originally identified, and termed constituitive, as it was found to be a binding 
partner to RXR and cause binding a transcription of some genes containing a retinoic acid 
response element in the absence of any ligand (Honkakoski and Negishi, 1998). Two 
isofoims of CAR have been identified, certainly in mice, and have been termed CARa 
and CARp (Baes et al., 1994, Choi et al., 1997). The response element for CAR is 
variable and has been shown for CYP2B6 to be a DR 5 response element (Baes et al., 
1994, Choi et al., 1997), but has also been shown to bind a DR3 response element 
(Honkakoski and Negishi, 1998, Sueyoshi et al., 1999) and for CYP 3A4 it bind to an 
everted repeat 6 (ER6) (Sueyoshi et al., 1999)
CAR expression is detected primarily in the liver, with lower levels in the kidney, heart 
and small intestine (Sueyoshi and Negishi, 2001, Swales et al., 2005). The CAR 
Phénobarbital response element had been shown to be a direct repeat 4 (Timsit and 
Negishi, 2007), i.e. the binding sequence runs in the same direction with the two 
sequences separated by(Kullak-Ublick et al., 2004) 4 bases. The phénobarbital induced 
activation of CAR involves the dissociation of the regulatory proteins which chaperon the 
receptor while cytosolic; cytoplasmic CAR retention protein (CCRP) and the heat shock 
protein chaperone hsp90. Once dissociated it was shown that CAR translocated to the 
nucleus (Koike et al., 2005).
1.9.2 Function with a difference and structural considerations
The mechanism of activation of CAR is somewhat unusual owing to the constitutively 
active nature of the receptor (Timsit and Negishi, 2007). CAR resides primarily in the 
cytoplasm when in the absence of ligand and upon addition of the activators 
phénobarbital it has been shown to translocate almost immediately to the nucleus 
(Kawamoto et al., 1999). This effect has been obseived in the HepG2 cell line with 
treatment of the agonist TCPOBOP (Kawamoto et al., 1999). Further investigation into 
the binding of CAR ligands has revealed that many, inclusing Phénobarbital, do not 
actually bind the receptor but displace an inhibitory androstance molecule (Swales and
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Negishi, 2004). The addition of okadaic acid to hepatocytes had opposite effect to that of 
TCPOBOP with this compound having a seemingly antagonistic effect on CAR. The 
antagonism of CAR with okadaic acid caused a reduction in the expression CYP2B6 and 
in increase in the translocation o f CAR to the cytoplasm and retention in the cytosol 
(Honkakoski and Negishi, 2000, Honkakoski and Negishi, 1998). The translocation 
mechanism of CAR is shown to be independent of the activation via the AF2 domain, as 
are the activation mechanisms of many other receptors. It seems to be dependent on a 30 
amino acids motif located in the C terminal region and is known as the xenobiotic 
response sequence (XRS) (Zelko et al., 2001).
When bound to a ligand helix 12 of the ligand binding domain assumes an active 
position, exposing the LXXLL motif to which co-activator proteins bind. Studies of the 
CAR LBD show that there is a short a helical turn consisting of 4 residues between helix 
ten and the AF2 containing helix 12 (Xu et al., 2004). This short insert of 4 amino acids 
constrains the normally fluid movement of helix 12 which leaves the LXXLL motif 
almost permanently in the active position and allows for the binding of RXR. This 
constitutive binding of RXR is enhanced by the interaction between the AF2 domain and 
helix 4 of the LBD (Xu et al., 2004). The CAR ligand binding domain has been found to 
be approximately 875 cubic angstroms which is a little smaller than that of PXR which 
ranges from 1200 to 1600 cubic angstroms, dependent upon the occupying chemical 
(Willson and Kliewer, 2002). For most receptors ligand binding depends on a number of 
hydrogen bonds between the ligand and the residues of the LBD (Brzozowski et al., 
1997, Tanenbaum et al., 1998), whereas CAR relies on a single hydrogen bond for 
ligand activation in at least some cases (Xu et al., 2004). Uniquely the ligand binding 
pocket of CAR has a physical barrier across its width, consisting of a loop of amino 
acids and prevents many molecules foim binding to the receptor, however the agonist 
ligand TCPOBOP was shown to penetrate this barrier and may allow the formation of 
further hydrogen bonds strengthening the interaction and activation of the receptor (Suino 
et al., 2004).
1.9.3 Interactions with co-regulators
Knowledge of the binding partners of CAR is limited, with the co-activator and co­
repressor complexes not well resolved. However, it has been shown that CAR binds tlie 
PPAR co-regulator la  (PGC-1 a) as well as the co-activators GRlPl, T1F2, and SRCl 
(Choi et al., 2005, Kim et al., 1998, Min et al., 2002, Muangmoonchai et al., 2001, 
Shiraki et al., 2003). CCRP and hsp90 (mentioned previously) have been found in 
complex together bound to CAR, acting as the mechanism of cytoplasmic retention 
(Kobayashi et al., 2003): Over-expression of the CCRP in HepG2 cells caused the 
sequestration of CAR in the cytoplasm (Kobayashi et al., 2003, Timsit and Negishi,
2007). Protein phosphatise 2A (PP2A) has also been found associated to the CCRP and 
hsp90, and hence may be part of the CAR-CCRP-hsp90 complex. PP2A catalyses the 
phosphoiylation of serine 202 of CCRP, resulting in the retention of CAR in the nucleus 
(Yoshinari et al., 2003, Hosseinpour et al., 2006). Overexpression of PP2A has been 
shown to enhance the nuclear translocation of CAR caused by addition of the agonist 
TCPOBOP in HepG2 cells (Timsit and Negishi, 2007). The GR interacting protein 1 
(GRIP 1) has been shown to bind to the XRS of CAR and assist in the nuclear 
translocation and accumulation of the receptor (Min et al., 2002). GRlPl has dual 
functionality towards CAR; while noimally viewed as a nuclear receptor co-activating 
protein, GRlPl both assists in the mechanism of nuclear translocation and actvation for 
CAR, causing an increase in the expression of CYP2B6 (Min et al., 2002, Hosseinpour et 
al., 2006). CAR has been shown to induce the expression of the important dmg 
metabolizing proteins, CYP3A11, MRP3 and SULT 2A1 (Zhang et a l, 2004a). When in 
the apo form CAR has been shown to bind to the co-activator SRCl and represents a 
constitutive co-activator activity at the receptor
1.10 Hypothesis
The nuclear receptor PXR is an integral cog in the organization of the response to a toxic 
event. Nuclear receptors, such as PXR, are regulated by ligand binding and co-regulator 
recruitment. It is not clear from the literature to what extent these two sources of 
regulation affect each other and interplay. The hypothesis which this thesis attempts to 
answer is that the ligand directs the recruitment of the co-regulator complex, which in 
turn direct the genes which are to be regulated.
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1.11 Aims and Objectives
To identify the co-regulator complexes of the nuclear receptor PXR 
(NR 112) by development of an immunoprécipitation method to isolate 
endogenous protein complexes containing PXR using native levels of 
protein.
Determination of the most effective method for the identification of those 
proteins complexes once isolated by immunoprécipitation. Followed by 
use o f a qualitative/semi quantitative assay to validate the invitro 
interaction between the proteins identified from the immunoprecipitate.
To address the concept that different ligands cause differential gene set 
expression by PXR using gene aiTay and QPCR technology on PCN and 
LCA treatments.
Statistical and pathway analysis o f the total gene changes to identify 
common and different patterns o f gene expression between the two 
ligands.
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Chapter 2: Materials and Methods
2.1 Materials
Table 2.1 shows a list of materials used during this project and tlie suppliers from whom 
the materials were obtained. Any other chemicals were obtained from Sigma Aldrich 
Poole, UK.
PXR primary antibodies goat (Sc7737) and 
rabbit( Sc25381), secondary antibodies anti 
goat (sc2304) and anti rabbit (sc230I)
Santa Cruz Biotech, Santa Cmz USA 
through Autogen Bioclear, UK
Protein A beads and general laboratory 
chemicals
Sigma-Aldrich Company Ltd. Poole, UK
2D gel zoom apparatus Invitrogen Ltd, Paisley, UK
Dulbeccos modified eagle medium 
Trypsin EDTA 
Penicillin Streptomycin 
MEM non essential amino acids 
Fetal Bovine semm
Gibco, a subsidiaiy of Invitiogen Ltd, 
Paisley, UK
dNTPs
cDNA synthesis reagents
Invitrogen Ltd, Paisley, UK
Tiyptone 
Yeast extract 
Bacterial agar
Phosphate buffered saline (PBS) tablets
Oxoid, Basingstoke, UK
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DNA modifying enzymes (Ligase, 
phosphatase)
Taq DNA polymerase
Pro mega UK, Southampton, UK
Min Elute gel extraction kit (28604) 
Qiaprep Spin miniprep kit (27106) 
Endofree Plasmid Maxi prep kit (12362) 
RNeasy mini RNA extraction kit (74104)
Qiagen, Crawley UK
Gene array fii-st and second strand cDNA 
synthesis kit
Gene aiTay cRNA labeling and synthesis 
kits
Affymetrix 2.0 Rat genome gene chips
Affymetrix, UK
PCR primers
RTQPCR Primers and probes
MWG, Milton Keynes, UK
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2.2 Methods
2.2.1 Primary hepatocyte cell culture
2.2.1.1 Routine hepatocyte culture
Media recipies are located in appendix one
Primaiy Rat hepatocytes (Sprague Dawley) were purchased from Dominion Phaimakine 
Barcelona and delivered in cold storage transport medium. Cells were pelleted at 60 xg 
for 3 minutes; the medium was replaced with 10 ml of 4 °C growth medium. Cell 
number and viability were checked by tiypan blue exclusion, witli routine viablilty 
exceeding 70 % viable. Cells were diluted to approximately 1 million live cells per ml in 
cold growth medium.
Six well plates or 25 cm^ culture flasks were pre-coated with a 1:45 dilution of bovine 
collagen in sterile PBS and incubated for 24 hours at 4 °C after which the surfece was 
washed with sterile PBS. One ml of diluted cells was added to one ml o f cold growth 
medium per well o f a six well plate; 2.5 ml of diluted cells were added to 2.5 ml of cold 
gi'owth medium per 25 cm^ flask. After 3 hours at 37 °C tlie culture medium was 
replaced with fresh medium and cells were incubated overnight at 37 °C.
Growth medium was changed for medium containing a 1:45 dilution of bovine collagen 
which was incubated for 24 hours at 37 °C forming a sandwich of collagen matrix. 
Medium was then changed eveiy 24 hours for a maximum of 5 days.
2.2.1.2 Measurment of MRP2 activity by CDFDA
To ensure the development of an intact biliary system, marked by the formation of bile 
cannaliculi at the juncture between adjacent cells, a marker of MRP2 activity, CDFDA 
was used. MRP2 only correctly localizes following cannaliculus formation and hence 
export of the hydrolysis product of CDFDA, the flourophore CDF, can be used to 
visualize canaliculi foimation.
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Growth medium was aspirated, replaced with 2.5 ml Hands buffered saline solution 
(HBSS) and incubated for 10 minutes at 37 °C. HBSS was replaced with 2.5 ml 37 °C 
HBSS containing 10 uM CDFDA and incubated at 37 °C for 30 minutes. Cells were 
washed twice with 37 °C HBSS with a thin layer of HBSS left on the cells. Following 
this incubation CDF export was visualized using a confocal fluorescence microscope 
with a FffC  filter, which operates between 480 and 520 nm. Hepatocyte cultures were 
only progressed fiirther is CDFDA analysis verified the presence of correct cannalicular 
foimation.
2.2.1.2Cell exposure to chemicals
In all cases compounds were made as stock solutions of lOOOx concentration in DMSO. 
A 1:1000 dilution into growth medium gave the working concentiation of compound, 
while ensuring that vehicle concentration did not rise to high, being 0.1%.
2.2.2 Huh? Cell culture
2.2.2.1 Recovery from liquid nitrogen
Media recpies located in appendix 1.
Huh7 are a human hepatoblastoma cell line derived fiom a 57-year old Japanese male 
(REF) and were a kind gift of Dr Steve Hood (Dmg Metabolism and Pharmacokinetics, 
GlaxoSmithKline, Ware, UK). Cells were stored in liquid nitrogen in a mixture of 90% 
FBS and 10% DMSO at a concentration of approximately 1x10'  ^ cells/ml. Cells were 
removed firom the fi*eezer and allowed to thaw at a 37 °C for 15 minutes. The cells were 
added to the 9 ml of warm medium in the culture flask and incubated overnight. After 24 
hours the medium was aspirated fi*om the surface of the cells, the surface washed with 5 
ml of sterile PBS, which was aspirated and replaced with 10 ml of fi’esh DMEM.
2.2.2.2 Continuous culture
When the cells had become 85-95 % confluent, medium was aspirated fi*om the cell 
surface, which was washed with 5 ml of warm sterile PBS. Two ml trypsin EDTA was
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pipetted into the flask agitated and placed in the incubator for up to 5 minutes. To ensure 
removal of cells from the culture surface the flask was agitated and 5 ml of DMEM was 
added to the flask. This was agitated with a pipette and 5 ml was added to a T75 culture 
flask (75 cm^ culture area) the volume of medium was made equal to 15 ml using fresh 
37 °C medium. The cells were allowed 24 hours to attach before replacement of 
medium.
2.2.3 Immunoprécipitation methods
2.2.3.1Tuxworth Immunoprécipitation
The use of the immunoprécipitation is wide spread in the literature, however tlie details 
of the procedure are sparse in the references. The most detailed reference for the use of 
an immunoprécipitation was that of Tuxworth et al and hence the intial experiments were 
performed using a method based on that of Tuxworth et al 2005 (Tuxworth et al., 2005).
Procedure
Buffer recipies located in appendix 1.
Huh7 cells were trypsinized by removing the culture medium and addition of 2 ml of 
trypsin EDTA. After incubation 5 minutes at 37 °C 5ml of sterile PBS was added and the 
cells mixed by pipette. The contents of the flask was transfeiTed to a sterile 50 ml tube 
and centriftiged at 1000 xg to pellet the cells without lysing them. The pellets of a 
minimum of 4 T150 flasks (approximately 2x10^ cells) were used for each IP reaction.
Next, the cells were incubated in cold (4 °C) IP buffer on ice for one hour and then 
passed through an 18 gauge needle and syiinge 10 times to ensure full lysis of the nuclei. 
The lysate was centrifuged in a bench centrifuge at 16000*g for ten minutes at 4 °C. The 
supernatant was removed and incubated at 4 °C for 6 hours with 50 pi of protein A 
agarose beads; this acts as a blocking step to remove and non-specific protein binding. 
Following blocking, beads were removed by centrifugation in a bench centrifuge at 
16000*g for ten minutes at 4 °C.
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Twelve |ig/ml of polyclonal goat PXR antibody was added to the resultant protein 
solution and incubated at 4 °C overnight with constant rotation to allow complete binding 
of antibody to antigen.
Fifty pi protein A sepharose beads were added to the protein-antibody mixture after the 
incubation and incubated for a further 6 hours at 4 °C wifti constant rotation. The 
mixture was removed fi'om the eppendorf tube and applied to a spin column; the unbound 
protein fraction was removed by centrifugation at 4500 *g for one min at 4 °C and kept 
on ice and frozen for later western blot analysis. The beads were washed five times with 
400 pi of wash buffer, with each wash being stored at -20 °C for subsequent western blot 
analysis if required. The final 400 pi of wash buffer was used to remove the beads from 
the spin tube and transferred to an eppendorf tube, centrifuged at 16000 xg for ten 
minutes at 4 °C with the supernatant removed and kept for further analysis.
Bound proteins were separated form the antibody and beads by addition of 50 pi of wash 
buffer and heating for 20 minutes at 95 °C, followed by centrifugation at 16000 xg and 
storage for westem blot analysis.
2.2.3.2Sussex Method
Buffer recipies are located in appendix 1.
The tuxworth immuniprecipitation method feiled to precipitate proteins which exceed the 
keratin background always present in protein samples. This method was supplied by Dr 
Lucas Bowler our collaborator from the mass spectrometry facility of the University of 
Sussex and is the propeify of this facility. This method had previously been shown by the 
fascility to produce reliable results.
Protein A sepharose antibody attachment
Protein A sepharose beads (50 pi) suspended in PBS were washed three times with 1.67 
ml PBS, centrifuging at 1500 xg for 1 min following each wash. Goat anti-human PXR 
polyclonal antibody was added at a concentration of 200 pg/ml to the washed protein A
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beads. This was made up to 1.67 ml with Ix PBS and allowed to incubate overnight at 4 
°C with rotation. Following incubation, beads were washed three times with sodium 
borate buffer and centrifuged at 1500 xg to pellet the beads following each wash. Beads 
were resuspended in 1.67 ml of sodium borate buffer, to which 17.2 mg of solid 
dimethypimelimidate was added and incubated for one hour at room temperature with 
rotation.
Beads were then washed twice in 1.6 ml of Tris-HCl pH 8.8, centrifuging at 1500*g for 1 
min after each wash. This was followed by a two hour incubation at room temperature in 
1.67 ml Tris-HCl pH 8.8 and washed as before three times with 1.6 ml PBS, three times 
with 1.6 ml glycine buffer and four more times with PBS. The final product was stored 
in 1.6 ml of PBS with 0.2 % sodium azide.
Immunoprécipitation procedure:
Huh7 cells were lysed by incubation in 1 ml buffer A with 0.1% triton X 100 for one 
hour at 4 °C and homogenized ten times using an 18 gauge needle and syringe to ensure 
frill lysis.
The membranous debris was removed by centrifugation at 16000*g at 4 °C for ten 
minutes, the supernatant removed into a firesh, labeled eppendorf tube. The supernatant 
was incubated with 50 pi of washed protein A sepharose beads for six hours at 4 °C with 
rotation.
The antibody bound protein A beads were prepared by washing as follows:
1 time with 500 pi buffer A
1 time with 500 pi buffer B
1 time with 500 pi PBS pH 6.8
2 times with 500 pi glycine buffer
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1 time with 500 pi buffer A
Beads were collected by centrifugation at 16000 xg for 1 minute and 50 pi of the 
prepared beads were used for the immunoprécipitation step below.
Blocking beads were separated by centrifugation at 16000*g at 4 °C for ten minutes and 
the supernatant was added to 50 pi of the prepared antibody bound beads. This mixture 
was incubated overnight at 4 °C with rotation.
The protein solution and beads were added to a spin tube where the liquid was separated 
and collected, the beads aie retained in the upper portion. The beads are washed as 
follows:
2 X 500 pi of buffer A
3x 500 pi of buffer B
1 X  500 pi PBS pH 6.8
3 X 20 pi Glycine buffer
The glycine buffer washes were pooled and stored immediately on ice; 6 pi Tris HCl 
buffer and 14 pi buffer A were added to bring the total sample volume to 80 pi. Samples 
were frozen at -80 °C and stored for ESIMS analysis.
2.2.4 Western Blotting
2.2.4.1 Gel Formation
See appendix one for buffers and gel recipesSeven hundred microlitreof 10% (w/v) 
ammonium persulphate was added to 20 ml resolving gel stock solution followed by 
addition of 50 pi TEMED and gentle mixing by inversion. This was pipetted between
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glass plates and overlayed with 1ml of 1% SDS solution. The resolving gel was allowed 
to set for approximately ten minutes.
Three hundred and fifty pi of 10% (w/v) ammonium pei*sulphate and 20 pi TEMED was 
added to 10 ml of stacking gel stock. The stacking gel was poured on top of the set 
resolving gel, after removal o f excess liquid from the top of the resolving gel and the 
plastic well comb was inserted into the unset stacking gel. The gel was allowed to set for 
approximately ten minutes.
2.2.4.2 Gel Running
Protein sample was mixed with an equal volume of sample loading buffer and then boiled 
for ten minutes at 95 °C. Denatured sample was loaded into the wells and molecular 
weight marker was added to a clean well. The gel was mn at 250 volts, limited at 200 
mA and 50 watts for approximately 90 minutes, or until the coloured loading buffer front 
has reached the bottom of the gel.
2.2.4.3 Transfer to Nitrocellulose membrane
Following size separation by electrophoresis, protein was transferred onto nitrocellulose 
blotting membrane (Amersham) for subsequent antibody detection. Protein transfer was 
undertaken using a Mini-Protean II blotting apparatus (BioRad) at 100 volts and 300 
milliamps for 90 minutes at 4 °C, or 100 volts and 100 milliamps overnight at 4 °C.
2.2.4.4Blotting
After transfer, membranes were checks for transfer efficiency using Ponceau reagent as follows, 
membranes were taken an washed in Ix TTBS before covering in Ix poncau reagent for 30 
seconds. Excess poncau reagent was removed by washing in fresh Ixn TTBS before overnight 
in 10 % Marvel in Tween-20 Tris buffered saline (TTBS). The anti-human goat polyclonal PXR 
antibody was diluted 1:1000 witli antibody dilution buffer and incubated with the membrane for 
one hour at room temperature after which the membrane was washed three times in TTBS for 
five minutes. The anti-goat IgG secondaiy antibody was diluted 1:20000 in antibody dilution 
buffer and incubated with the membrane for one hour at room temperature after which the 
membrane was washed three times with 50 ml TTBS for 10 minutes per wash. Membranes were 
treated with chemiluminescence developing reagent according to the manufacturers instructions 
and exposed to X-ray film.
2.2.5 2D Gels
Single dimension polyacrylamide gel electrophoresis does not necessarily have the resolution to 
separate complex protein mixtures. In this case, separation in two dimensions, isoelectric point 
and size, is more appropriate.
For 2D gels, immunoprécipitation product was first further concentrated by acetone 
precipitation; four volumes of cold (-20°C) acetone was added to the immunoprécipitation 
product and incubated at -20 °C for one hour. Protein pellets were dried and resuspended in 140 
pi isoelectric focusing (lEF) strip rehydration buffer containing 20 pi of protein solubilizer. 
Samples were added to lEF cassette lanes and the pH 3-10 non linear lEF was inserted and 
allowed to rehydrate for one hour at room temperature. Precut filters were placed to cover both 
ends of the rehydrated strips and the lEF was performed as follows, all limited to 1 W and 1 
milliamp:
200V, 20 minutes
450 V, 15 minutes
750 V, 15 minutes
2000V, 90 minutes
After isoelectric focusing, strips were incubated in prePAGE incubation buffer containing 50 
mM DTT for 15 minutes at room temperature, followed by incubation in prePAGE incubation 
buffer containing 125 mM fiesh iodoacetamide for 15 minutes at room temperature. Strips were 
then placed onto 4-12% Bis-Tris precast Zoom well gels and overlaid with 0.5% agarose in 
MOPS mnning buffer (Invitrogen, Poole UK). 10 pi of coloured marker was added to the 
marker well. Zoom gels were run at 200 V, 40 W and 300 mA for approximately one hour.
2.2.6 Silver staining
Buffer recipies located in appendix 1
A polyacrylamide gel was fixed by placing in fix/stop buffer for approximately 20 minutes after 
which it was rinsed 3x in ultra pure water and placed into staining solution for 30 min. The gel 
was washed in ultra pure water and placed in tlie cold developer buffer until some bands/spots 
become apparent at which point fiesh developer buffer was added and bands/ spots developed 
further. Development was stopped by addition of fix/stop buffer, changing the buffer eveiy few 
minutes until the colour has stopped developing.
2.2.7 Electrospray-Ionîsatîon Mass Spectrometry
This method was perfomied by Dr Lucas Bowler of the University of Sussex. This method is 
used for the identification of proteins within a complex mixture. The principal relies upon 
proton transfer along the amino acid backbone to foimulate a fragmentation pattern. The pattern 
is dependent on the primary structure of the polypeptide and as such is unique for each 
polypeptide. Subsequent inteiTOgation of protein databases produces a statistical match for each 
fragmentation pattern.
Procedure
Protein samples prepared by immunoprecipication and were precipitated overnight at -20C by 
the addition of four volumes o f ice-cold acetone and pelleted at 16000 g for 30 min at 4C. 
Pellets were washed with Ix with ice-cold 90% methanol and re-pelleted at 16000g for 30 min at 
4C. Pellets were air dried and resuspended in 50mM ammonium bicarbonate (pH 8.0), lOmM 
DTT + 50% 2,2,2-Trifluoioethanol. Samples were denatured by incubation at 60C for 1 hour 
followed by cooling to room temperature and the addition of 3-(3-Indolyl)acrylic acid (lAA) to a 
final concentration of 30mM. Samples were incubated in the dark at room temperature for 45 
min. Samples were diluted 6-fold with 50mM ammonium bicarbonate ^HB.O and digest with 
modified porcine tiypsin (Promega) using a protein-to-trypsin ratio of 100 :1 (w:w) for 16 h at 
37C. Digestion was stopped by addition o f TFA to 1% v/v and samples were stored at -20C until 
use.
Resulting digests were then fiactionated on a 150 mm x 0.075 mm reverse phase column 
(PepMaplOO CIS, Dionex, CA) using an Ultimate U3000 nano-LC system (Dionex, CA) 
equipped with a 20 uL injection loop. Samples were run on a CIS reverse phase column 
(PepMap 100, Dionex) using an Ultimate U3000 nano-LC system (Dionex) equipped with a 20 
uL injection loop. Peptide separation was performed using a linear gradient firom 100% solvent 
A (water, acetonitrile, formic acid; 97.9:2.0:0.1 v:v) to 60% solvent B (acetonitrile, water, 
formic acid; 90:9.9:0.1 v:v) at a flow rate of 350 nL/min. Eluting peptides were directly analysed
by tandem mass spectrometry using a LTQ Orbitrap FT-MS (ThermoScientific) fitted with a
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nanospray ion source and using stainless steel nano-bore emitters (both Proxeon Biosystems, 
Odense). Tandem mass spectra were collected in a data-dependent fashion by collecting one full 
MS scan in the Orbitrap detector (FT) {m/z range: 350-1800) followed by MS/MS spectra of the 
six most abundant precursor ions (in ion trap). Lock-mass to ensure mass accuracy (by real-time 
recalibration of masses) was enabled on the Orbitrap, using two background ions 
(Polymethylcyclosiloxanes) naturally generated during the electrospray process.
The resulting MS/MS spectra were then used to search against an annotated database (NCBI) 
using the TurboSEQUBST protein identification algorithm as implemented within Bio Works 
v3.2 (Thermo Scientific). Stringent filtering criteria used for positive protein identifications were 
XcoiT values greater than 1.9 for +1 spectra, 2.2 for +2 spectra and 3.75 for +3 spectra and a 
delta correlation (5Cn) cutoff of 0.1. Results were confirmed by a non-redundant pBLAST 
search using the NCBI database.
2.2.8 Half GFP interaction assay
In order to examine if protein:protein interactions identified by ESIMS were real a second 
interaction assay was perfonned. The half-GFP interaction assay was designed by Regan et al 
(Wilson et al., 2004)and utilizes two plasmids that each contain one-half o f green fluorescent 
protein. Potentially interacting proteins are sub-cloned to produce half-GFP fusion proteins, and 
then expressed in a bacterial system; if the two proteins interact the GFP can be reformed, 
resulting in measurable fiurosecence. All plasmids for the protocol (mRBAD-link-CGFP, 
inRBAD-Z-CGFP, PET 11 A-link-NGFP and PETllA-Z-NGFP) were supplied by the lab of 
Professor Lynne Regan of Yale University (Wilson et al., 2004, Magliery et al., 2005).
Subcloiiing of potentially interacting proteins
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For the interaction assay, PXR is required to be sub-cloned in to one half-GFP plasmid pETllA - 
link-NGFP, and any other potentially interacting proteins sub-cloned into the other half-GFP 
protein mRBAD-link-CGFP.
Primer design
Primers were designed using the PrimerExpress software (ABI, Warrington, UK) and sequences 
taken from Pubmed NCBI. Primers were designed according to directions from Regan et al 
(Maglieiy et al., 2005, Wilson et al., 2004), such that PXR primers were designed with Xhol and 
BamHI sites integrating, Xhol 5 ’ and BamHI 3’, allowing PXR to be inserted into the pETl 1A- 
link-NGFP plasmid.
In contrast, potentially interacting proteins were amplified with primers containing Ncol and 
Aatll sites added 5’ and 3 ’ respectively, allowing sub-cloning into the mRBAD-link-CGFP 
plasmid, hi cases where genes contained multiple Ncol sites Bsal was used as an alternative 
restriction enzyme due to its ability to cut at an adjacent Ncol site.
Primers were ordered from MWG (London, UK) the sequences are indicated below.
Primer designation Primer sequence Destination plasmid
PXR forward Xhol CCACCACACGAGGGACCCCAGGGG
AGAAGTCGGAG
pETllA-Link-NGFP
PXR reverse BamHI TGTGTCGGATCCTACCTGTGATGCC
GAACAACTC
niRBAD-Link-CGFP
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RXR foiward Bsal (Ncol) CACCACGGTCTCCCATGGACACCA
AACATTTCCTGCCGCTCG
mRBAD-Link-CGFP
RXR reverse Aatll GTGGTCGACGTCATTTCCTGCGGCT mRBAD-Link-CGFP
ABL fragment A Foiward 
primer (Ncol-Clal)
GGTGAACCATGGCAGAGCTG mRBAD-Link-CGFP
ABL fragment A Feverse 
primer (Cla 1 -Nco 1 )
CTGTGTAATCGATAGGTTTCCGAA
TA
mRBAD-Link-CGFP
ABL fragment B Forward 
primer (Clal-Aatll)
GGAAACCTATCGATTACACAGTTC
TGG
mRBAD-Link-CGFP
ABL fragment B Reverse 
primer ( Aatll-C la 1 )
GAAAAAAAAAGACGTCTCAGTATA
GTGCATG
mRBAD-Link-CGFP
SF3B2 Fragment 1 
(Forward) Bsal (Ncol) - 
Drain
ATGGCGAGGTCTCCCATGGATCCC
GAGCCTCCCAAAG
mRBAD-Link-CGFP
SF3B2 Fragment 1 
(Reverse) DralH-Bsal 
(Ncol)
GCAGGACCCTAAGCTCTTGGTTCA
CCTCAAGGCCACTCGG
niRBAD-Link-CGFP
SF3B2 Fragment 2 
(Forward) Dralll-Aatll
CAGCTGGTGGCTCGGCCCGATGTC
GTGGA
mRBAD-Link-CGFP
SF3B2 Fragment 2 
(Reverse) AatU-Dralll
CCGTGGGGGCAGCAAGAAATATAA
GGAGACGTCGTTTTAG
mRBAD-Link-CGFP
2.2.9 PCR
Once primers had been received the gene was amplified from eiüier human liver cDNA supplied 
by AstraZeneca, or from a plasmid containing the gene of interest. Initially Taq polymerase was
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used to demonstrate amplification of a gene of the correct size fi'om the starting material; 
following this the proof reading enzyme PrimeSTAR (Ambrex, Nottingham, UK) was used to 
produce amplicons for cloning.
Taq PCR
Taq PCR methods are used as fast cheap method to check the efficacy of primer pairs, this is not 
a proof reading method and so an alternative enzyme is needed to make the final product.
Green Taq PCR(Promega, UK) was used to make a master mixture as follows:
lOpl 5x GreenTaq buffer
Primers to a final concentration of 833 nM
dNTPs to a final concentration of 167 nM
1 pi undiluted cDNA (~## ng) or 10 ng plasmid stock
1 pi Taq polymerase (~10 units)
34 pi RNAse/DNAse fi'ee water
PCR was mn as follows:
The master mix was divided into 10 1 reactions, overlayed with oil, and cycled as follows:
95 °C for 2 minutes
34 cycles of 95 °C for 1 minute
34 cycles 50-70 °C gradient for one minute
34 cycles of 72 °C for one minute
72 °C for 5 minutes
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Primestar Proof reading PCR
PrimeSTAR comes with a set of pre-deteimined optimized conditions for PCR. Reaction master 
mixtures were set up as follows:
10 pi 5x buffer
dNTPs to a final concentration o f250 nM
Primers to a final concentration o f250 nM
Approximately 10 ng template DNA
0.5 pi Primestar enzyme
RNAse firee water to 50 pi.
The master mix was divided into 10 01 reactions, overlayed with oil, and cycled as follows: 98 
°C for ten seconds followed by 30 cycles of heating to 98 °C for ten seconds, 55 °C for 15 
seconds, 72 °C for one minute per kilobase and finally 72 °C for 5 minutes.
2.2.10 Agarose gel electrophoresis
PCR products were resolves by electrophoresis through a 1% (w/v)_agarose gel containing 
approximately 10 nm ethidium bromide. 1 g agarose was dissolved in Ix tris EDTA buffer (TE) 
and heated by microwave until completely in solution. Once cooled ethidium bromide was 
added after the gel cooled somewhat and the gels were poured. Once set the gels were placed in 
Ix TE and loaded with sample containing 20% loading dye. Samples were resolved at 100 V 
until loading dye had travelled t  of the length of the gel.
2.2.11 Crystal Violet Gel extraction
The product of the ethanol precipitation was added to 2 pi of loading dye and run on a 1% (w/v) 
agaiose gel containing 10 mg/ml crystal violet, the bands were excised and mn through a 
MinElute gel extraction kit (Qiagen).
2.2.12Phenol:Chloroform extr action and ethanol precipitation
Two Hundred pi phenohchlorofoiin (1:1 v/v) at pH 7.5 was added toPCR product and mixed by 
vortex, followed by centrifugation at 10000 xg for 5 minutes. The aqueous layer was removed 
and 20 pi 3M acidified sodium acetate and 1 pi 10 mg/ml tRNA were added. To precipitate the 
DNA 600 pi -20 °C 100% ethanol was added, mixed by vortex and centrifliged at 16000 xg for 
15 minutes. DNA pellets were washed by addition 500 pi 70% ethanol and centiifuge at 10000 
xg for five minutes. Pellets were air dried and resuspended in Tris buffer pH 8.
2.2.13 Restriction endonuclease digests
Before ligation PCR products and plasmids were digested to give compatible ends for ligation. 
Restriction digests were as follows:
PCR product or 0.5 pg plasmid DNA
1.5 pi lOx NEB buffer
0.5 pi lOOx acetylated BSA
1 pi of restriction enzymes
RNase free water to 15 pi
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Digestion was allowed to proceed overnight at 37 °C or at 50 °C for 2-3 hours, dependent on the 
enzyme used. An extra 1 pi of enzyme being added after the first two hours and for one horn* in 
the morning.
2.2.14 DNA dephosphorylation by Calf Alkaline Phosphatase
Following endonuclease digestion the plasmids were dephosphorylated using calf alkaline 
phosphatase to prevent relegation of the cut ends of the plasmid. This is especially important for 
single enzyme digestion where the two cut ends of the plasmid are compatible, whereas with a 
double enzyme digestion the cut ends are often incompatible preventing relegation in most cases.
2.2.15 Ligation
One microlitre of both insert and vector was run on a 1% (w/v) agarose gel containing ethidium 
bromide as described in section #.#. Band intensity for plasmid and insert was comparedand the 
plasmid diluted to produce approximately equal intensities; this will produce a plasmid: insert 
ratio in the range 1:3 to 1:10. An equal volume of ligadtion mighty mix (containing ATP and a 
uique DNA ligase) (TaKaRa Bio Inc, Otsu, Japan) was added to the mixture of plasmid vector 
and insert, this was incubated at 16 °C for one hour.
2.2.16 Transformation and culturing
Chemically competent DH5a cells were removed from -80°C storage and defrosted on ice for 5- 
10 minutes. 1/10 of the ligation mixture was added to 50 pi chemically competent cells and 
incubated on ice for 30 minutes. Following that, cells were heat shocked at 42 °C for 45 seconds 
then recovered on ice for 2 minutes. To allow expression of antibiotic resistance genes 450 pi 
LB broth was added and cells were incubated at 37 °C for 1 hour with shaking.
Cells were centrifuged at 7000 rpm for one minute, 400 pi of LB medium removed, and the 
bacteria resuspended by gentle pipetting and plated onto LB agar plates containing Kanamycin 
(50pg/ml) for the mRBAD plasmids and Ampicillin (50 pg/ml) for the PETl 1A plasmids.
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Plates were grown overnight at 37 °C, after which colonies were picked and placed into 5 ml LB 
broth containing Kanamycin (50 pg/ml) or Ampicillin(50 pg/ml) as required. 5 ml Cultures were 
grown overnight at 37 °C with shaking, and then alOO pi aliquot added to 200 ml LB broth 
containing 50 pg/ml of the appropriate antibiotic in a 1 L conical flask and grown ovemight at 37 
°C with shaking.
2.2.17Maxi prep and plasmid purification
This method was performed using the Qiagen maxiprep kit, and was perfonned according to the 
manufacturers guidelines. Bacterial cells were lysed by addition of buffers PI and P2, with lysis 
being stopped after 10 minutes by addition of buffer P3. Filtered precipitate was incubated witli 
buffer ER on ice for one hour to remove endotoxins. Treated filtrate was passed through 
QIAGENtip-500 columns. Columns were washed with buffer QC and DNA eluted with Buffer 
QN then was precipitated by addition of 0.7 volumes of isopropanol followed by centrifugation 
at 13000 xg. Pellets were washed with 70 % ethanol before air drying and resuspension in buffer 
TE.
2.2.18 Quantitative RT-PCR (TaqMan)
Probe and primer design and supply
Probes and primers were designed using the Primer Express software and were designed to gene 
sequences retrieved from NCBI. Primers and probes were designed within exons in order that 
genomic DNA could be used to produce a standard cuiwe of copy number. The probes 
incorporated a Fam/Tamra fluorescence/quenching system to allow quantitative detection within 
an Applied Biosystems SDS7000.
Preparation of Genomic Standards
Species specific genomic DNA was sheared by passage through a 19G needle and diluted in a 
serial dilution to 10 ,^ 10\ 10 ,^ 10  ^and 10  ^copies of the target gene. These were run in duplicate 
alongside the sample using the same stock of mastennix and probe/primer dilutions. Standard 
curves were analyzed using AB proprietaiy software, with an of no less than 0.985 considered
acceptable.
Calculation of standard concentration
Sample Preparation 
RNA extraction
cDNA samples were prepared fiom RNA isolated as before RNA extractions were performed 
using the RNAqueous-4PCR RNA extraction kit (Ambion, UK).
DNAse treatment and cDNA synthesis
Once extracted RNA was quantiated by Nanodrop and diluted to 0.5 pg/ml before treatment with 
DNAse I (Invitrogen, Poole, UK) for thirty minutes to remove contaminating DNA. cDNA was 
synthesized using Superscript II (Invitrogen, Poole, UK) as before but using random hexamer 
primers (Invitrogen, Poole, UK) instead of gene specific primers.
Taqman QRTPCR
Taqman was performed in a white 96-well plate (Abgene, Epsom, UK). Taqman master mix was 
freshly prepared for each plate as described below:
Foiward and Reverse primers to a final concentration 500 nM
Probe to a final concentration 125 nM
5 pL nuclease free water
12.5 pL 2x Taqman master mix (Abgene)
89
Sample cDNA was diluted 1:5 with nuclease free water, with most samples requiring a further 
1:10 dilution (1:50 total) depending on transcript levels and 5 pi of each samples added to the 
plate, followed by 20 pi of the Taqman master mix
Once the wells had been filled the plates were sealed with a QPCR seal (Abgeme). The plate 
was cycled in an ABI 7000 sequence detection system (Applied Biosystems, Foster City, CA, 
USA). Cycling conditions were as follows:
50 °C for 2 minutes
95 °C for 15 minutes
95 °C for 15 seconds
60 °C for 1 minute
40 cycles
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2.2.19 Gene array
The following work was performed with the help and advice of Jane Wrigley, Victor Oreffo, 
Alison Scally, Phil Glaves, and Mark Graham. Experimental planning was performed by myself 
with the advice of the above and I was present for and assisted or obseiwed the gene array 
procedure.
RNA extraction
Primary rat hepatocytes were cultured in sandwich culture and dosed as described previously ii(section #.#), RNA extractions were perfonned using the RNAqueous-4PCR RNA extraction kit j
(Ambion, UK). Once extracted RNA was quantiated by Nanodrop. |
First Strand synthesis
First strand cDNA synthesis was performed following the Affymetrix guideline and is using the 
affymetrix
4 pi 5x First strand synthesis
0.1 M DTT to a final concentration of 86 mM
10 mM dNTPs to a final concentration of 1.42 mM
First strand mixture was prepared, flick mixed, collected by centrifiigation and incubated at 42 
°C for 2 minutes. 1 pi Superscript II (Invitrogen, Poole, UK) was added, flick mixed, collected 
by centrifugation and incubated at 42 °C for a further 1 hour; this was followed by a 2 minute 
recovery on ice.
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Second Strand Synthesis
91 pi RNase free water
30 pi 5x Second strand synthesis buffer
10 mM dNTPs to a final concentration of 218 pM
1 pi E.co/z DNA ligase
4 pi E. coli DNA polymerase
1 pi RNAse H
130 pi of second strand reaction mixture was added to the first strand synthesis mixture mixed 
by flicking, collected by centrifuged and incubated at 16 °C for 2 hrs. After two hours 2 pi T4 
DNA polymerase was added and incubated at 16 °C for 5 minutes, this was followed by addition 
of 0.5 M EDTA to a final concentration of 30 pM.
Double stranded DNA purification
Six hundred microlitres of cDNA binding buffer was added to the second strand synthesis 
mixture, mixed by vortex and 500 pi was added to a cDNA cleanup spin column which was 
centrifiiged at 8000 xg for 1 minute. The remaining 100 pi was added to the column and 
processed in the same way.
Columns were washed once by addition o f750 pi cDNA wash buffer and centrifuged at 8000 x g 
for one minute. The columns were dried by centrifuge at 25000 x g for 5 minutes before 14 pi of 
cDNA elution buffer was added.
To purify cDNA 600 pi cDNA binding buffer was added to the second strand synthesis mixture. 
This was mixed and added to a cleanup spoin column by centrifuge at 8000 xg for 1 inute. 
Columns were washed by addition o f 750 pi wash buffer and centrigugation at 8000 xg for 1 
minute. cDNA was eluted by addition of 14 pi of cDNA elution buffer.
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Synthesis of biotin labeled cRNA
Reaction mixture was assembled as follows:
15 pg cDNA from purification
4 pi 1 Ox IVT labeling buffer
12 pi IVT NTP mix
4 pi rVT labeling buffer
Reaction mixtures were mixed by vortex, collected by centrifuge and incubated at 37 °C for 16 
hours.
cRNA samples were purified as follows:
60 pi RNase free water
350 pi IVT cRNA binding buffer
250 pi 100 % ethanol
cRNA cleanup stock was added to the cRNA synthesis reactions which was then passed 
through cRNA cleanup columns by centrifugation at 8000 xg for 15 seconds. Columns were 
washed with 500 pi IVT cRNA wash buffer followed by 500 pi 100 % ethanol. cRNA was 
eluted by two additions of 11 pi RNase fiee water and centrifiigation at 25000 xg for 1 minute.
cRNA fragmentation
Fragmentation of the cRNA molecules is important for optimal array sensitivity. 
Fragmentation mixtures were as follows:
15-20 pg cRNA
8 pi 5x fragmentation buffer
RNase free water was added to 30-40 pL
Reaction mixtures were incubated at 94 °C for 35 minutes.
Target Hybridization
Array chips were hybridized by addition of Wash buffer A ( See appendix 1) and incubation at 
45 °C for 10 minutes. Hybridization mix was assembled as follows;
15 pg fragmented cRNA
5 pi oligonucleaotide B2
15 pi 20x hybridization controls
3 pi 10 mg/ml helling speim DNA
3 pi 50 mg/ml BSA
150 pi 2x hybridization buffer
30 pi DMSO
RNase free water to 300 pi
The hybridization mix was heated to 99 °C for 5 minutes, tiansferred to 42 °C for ten minutes 
and centiifuged at 25000 xg for 5 minutes. Buffer A was removed from chips and hybridization 
mix was added, chips were incubated at 45 °C for 16 hours.
Washing and staining
Washing and staining was performed using Genechip fluidics stations. All buffers are available 
in Appendix 1.
Hybridization mix was removed and replaced with 160 pi wash buffer A, fluidics station follows 
washing and staining protocol and 600pl of antibody staining solution followed by 600 pi of 
staining solution containing streptavidin and phycoerythrin is added. The chip is ejected and 
taken for analysis on the
Chapter 3: An Immunoprécipitation approach to the 
identification of the co-regulator protein complexes of the 
nuclear receptor PXR (NR112)
3.1 Introduction
Nuclear receptors such as PXR rely on a complex of proteins to enhance and regulate their 
transcriptional activity. It is suggested that the differential recmitment o f co-regulator proteins by 
nuclear receptors in a ligand dependent manner provides for a mechanism of ligand dependent 
gene selection; it is thus important to understand which co-regulator proteins interact with a 
particular nuclear receptor under differing conditions. Whereas several other receptors have 
been extensively studied with regard to their co-regulator proteins at present few have been 
identified as interacting with PXR.
3.1.1 Immunoprécipitation as a method for protein complex isolation
Immunoprécipitation (ip) is a series o f methods for isolating proteins or protein complexes from 
cell lysates using antibodies to the target protein, or a member of the protein complex. Lysis of 
cells often leaves biologically functional protein complexes intact, and these can be isolated to 
reveal proteins in functional complexes. These methods can be used to purify or isolate 
individual proteins but is a much more powerful tool for the identification of novel protein- 
protein interactions as members of the protein complexes are resolved. The wash steps and 
control incubations may cause dissociation of peripheral or transiently associated proteins, 
making it difficult to isolate complete protein complexes intact. Such problems can be mitigated 
by the use of formaldehyde to crosslink proteins; however, this is rarely used as it leads to high 
numbers of false positive identifications (Peter D. Adams, 2005).
Due to the potential for false positives, immunoprécipitation techniques are not usually 
performed alone, as the identified interactions require validation through a second technology. 
This might be through analyzing the biological function of the proteins, i.e. a coactivator of PXR
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would increase the tmnscriptional function of the receptor when jointly over expressed. Use of a 
second method of isolating proteins and protein complexes such as his tagging, tandem affinity 
purification or GST tagging can help confirm protein identifications (Peter D. Adams, 2005).
In this chapter, two different immunoprécipitation methods were used to identify PXR 
interactions: First, the Tuxworth method (Tuxworth et al., 2001) is a solution based approach 
which uses the protein A beads only in the last stage of the isolation. Second, the Sussex method 
(Dr Lucas Bowler, University of Sussex) uses antibodies peimanently crosslinked using 
dimethylpimelimidate to the protein A beads. Proteins isolated fiom the immunoprécipitations 
were originally analyzed by two dimentional gel electrophoresis and later by electrospray 
ionization mass spectrometry.
3.1.2 Electrospray ionization mass spectrometry
Solvent used to resuspend the protein sample following concentration is evaporated, the droplets 
of solvent reduce in size until the surface tension can no longer sustain the charge known as the 
Rayleigh limit and results in an explosion which tears the droplet apart. Smaller droplets are 
formed and the process is repeated which can repeat the process results in the production of 
charged analyte molecules (Griffiths et al., 2001). This method of ionisation leaves little energy 
to alter the analyte after ionisation. ESI-MS is a useflil technique which means that non-covalent 
molecule-protein modifactions or protein-protein interactions are seen in the gas-phase. The 
identification o f structures requires tandem mass spectrometry where the analyte molecules can 
be fi*agmented (Griffiths et al., 2001) (http://www.chm.bris.ac.uk/ms/theory/esi-ionisation.html).
The fi agmentation of the ions occurs when they enter the ion trap of the ESI MS. The ion trap is 
typically a quadmpole mass analyser, although in the following results chapter an octupole mass 
analyser is used. The ions are selected based on their mass to charge (m/z) ratio and are fed into 
the mass analyser in species. These species are then bombai'ded with inert gasses, collisions 
causeing fiagmentation of the large ions. From here the ions are fed into the second MS to be 
analysed (Griffiths et al., 2001) (http://www.chm.bris.ac.uk/ms/theoiy/esi-ionisation.html).
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The patterns of mass fragments which are foi-med are analysed by specific software which 
accumulates the data on the charged ions. The computer program assigns statistical values to 
each identification which are based on the number of fragments identified which are found to co­
inside with the predicted amino acid sequence of the protein or peptide (Griffiths et al., 2001). 
These identities are located from a data base such as NCBI and are screened according to the 
statistical likelihood that the ion fragmentation contains the amino acid sequence known within 
the database. The abscence of ions coiTesponding to known peptide fragments from a protein 
weaken the statistical likelihood that this protein is the one suggested from the database 
(Griffiths et al., 2001) (http://www.chm.bris.ac.uk/ms/theory/esi-ionisation.html).
3.1.3 Half GFP reassembly assay
Proteins identified as binding partners by ip or by one of the alternatives, i.e. his tag or tap tag 
require experiments to demonstrate a direct interaction. Many technologies for identifying 
protein binding partners rely on preexisting protein databases of binding interactions and 
structural associations. As immunoprecipitation-based methods are used to identify novel 
interactions such databases may be of only minimal use; for such novel associations an alternate 
validation methodology is required. The half GFP method requires firm association between the 
two proteins and may not detect loose but biologically important transient associations, a fact 
which is commented upon in the literature (Magliery and Regan, 2006, Magliery et al., 2005, 
Wilson et al., 2004).
The most common method of validating protein associations is by a Yeast 2 hybrid screen. This 
method has been successfully used in many cases birt comes with a set of caveats which may 
limit its functionality. The isolated proteins must be expressed and folded properly in Yeast, the 
biological process that underlies the interaction needs to be conserved in Yeast, and the process 
requires nuclear importation and function of the cloned protein. In addition, Yeast 2 hybrid 
methods also commonly identify proteins that bind as part of a larger complex rather than direct 
associations, reporting false positives as a result (Magliery and Regan, 2006). A somewhat 
newer adaptaion of the yeast two hybrid screen is the mammalian 2 hybrid system in which
proteins are isolated from a mammalian cell. This is useful in identifying the interactions 
between proteins which require a higer level o f modification and assistance in folding coiTectly 
(Shioda et al., 2000).
An alternative to Üie Y2H and M2Y binding assays is the half GFP reassembly assay, which was 
developed to validate die direct interaction of two binding partners. This method is centered 
aiound two expression plasmids, each o f which contains one opposing half of GFP, generated by 
splitting GFP between residues 157 and 158. Subcloning of a ‘bait’ protein into the pETllA - 
link-NGFP plasmid and a predicted ‘predator’ protein into pMRBAD-link-CGFP enables the 
production of fusion proteins either the modified N of C terminal of GFP (Magliery and Regan, 
2006, Maglieiy et al., 2005, Wilson et al., 2004). Direct interaction between the bait and 
predator proteins allows re-association of the two halves of GFP through interaction of the 
hybridized protein. Importantly, the two halves of GFP do not reassemble unless they are fused 
to interacting partner proteins, reducing tlie false positive rate, and that it was the affinity o f these 
interacting partners that directed the strength of the fluorescent response, allowmg a degree of 
semiquantitative analysis of the interaction to be undertaken, although use as a quahtative 
method is a much sounder approach (Magliery and Regan, 2006, Magliery et al., 2005).
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Figure 3.1.1 Reassembly of NGFP and CGFP by association of leucine zipper 
fusion proteins.
NGFP shown in green is irreversibly associated with the CGFP shown in red. The 
structures of these proteins are derived form the protein data bank and correspond to 
the structure of the GFP fluorophore. The interaction is mediated by the strongly 
associative nature of the two leucine zipper proteins shown here in blue, the 
association between other proteins should be detectable using this method, i.e. PXR 
and co-regulator proteins. Adapted from (Magliery et al., 2005).
In most cells GFP is synthesized and folded successfully to form a fluorescent product; however, 
the folding of the fusion protein is another matter, with not all proteins being suitable bait of 
predators for this method (Magliery and Regan, 2006, Magliery et al., 2005). The success of this 
method is largely due to the selection of plasmids and their ability to be used in most expression 
platforms which can operate on a T7 viral promoter which includes E. coli strains such as BL21 
and its derivatives (Wilson et al., 2004).
To further the understanding of the co-activator complexs of PXR the development of an ip 
method suitable for isolating PXR and its interacting partners. Two antibodies were available 
and the best selected and taken forward into the tuxworth and Sussex ip methods. Two methods 
for the physical identification of the proteins once isolated were used, while two dimensional gel
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electrophoresis proved to require too much protein ESIMS generated a list of protein identities 
the most consistent o f which were taken forward for fiirther analysis.
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3.2 Results
3.2.1 Optimization of Antibodies
Two PXR antibodies were available which were suitable for ip and western blotting, Goat anti 
human PXR antibody (Sc7737) and die Rabbit anti human PXR antibody (Sc 25381). These 
antibodies were tested with the Huh7 cell samples which were chosen as a starting material. 
Figure 3.2.1.1 shows an immunoblot for PXR in Huh7 protein samples. Total protein samples 
were prepared and are shown in lanes 2 and 3 of fig 3.2.1.4, the total proteins were further 
fiactionated into nuclear and cytosolic proteins with the nuclear proteins shown in lanes 4 and 5 
of fig 3.2.1.4. The Rabbit anti PXR antibody antibody (Sc25381) shows both specific (band at 
approx 54 kDa), and non specific binding (all other bands) with an unacceptable signal to 
backgroimd ratio.
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Figure 3.2.1.1: Western blot for PXR in Huh? total protein using the rabbit anti 
human PXR antibody (Sc25381).
Molecular weight marker (Invitrogen, Poole, UK) is loaded in lane 1. 150 pg of total 
protein was loaded into lane 2 and 175 pg into lane 3. Huh7 cells were fractionated 
into cytosolic and nuclear fractions following the Dignam method (Dignam et al., 
1983), the nuclear fraction was loaded into lanes 4 and 5 with approximately 25 and 50 
|ig respectively. Proteins were probed with the Rabbit anti PXR from Santacmz 
biotechnology (Sc25381). The band of molecular weight corresponding to PXR, 
approx 50-55 kDa (Saradhi et al., 2005), is shown by a red arrow ( ^ " " ) .
Figure 3.2.1.2 shows an immunoblot against PXR in Huh7 protein samples using the anti PXR 
primary antibody Sc7737. Total protein samples were prepared and shown in lanes 2 and 3 of 
fig 3.2.1.3. The total protein was further processed according to the method by Dignam (Dignam 
et al., 1983) to isolate nuclear proteins and is shown in lanes 4 and 5 of fig 3.2.1.3. Proteins 
were resolved by electrophoresis through a 12.5% polyacrylamide gel at before transfer onto 
nitrocellulose membranes which were probed for PXR with the goat anti PXR (Sc7737) before 
visualization of the proteins. Previous work with the laboratory has shown that Huh7 cells 
express relatively low levels of PXR (Elizabeth Andersen, persoAra/ communication), making the
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use of larger amounts of protein to detect sufficient protein. A band of the predicted size for PXR 
can be seen in all lanes of Huh7 protein extract, with band intensity and resolution being 
significantly better in the nuclear finction. (Fig 3.2.1.2).
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Figure 3.2.1.2: Western blot for PXR in Hub? protein samples using the Goat 
anti PXR antibody SC7737.
Molecular weight marker (Invitrogen, Poole, UK) is loaded in lane 1. 150 pg and 175 
ug of total protein loaded into lanes 2 and and 3 respectively. Huh7 cells were 
fractionated into cytosolic and nuclear finctions following the Dignam method 
(Dignam et al., 1983), and the nuclear finction was loaded into lanes 4 and 5 at 
approximately 50 pg per lane. Proteins were probed with the goat anti PXR antibody 
(Sc7737). The band of molecular weight corresponding to PXR, approx 50-55 kDa 
(Saradhi et al., 2005), is shown by a red arrow ( ^ ^™ ).
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Following the selection of sc7737 as the anti-PXR antibody of choice, 1 next examined the effect 
of protein loading on the degree of non-specific binding. Figure 3.2.1.3 shows an immunoblot of 
increasing amounts of nuclear protein extract samples. Nuclear proteins were extracted 
following the Dignam method; a progressive increase of 5, 10, 20, 30, 40 and 50 pg of protein 
were loaded into lanes 2-7 The goat anti PXR antibody has detected two protein bands between 
50 and 60 Kda in size, with the lower, non-specific, band increasing in intensity as protein 
loading increases.
□  □  □  □  □  □  □
100
80
60
50
40
30 —
Marker 5pM IQ I^VI 20nM 30|iM 40|iM 50pM
Figure 3.2.1.3: Western blot for PXR in Huh? total protein using the goat anti 
human PXR antibody.
Molecular weight marker in lane 1, nuclear fraction protein was extracted from 
approximately 2x10^ Huh7 cells and 5, 10, 20, 30, 40 and 50 pg were loaded into lanes 
2-7. Proteins were resolved and blotted as described in figure 3.2.1.2 including use of 
the goat anti PXR antibody(Sc7737). The band of molecular weight corresponding to 
PXR, approx 50-55 kDa (Saradhi et al., 2005), is shown by a red arrow ( ^ ™ ) .
3.2.2 Optimization of Immunoprécipitations
The goat anti PXR antibody sc7737 was shown to give a better signal to background ratio in the 
human samples (figures 3.2.1.1 and 3.2.1.2) and for this reason it was decided to take this 
antibody forward to the ip. Figure 3.2.2.1 shows an immunoblot (a) and silver stained 
polyacrylamide gel (b) of a PXR immunoprécipitation performed following the Tuxworth
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method and using the goat anti human PXR antibody (Sc7737). Huh7 total protein was extracted 
following the Tuxworth method and incubated with the goat anti human PXR antibody (Sc7737). 
Protein samples pre immunoprécipitation were loaded into lanes 2 and 3, with 
immunoprecipitate loaded into lane 4. A band consistent with the predicted size of PXR is 
detected within the immunoprecipitated samples (lane 4); the silver stain gel demonstrates that 
significantly fewer protein species are present within the immuoprecipitate versus the total 
protein extracts.
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Figure 3.2.2.1: Tuxworth method immunoprecipitates using the goat anti PXR 
antibody.
Molecular weight marker is loaded in lane 1 of both a) and b). Total protein was 
extracted from approximately 2xl0’ Huh7 50 pg and 25 pg of the total protein are 
loaded in lanes 2 and 3. Immunoprécipitation was performed on Huh7 total cell lysates 
using the PXR antibody (Sc7737). The entire immunoprecipitate loaded into lane 4. 
Membranes were probed with the goat anti PXR from Santacruz biotechnology 
(Sc7737) shown in 3.2.2.1 a) and by silver staining 3.2.2.1 b). The band of molecular 
weight corresponding to PXR, approx 50-55 kDa (Saradhi et al., 2005), is shown by a 
red arrow ( ^ " " " ) .
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Immunoprécipitation of PXR has successfully concentrated the protein from the total cell lyates, 
to show that the Figure 3.2.2.2 shows an immunoblot of PXR imunporecipitations of Huh7 total 
protein using the goat anti PXR (Sc7737) antibody and performed following the Tuxworth 
method. Immunoprecipitates and the total protein post antibody incubation were resolved in a 
12.5% poly arylamide gel, the proteins transferred to nitrocellulose membrane and the membrane 
probed with goat anti PXR antibody (Sc7737). The NaCl concentration in the 
immunoprécipitation buffers was varied between 0 and 500 mM as indicated and resulted in an 
overall decrease in total bound protein with salt concentration. In addition, non-specific bands 
appear to decrease faster than the immunoreactive band corresponding to the molecular weight 
of PXR across the concentrations. At 500 mM solution viscosity will have decreased the amount 
of product retrieved with PXR signal almost non existent. The concentration of 250 mM NaCl 
appeared to give the best result and was used in further experiments.
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Figure 3.2.2.2: Western blot of immunoprecipitates of PXR using the Goat anti 
human PXR antibody.
Immunoprécipitations were performed following the Tuxworth method on Huh7 total 
protein samples using the Santa Cmz goat anti human PXR (Sc7737) antibody. Salt 
concentrations in the immunoprécipitation buffer were varied from 0 mM to 500 mM. 
T. Membranes were probed using the Santa Cruz goat anti human PXR (Sc7737). 
The band of molecular weight corresponding to PXR, approx 50-55 kDa (Saradhi et 
al., 2005), is shown by a red arrow ( ^ ^ " ) .
Figure 3.2.2.3 shows a western blot of wash fractions of an immunoprécipitation of PXR from 
Huh7 total protein using the goat anti human PXR antibody. 25 pi of each wash step was loaded
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into lanes 2-6, 25 pi of the immunoprecipitate was loaded into lane 6. PXR was probed using 
the goat anti PXR antibody (Sc7737) and was only detected in lane 6, which corresponds to the 
final eluate.
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Figure 32 .23  Western blot of wash fractions of immunoprécipitation of PXR 
using the Goat anti human PXR antibody.
Molecular weight marker is loaded into lane 1. Huh7 total protein from 
approximately 2x107 cells was prepared and an immunoprécipitation for PXR using 
the goat anti human PXR (Sc7737) following the Tuxworth immunoprécipitation 
method. Successive wash steps were loaded onto the gel lanes 2-6 and bound eluate 
was loaded into lane 7. Membranes were probed for PXR using the goat anti 
human PXR (Sc7737) antibody. The band of molecular weight corresponding to 
PXR, approx 50-55 kDa (Saradhi et al., 2005), is shown by a red arrow (^ ^ ™ ).
Figure 3.2.2.4 shows a two dimensional polyacrylamide gel of Huh7 total protein silver stained 
to show proteins. Proteins were separated to isoelectric point followed by separation in the 
second dimension through a 12.5% polyacrylamide gel. The second dimension gel was stained 
with silver and proteins visualized. A good resolution of individual spots can be detected, 
suggesting the viability of this technique for separating comlex protein mixtures. PXR has an
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isolelectric point of approximetiey 8.4 and a molecular weight of approximetley 50 kDa and 
should be found in the region shown.
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Figure 3 .2 2 .4 : Two dimensional gel electrophoresis of Huh? total protein.
Total protein was extracted from Huh? cells following the Tuxworth immunoprécipitation 
method, approximately 100 pg was mixed with rehydration buffer and applied to non 
linear pH 4-10 lEF strips for overnight absortion. Proteins were focused to their 
isoeclectric point before the strip was applied to a precast 12.5 % aery mal ide gel. 
Electrophorsesis was performed limited at 200 mA and 50 W for approximately 50 
minutes. Proteins were silver stained an image taken by digital camera. As indicated on 
the gel proteins are resolved to their pH between 3 and 10, the marker lane (labeled M) is 
added to provide information regarding molecular weight.
Following demonstration o f the utility of 2D-gel electrophoresis for separating total protein 
extract it was important to see if this method had sufficient sensitivity to deal with the lower 
protein concentrations produced following immunoprécipitation. Figure 3.2.2.4 shows a two 
dimensional gel of an immunoprecipitate of PXR from Huh? total protein using the goat anti 
PXR antibody (Sc??37). Proteins were separated by isolelectric focusing before separation in 
the second dimension through a 12.5% polyacrylamide gel. Second dimensional gel was stained
1Ô9 I
with silver to visualize proteins. PXR has an isoelectric point of approximately 8.4 and a 
molecular weight of approximetley 50 kDa and should be found in the region indicated. Protein 
levels were too low for visualization of precipitated proteins.
Marker
Figure 3.2.2 5: Two dimensional gel electrophoresis of PXR immunoprecipitate from 
Huh7 total protein.
Huh? total protein from approximately 2x107 cells was prepared and an 
immunoprécipitation for PXR using the goat antihuman PXR 
(Sc7737) antibody was performed following the Tuxworth method. Proteins were moved 
to their isoelectric point on a non linear pH 3-10 BEF strip and incubated for overnight 
absorption. As indicated on the gel proteins should be resolved to their isoelectric pH 
between 3 and 10, the marker lane (labeled M) is added to provide some information
To examine if PXR itself could be detected on a 2D-gel, a Western blot of the separated 
immuoprecipitate was undertaken. Immunoprecipitate o f PXR from Huh7 total proteins was 
prepared using the goat anti PXR antibody. Samples were separated by isoelectric focusing 
followed by resolution on a 12.5% polyacrylamide gel. Proteins were transferred to 
nitrocellulose membrane and probed for PXR using the goat anti PXR antibody (Sc7?37). As
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can be seen from figure 3.2.2.6 a specific spot corresponding to PXR was not detected in this 
blot, although some non-specific immunospots were.
Marker
Figure 3 2.2.6: Western blot of 2D gel of PXR immunoprecipitate from Huh? total 
protein.
Huh? total protein from approximately 2x10^ cells was prepared and an 
immunoprécipitation for PXR using the goat anti PXR 
(Sc7737) antibody was performed following the Tuxworth method. Proteins were moved 
to their isoelectric point on a non linear pH 3-10 lEF strip and incubated for overnight 
absorption, membranes were probed for PXR using the goat anti human PXR (Sc7737) 
antibody. The proteins were separated to their isoelectric point between pH 3 and 10 
(labeled on gel), the marker (labeled M) was added to provide information regarding 
molecular weight.
3.23 Electrospray ionization mass spectrometry
As 2D-gel electrophoresis did not provide the sensitivity required for spot identification I next 
used ESI-MS, as this is a more sensitive method. The Tuxworth method used and optimized in 
section 3.2.2 produced 4 immunoprecipitates fi-om Huh7 cell total protein which were analysed 
by ESI-MS for protein content. The yield of specific protein fiom this technique remained low,
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with identified proteins mainly comprising of contamination from keratins and coHagens; as such 
no potential PXR-interacting proteins could be identified. On the advice of Dr Lucas Bowler of 
the University of Sussex Mass spectrometry facility the “Sussex” method immunoprécipitation 
protocol was adopted as it was known to produce samples that were analyzed well by his ESI- 
MS,
Protein Name Function
SFPQ protein [Homo sapiens] splicing factor
chaperonin containing TCPl, subunit 2 (beta) Protein folding
paraspeckle protein 1 Chromatin related proteins
S41768 splicing factor homologue splicing factor
Splicing factor 3B subunit 2 splicing factor
splicing factor 3a, subunit 3, 60kDa Splicing factor
low density lipoprotein receptor-related protein Co-regulator
eukaryotic translation elongation factor 1 alpha 1 Transription protein
thyroid hormone receptor-associated protein, 150 kDa Co-regulator
chaperonin containing TCPl, subunit 3 Chaperone protein
Sin3A transcription protein
protein disulfide isomerase-related protein protein folding
golgi SNAP receptor complex member 2 isofoim A; Golgi protein
BTF protein BCL2 associate transcription factor
SRC8_HUMAN Src substrate cortactin Known associate of other nuclear
TCPQ_HUMAN T-complex protein 1, theta subunit Chaperone
splicing factor 3a, subimit 1 ,120kDa splicing
splicing factor 3b, subunit 4 splicing
SF3blO Splicing
insulin receptor tyrosine kinase substrate SRC related protein
BASSl DNA binding protein
HSPC043 protein chromosome 9 open reading frame
SWI/SNF-related matrix-associated DNA opening complex
CCT2_HUMAN Cyclin T2 Cyclin-transcription related
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protein disulfide isomerase-related protein 5 protein folding
hepatocyte nuclear factor 3, beta transcription factor
DNA helicase-primase complex component helicase "viral"protein
138369 beta-tubulin Tubulin
nucleoside-diphosphate kinase 1 Nucleoside binding protein
Table 3.2.3.1: Proteins identified from ESI-MS analysis of PXR immunoprecipitates 
from Hub? total protein.
Huh? total protein was extracted from approximately 2x10^ cells and an 
immunoprécipitation for PXR was performed using tlie goat anti human PXR (Sc7737) 
antibody following tlie Sussex method. hnraunoprecipitates from two separate 
experiments were sent for analysis by ESI-MS to identify protein content. The above 
proteins are those identified in two separate immunoprecipitates firom separate total 
protein sources using the goat anti PXR (Sc7737) antibody.
Immunoprecipitates for PXR were prepared following the Sussex method using the goat anti 
human PXR antibody and were sent for analysis by ESI-MS, results are shown in table 3.2.3.1. 
The list contains protein found throughout the cell, which is to be expected for two reasons; first, 
the immunoprecipitate was performed on Huh? total protein; second, although PXR is mainly 
nuclear localized a percentage of it is localized within the cytoplasm and hence it is not 
surprising to identify proteins from this sub-cellular compartment as well as the nuclear 
compartment.
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3.2.4 Half GFP optimization and validation
Gene sequences for several of the proteins contained witliin table 3.2.3.1 were obtained fonn 
NCBI Gene (http://www.ncbi.nlm.nih.gov/sites/enti*ez?cmd=search&db=gene) and these 
sequences were used by the Primer express softwaie (Applied Biosystems, Warrington, UK) to 
design PCR primers to clone these proteins in the half GFP interaction assay. Cloning was 
modeled using the Vector NTI software (Invitrogen, Poole, UK) in order that restriction sites and 
predicted digests could be established plasmid diagrams may be seen in appendix 1.
Primestar (TaKaRa, Japan) PCR replication and amplification of PXR RXR and p54mb from 
human liver cDNA (Astra Zeneca) is shown in figure 3.2.4.1. Part A shows PXR, RXR and 
p54nrb which all have genes which are approximately 1.4 kbp in length and appeared to have 
been successfully amplified in one fi:agment. Part B shows ABL interactor protein isofoim a 
which contains multiple Ncol restriction sites and multiple Bsal restiiction sites witliin its 
sequence. The gene was split using the Clal restriction site to ligate the two halves of the gene 
together in order that Bsa 1 and Ncol could be used to clone into pMRBAD-link-CGFP. As can 
be seen in the gene was split into one fragment of approximately 1 kbp and another fragment of 
approximately 400 bp. Part C shows SF3B2 which is a long gene of approximately 2.8 kbp, a 
previous cloning attempt had foiled to extiact the gene as one fragment and so it was split into 
two fragments, using the Dralll restriction site to re-ligate the two halves. This meant that there 
should be two fragments of approximately 1.4 kbp, as is shown in this figure.
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1.58kbp
Marker
1 1 kbp 
791 bp 
517 bp 397 bp
RXR p54nrb Marker ABL a ABL b
1.58 kbp 1.3 kbp 1.1 kbp
Marker SF3B2 a SF3B2 b
Figure 3.2.4.1 Primestar PCR product of PXR, RXR and p54nrb, ABL 
interactor and SF3B2.
10 fmoles each of forward and reverse primer were added to 0.1 pg template rat liver 
cDNA (Astra Zeneca) and cycled with the Primerstar proof reading DNA polymerase 
(TaKaRa, Japan) for 35 PCR cycles according to the Primestar protocol. A) shows the 
PCR products of RXR and p54nrb, B) shows the PCR products for ABL interactor and 
C) shows the PCR products for SF3B2.
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Figure 3.2.4.2 shows diagnostic digests of ail plasmids discussed in this section. The digestion of 
pMRBAD-p54-CGFP and pMRBAD-SF3B2-CGFP with Mlul and Acc651 should produce 
fragments of 4.7 and 1.4 kbp and 5.2 and 2.2 kbp respectively, which they have done as shown 
in lanes 1 and 2. The digestion of pETllA-Link NGFP and pET 11A-PXR-NGFP with Xmal 
and Nhel should result in the digestion ofpETl lA-link-NGFP only as the Xmal site is removed 
during cloning, this is the case and is shown in lanes 3 and 4. pMRBAD-RXR-CGFP when 
digested with Bsal should produce thiee bands at 3.0, 2.2 and 0.8 kbp which is shown in lane 5, 
with some undigested plasmid remaining abouve. The digestion of pMRBAD-ABL-CGFP with 
Mlul and PvuII should produce bands of 4.3 and 1.9 kbp which is that case and is shown in lane 
6. Finally in lane 7 the digestion of pET 11 A-PXR-NGFP with Xhol and BamHl should 
produce fragments of 6.1 and 1.4 kbp which is the case with a little undigested plasmid 
remaining above. Over all this suggests that all plasmids have inserts and that the inserts are of 
sizes corresponding to the genes which they should contain.
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ACC651
M lul
X m al
Nhel B sal
M lu l  X hol 
PvuII BamHl
5 0 kbp .  
3 3 kbp 
2.25 kbp 
1.58 kbp 
1.3 kbp 
1.1 kbp 
791 bp 
517 bp ^
Marker/ / / / / / //  /  /
Figure 3.2 4.2 Diagnostic digests to assess content of plasmids containing PXR, RXR, 
p54, ABL and SF3B2.
0.1 ug of each plasmid was digested with the enzymes as indicated above. Digestion of 
pMRBAD-p54-CGFP and pMRBAD-SF3B2-CGFP with Acc651 and Mlul (lanes 2 and 3) 
gave the expected digest bands of approximately 1.4 kb and 1.8 kb respectively. Digestion 
of pETl 1 A-link-NGFP with Xmal and Nhel should produce a digestion product of around 
600bp which digestion of pET 11 A-PXR-NGFP should not as seen in lanes 4 and 5. 
Digestion of pMRBAD-ABL-CGFP with Bsal produces 3 expected bands of approximately 
3, 2.2 and 1 kb (lane 6). Digestion o f pMRBAD-RXR-CGFP with Mlul and PvuII produced 
the expected digest product at approximately 1.6kb (lane 7). Digestion of pET 11 A-PXR- 
NGFP with Xhol and BamHl gave the expected 1.4 kb product (lane 8).
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3.2.5 Half GFP interaction assay
The plasmids shown in section 3.2.4 were taken forward for use in the Half GFP interaction 
assay as discussed in the papers by Wilson and Maglieiy of the lab of Lynne Regan at Yale 
Univei-sity (Magliery and Regan, 2006, Magliery et al., 2005, Wilson et al., 2004).
In order to test the fimctionality o f the generated constmcts, the GFP-PXR and GFP-RXRa 
constructs were examined via Western blotting, as remaining immunoreactivity is a good 
indication of at least partial functionality. Half GFP expression plasmids were prepared as 
described in section 3.2.4. These plasmids were transformed into Rosetta competent cells in 
combination with the control, empty, expression plasmids and cells were grown for 24 hours at 
37°C followed by 48 hours at 20°C; medium contained the antibiotics ampicillin, 
chloramphenicol and kanamycin for selection and the inducing agents Isopropyl P-D-1- 
thiogalactopyranoside (IPTG) and arabinose. Protein was extracted and resolved by 
electrophoresis through a 12.5% polyaciylamide gel. Proteins were tiansfened onto a 
nitrocellulose membrane which was probed for PXR using a goat anti human PXR antibody 
AZ485 and is shown in figure 3.2.5.1. PXR can be seen expressed in the large band indicated on 
the gel, hwoever expression of PXR appears to produce other proteins which are immunoreactive 
with the antibody. Parallel gels were prepared containing the same format but were stained with 
silver to reveal proteins and is shown in fig 3.2.5.Lb. Staining shows less protein loaded in PXR 
expression lanes while the band indicating PXR at 55 kDa is only present in these lanes.
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Half GFP expression plasmids were prepared by subcloning PXR into pETl 1 A-link-NFGP and 
RXR and Abl interactor and SF3b2 into pMRBAD-link-CGFP. 0.1 pg of these plamids was 
added to TNT reaction mix and the reaction allowed to proceed for 2 hours at 37°C. Produced 
proteins were resolved through a 12.5% polyacrylamide gel before transferring to a 
nitrocellulose membrane and probing for PXR with goat anti human PXR antibody (shown in fig 
3.2.5.2). PXR expression can clearly be seen in only those lanes containing pET 11 A-PXR- 
NGFP.
p E T llA -link -  NGFP + + +  + -
pETllA -PX R -N G FP +
pMRBAD-RXR-CGFP -  + - - +
pMRBAD-ABL- CGFP - - +  -
pMRBAD-SF3B2-CGFP +
100
301
M arker Controls PXR
Figure 3.2.5.2: Western blot of PXR expression from pET 11 A-PXR-NGFP in a TNT 
reaction using the AZ 485 goat anti PXR antibody.
Plasmids were added to the TNT reaction mix and the reaction allowed to proceed for 2 hours at 
37°C. 25pl of the reaction mixture was loaded onto a 12.5% polyacrylamide gel were resolved 
through the gel at 200 mA and 50 W for approximately 50 minutes before transferring to 
nitrocellulose membrane at 300 mA for 90 minutes. Membranes were probed for PXR using the 
goat anti human PXR antibody (AZ485). . The band of molecular weight corresponding to 
PXR, approx 50-55 kDa (Saradhi et al., 2005), is shown by a red arrow ( ^ ^ " ) .
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Figure 3.2.5.3 shows the fluorescence emission spectrum of the half GFP interaction assays of 
PXR with RXR and the control plasmid pMRBAD-Z-CGFP. Frame A) shows the PXR RXR 
interaction with a large peak at approximately 509 nM, a wavelength corresponding with GFP 
fluorescence (Magliery and Regan, 2006, Magliery et al., 2005, Wilson et ai., 2004). B) shows a 
TNT experiment in which the product PXR and RXR do not appear to interact with the emission 
peak seen resembling that of C) which shows the emission spectrum of a control reaction of the 
PXR plasmid with the pMRBAD-Z-CGFP.
Figure 3.2 5.3: Fluorescence emission spectra of half GFP interaction assays for PXR RXR 
and a control PXR with the pMRBAD-Z-GFP.
Plasmids were added to the TNT reaction mix and the reaction allowed to proceed for 2 hours at 
37°C. The reaction mixture was transferred into a Nunc Ion delta surface 96 well plate and 
assessed for fluorescent activity which indicates protein-protein interaction GFP reassembly. A) 
Representation of the fluorescent activity of a TNT reaction containing PXR and RXR, B) 
Representation of the fluorescent activity of a TNT reaction containing PXR and RXR, C) 
Representation of the fluorescent activity of a control TNT reaction of PXR and the control 
plasmid pMRBAD-Z-CGFP.
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Table 3,5.1 shows the results of a series of TNT-expressed half-GFP constructs testing for 
interaction between PXR and RXR, p54nrb, ABL, or SF3B2. The results o f these experiments 
are consistent with the known interaction between PXR and RXRa, although detection of the 
interaction is not robust. No interaction was detected between PXR and any o f the other protein 
species. Further study is required to ascertain if these negative results are due to a failure in the 
technique, failure of the half-GPF constmcts to fold correctly or a lack of interaction.
Plasmid combination Flourescence 
activity (4 
experiments)
pETl 1A-Z -NGFP + pMRBAD -Z - CGFP N ,N ,N ,N
pETllA -Z-N G FP + RXR-CGFP N,N, N ,N
pETllA-Z-NGFP + ABL-CGFP -, - ,N ,N
pETl 1A-Z-NGFP + SF3B2-CGFP -, - ,N ,N
PXR- NGFP + PETl 1 A-Z -NGFP N, Y,N,Y
PXR- NGFP + RXR - CGFP Y ,Y ,N ,N
PXR-NGFP + P54nrb - CGFP N ,N ,N ,N
PXR-NGFP + ABL-CGFP -, - ,N ,N
PXR-NGFP + SF3b2-CGFP -, - ,N ,N
Table 3.2.5.1 Tabulated fluorescence data from experiments using the TNT 
expression.
0.1 (ig of control plasmids or expression plasmids for PXR, RXR, p54nrb, ABL interactor a 
and SF3B2. Plasmids were added to 150 pi TNT reaction mix with added unlabelled 
methionine (Promega, Southampton, UK), and were incubated at 37 °C for 2 hours. 
Reaction mix was then added to a black fluorescence suitable 96 well plate and read in a 
Molecular Devices spectrMAX GeminiXS plate fluorimeter. The samples were exposed to 
an excitation range of between 350 and 750 nm with emission detected an 509 nm. The 
typical positive peak had emission beginning excitation wavelengths between 460 and 540 
nm with a peak at 520 nm. Four experiments were run in total, and are represented in the 
right hand column abouve with each experiments positive or negative result being 
represented with a Y orN  respectively.
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3.3 Discussion
3.3.1 Antibody optimization and protein identification
In order to identify the protein co-regulators which associate with PXR it is necessaiy to isolate 
these complexes firom the morass of proteins complexes within the cell. To do this we chose to 
use immunoprécipitation which is a common, antibody dependent, method for isolating proteins 
from solution. As discussed above the goat anti PXR antibody proved the most effective in 
initial testing (figs 3.2.1.1-3). Subsequent method development lead to use of the Tuxworth 
method with 250 Mm NaCl to optimize the binding conditions within the immunoprécipitation 
reaction (fig 3.2.2.-2) as the variation in the salt concentration, hence the ionic strengtli of the 
buffers, leads an increase in specificity of the pull down, as suggested by the klenova et al 
(Klenova et al., 2002).
Following the development of the method it was time to take the procedure foiward. It is 
common to isolate the proteins form an immunoprécipitation by running 2-dimentional gels, 
shown in figures 3.2.2.4-6. This course of action was not appropriate under the circumstances as 
the protein levels in the immunoprecipitate were not high enough for detection. ESI-MS was 
employed as a second method of detection and following the recommendation of Dr Lucas 
Bowler the Sussex method immunoprécipitation was used to boost protein levels. The resulting 
proteins can be seen in table 3.2.3.1.
The scarcity of available literature on the identification of PXR co-regulators using 
immunoprécipitation means that it is possible that this experiment is one o f very few projects 
taking a direct approach to the identification of PXR regulating proteins. Below is a table 
detailing the studies which have employed an immunoprécipitation approach to this problem:
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Author Use o f antibody and findings
Roth et al (Roth et al., 2008) Used chromatin immimop recip itation (chip) to 
demonstrate an interplay between PXR and a no 
competitive inliibitor of PXR co-activator binding.
Iwazaki et al(Iwazaki et al., 2008) Used chip to deomonstrate an interaction between PXR 
and the co-activator SRCl.
Igaraski et al(lgarashi et al., 2007) Demonstrates using chip that vitamin K activates PGR 
and recruits the p300 co-activator to PXR.
Liu et al (Liu et al., 2008) Uses chip to demonstrate preferential binding o f PXR to 
the procimal enhancer o f the CYP3A4 gene.
Kodama et al (Kodama et al., 2007) GST pull downs and ip usd to deomonstrate PXR 
binding to the cAMP response element binding protein 
to surpress the glucose-6-phosphatase gene.
Seo et al (Seo et al., 2007) Uses chip to demonshate that tliere is no effect o f aging 
on the ability o f PXR to bind DNA.
Li et al(Li et al., 2007) Uses chip to demonstrate PXR binding SRCl and 
activation o f the CYP27A1 gene.
Itoh et al(Itoh et al., 2006) Demonstrates suing chip PXR binging the CYP2A6 
promoter and recruiting the peroxisome proliferator 
receptor gamma co-activator 1 alpha.
Gu et al(Gu et al., 2006) Shows NF-kappaB as an inhibitory agent disrupting 
PXR-RXR dimérisation using chip.
Li et al(Li and Chiang, 2006) Uses chip to deomonstrate recruitment o f HNF4a and 
SRCl to the CYP3A4 promoter and shows PXR 
suppression of SHP expression.
Squires et al (Squires et al., 2004) Uses ip to demonstrate binding of PXR to the CAR 
cytosolic retention protein (CCRP), uses HSP90 
antibody.
125 f
Li et al (Li and Chiang, 2005) Uses co-ip to show PXR in complex with HNF4a and 
tlie peroxisome proliferator receoptor gamma co­
activator 1 alpha.
Song et al (Song et al., 2004) Uses chip to show preferential binding of PXR to the 
proximal CYP3 A4 promoter
Table 3.3.1 Review of previous PXR immunoprécipitation literature.
Table shows author and significant findings including metiiods used to isolate the 
proteins and what the objectives of the study were.
The use of chip appeal's to be the most widespread method to isolate the binding partners of PXR 
although direct ip and co-ip are also used. These works have contributed widely to both the 
identification of PXR interacting partners which include the nuclear receptor HNF4a (Li and 
Chiang, 2006, Li and Chiang, 2005), the common co-activator protein SRCl (Li and Chiang, 
2005, Li and Chiang, 2006, Iwazaki et al., 2008), the peroxisome proliferator receptor gamma 
co-activator protein 1 alpha (Li and Chiang, 2005, Itoh et al., 2006) and the CCRP (Squires et al., 
2004). The interactions of these proteins were not seen in this experiment, table 3.2.3.1. This 
possibly indicates that the interactions mentioned above aie gene or ligand specific, or that by 
using Huh? total protein the proteins identified are the most abundant proteins within the cell 
which interact with PXR.
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Figure 3.3.1 is a representation of the distribution of proteins found to be present in both o f the 
samples represented in table 3.2.3.1. Sin3A is a protein known to be a co-repmssor protein 
known to be associated with the thyroid hormone receptor; it has its activity as it is a histone 
deacetylase (Lutz et al., 2000). Bromodomain 4 containing protein has two known isoforms, 
short and long is, and it is involved in transcriptional suppression during certain viral infections, 
during cell cycle changes and is known to be important in the proliferation of some tumors 
(French et al., 2001, Maruyama et al., 2002, Wu et a l, 2006). P54nrb is a nuclear receptor 
binding proteins found in the nucleus hand has many functions in the regulation of transcription 
and is known to be associated with the androgen receptor (Dong et a l, 2007, Shav-Tal and 
Zipori, 2002, Kaneko et a l, 2007). The amino terminal enhance of split proteins have been 
identified as involved in foetal development through Six protein biology, in regulation of the 
interleukin 6 transcription factor gp 130 and in the suppression of activity of the transcription 
factor NficB (Liu et a l, 2002, Tetsuka et a l, 2000, Lopez-Rios et a l, 2003).
The chaperon proteins of the ABL interactor I family are involved in chaperoning proteins 
transfer between Ras and Ran small GTPase proteins, they have roles in the assembly of the 
cytoskeleton and have possible in tumorigenesis (Ichigotani et a l, 2002, Di Fiore and Scita,
2002). Sec31 like proteins are chaperon proteins associated with the endoplasmic reticulum exit 
sites and with important calcium binding proteins located in this area (Shibata et a l, 2007, 
Yamasaki et a l, 2006). The members of the Chaperonin containing TCP family are a group of 
ring stmctured chaperone proteins that have somewhat obscure fonctions in die cell, some are 
involved in the folding and processing of the actins and tubulins of the cytoskeleton, of members 
of the Cyclin cell cycle regulators such as cyclin E; essentially these proteins are responsible for 
the transportation and folding of proteins in tlie cytosol (Hynes and Willison, 2000, Won et al, 
1998).
The hetrogenous nuclear ribonuclearproteins are a foim of molecular chaperone which is 
responsible for protecting and guiding the formation of mRNAs from pre mRNAs (Dreyfoss et 
a l, 1989, Hui et a l, 2003a, Hui et a l, 2003b). The splicing factor proteins associate to form the 
spicing elements of the splicosome and interact with other splicosomal proteins and calmodulin 
(Das et a l, 1999, Agell et a l, 1998, Will et a l, 2002). The PHD finger like proteins (PHD 
finger like 5A) is a protein associated with the splicing fector 3B as part o f the spicosome (Will
et a l, 2002, Trappe et a l, 2002). NME1-NME2 protein is a gene product tmnscribed as a read 
through product of the NMEl and NME2 proteins. The function of this protein is almost 
completely unknown although NMEl and 2 are nucleoside diphosphate kinase proteins 
(Valentijn et a l, 2006).
It is possible to formulate a biological rational for the presence of these proteins bound to PXR. 
The nuclear proteins such as bromodomain containing 4, Sin3A, p54nrb and the amino terminal 
enhancei-s are all transcriptionally related or are known nuclear receptor interacting proteins and 
hence might legitimately be found interacting with the PXR complex or directly with PXR in the 
nucleus. As experiments were perfoimed on total protein and as a result the proteins identified 
will be from the entire lifecycle of PXR, hence those proteins found in the cytosol, namely the 
ABL interacting isofoms, the Sec 3 isofomis and the chaperonin containing TCP isoforms are all 
known chaperone proteins which bind to either forming or foimed proteins directing the 
refolding or movement throughout the cell. The splicing factors are usually found in the cytosol 
as they deal with the editing of the mRNA sequences however it is my belief that the 
heterogenous nuclear ribonuclear proteins as cheprones for the mRNA molecular may interact 
with the active PXR complex to lead and guide the mRNA molecules though to the remaining 
splicing factors. These proteins may all have as yet unknown functions although much more 
work would be needed to demonstrate these interactions both physically and functionally,
3.3.3 Half GFP Protein-Protein interaction assay
The half GFP assay requires the use of the pMRBAD-link-CGFP and pET 11 A-link-NGFP 
plasmids. Cloning schedules were designed for all o f the genes identified and shown in table
3.2.3,1 and figure 3.3.1, however due to problems with the cloning there was not time to clone 
all of the genes into the system.
The half GFP method has been used to characterize interactions between leucine zipper 
containing proteins and can identify direct interactions with a Kd as high as ImM (Magliery and 
Regan, 2006, Magliery et a l, 2005, Wilson et a l, 2004). This particular* method was developed 
for use in competent bacteria containing mammalian codons and some o f the chaperones 
required for folding mammalian proteins, such as B121, rosetta and rosetta pLysS cells (Wilson 
et a l, 2004, Magliery and Regan, 2006, Magliery et a l, 2005). In the course of method
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development both the rosetta and rosetta pLysS cellswere used with no positive interactions 
found, including for the positive control PXR-RXR interaction. The rosetta competent cells 
contain a chloramphenicol plasmid expressing tRNAs with the codons AUA, AGG, AGA, CUA, 
CGC, CGG, and GGA which enable the expression and folding of many proteins (Lobel et al., 
2002, Lobel et al., 2001, Prinz et al., 1997). The rosetta pLysS cells contain the tRNA codons 
AUA, AGG, AGA, CUA, CCC, CGG, and GGA and also express a T7 lysozyme gene which 
inhibits the activity of the T7 RNA polymerase preventing expression of recombinant proteins 
which may be detrimental to the cells growth before induction witli fPTG (Crosson et al., 2005). 
These cells are derivatives of the BL21 E.Coli line used in the original papers (Magliery and 
Regan, 2006, Magliery et al., 2005, Wilson et al., 2004, Lobel et al., 2001, Lobel et al., 2002, 
Prinz et al., 1997, Crosson et al., 2005) and were expected to have been amenable to the simple 
method of detection with a handheld UV light as described by Magliery et al (Magliery and 
Regan, 2006, Magliery et al., 2005, Wilson et al., 2004).
The failure of the bacteria to fluoresce but express the protein, as shown in fig 3.2.5.1 suggested 
that the proteins were incoiTectly folded in the bacterial system, preventing intertaction. To test 
this TNT otherwise known as Transcription and Translation, a rabbit reticulocyte lysate invitro 
transcription and translation kit, was used to provide the mammalian folding proteins which may 
be required to demonstrate positive interactions in this stysem (Krieg and Melton, 1984). The 
system can use any plasmid with a T7 promoter to transcribe and translate mammalian proteins, 
the system is also capable of mammalian protein folding and to a lesser extent post translational 
modification (Kiieg and Melton, 1984). pETl 1 A-Link-NGFP and pMRBAD-link-CGFP both 
contain T7 promoters and are suitable for processing using this method.
RXR, p54nrb, ABL intearactor, and SF3B2 were tested with PXR in a TNT reaction. The results 
are shown in table 3.2.5.1. The inconsistency in the positive control PXR-RXR interaction was 
may suggest that in some reactions not all proteins are folder or expmssed correctly. This 
method may not be suitable for the expression of the proteins using these plasmids. It is my 
belief that the T7 promoter present in pETl 1 A-link-NGFP and pMRBAD-link-CGFP is not a 
strong enough promoter to get consistent results. Subcloning of a stionger promoter into both 
plasmids would enable this system to work more efficiently, alternatively subcloning the half 
GFP into a vector suitable for expression in mammalian cells such as pCDNA3 where a
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cytomegaloviras promoter provide strong promotion of the gene contained within frame o f the 
promoter (Andersson et al., 1989).
3.4 Summary
The identification of a number of proteins wifii feasible biological rationales for their interaction 
with PXR by ESIMS anlaysis of the products of PXR ips was a significant step forwards in this 
field. The half GFP assay in conjunction with the TNT reaction may yet prove to be valuable in 
moving this work forwards and with some adaptation of the plasmid vector it is possible that the 
results will become more reliable. These experiments represent a somewhat novel and direct 
approach to identify PXR co-regulators and has shown that an antibody based method to isolate 
the PXR complexes may not be the best approach.
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Chapter 4: Transcriptome Analysis o f the effect o f PCN 
and LCA on primary rat hepatocytes: Pilot Study.
4.1. Introduction
The central hypothesis that has driven this thesis revolves around the concept of nuclear 
receptor-activated gene expression being regulated in a ligand-specific manner. It is believed 
that different ligands, active against the same receptor, drive recruitment of subtly different co­
activator complexes, which ultimately cause variation in the gene sets that are regulated when 
the receptor is activated by these different ligands, hi order to examine this hypothesis it is first 
necessary to demonstrate that different ligands for a single nuclear receptor may result in distinct 
tmnscriptome effects. This chapter represents the experimental design and preliminary 
experiments that were required before undertaking a genome wide analysis, through use of gene 
airay teclinology. Two PXR ligands, Lithocholic acid (LCA) and Pregnealone carbonitrile 
(PCN), were chosen as they are both classical ligands for PXR with a history of use in studies of 
PXR biology, as discussed below.
As discussed in the introduction, PXR has complicit roles in regulating many hepatic anabolic 
and catabolic pathways; notably in the regulation of genes involved in xenobiotic metabolism 
and bile acid bioregulation (Staudinger et al., 2001b, Kliewer and Willson, 2002). Most genes 
come under the regulation of multiple metabolic pathways and may be activated by any o f them 
as a result of dosing, for instance activation of nuclear receptors other than PXR such as VDR, 
CAR and FXR Experimental controls need to be employed which are essential in this type of 
experiment to dissect out the possible involvement of other transcriptional mechanisms. This 
chapter represents a preliminary pilot study to assess appropriate dose ranges and to explore 
possible ligand cross reactivity between receptors before embarking on a more comprehensive 
gene array study.
4.1.1 Lithocholic acid as a PXR agonist
LCA is a hydrophobic secondary bile acid synthesized in the liver by the dehydroxylation of 
chenodeoxycholic acid. LCA is detergent in nature and exhibits acute and chronic pathologies if
allowed to accumulate within die body, defined as cholestasis (Javitt, 1966, Ramakiishnan et ah, 
1993). Cholestasis is a functional perturbation of the flow in bile in the enterohepatic system 
and is characterized ranging from flu like symptoms to jaundice, a result of inteniipted bilirubin 
excretion and bile acid accumulation (Trauner et al., 1998). The concentration of LCA is sub 
micromollar within cells under normal conditions, although levels can rise to between 5 and 15 
pM during acute cholestasis (Setchell et al., 1997). In 1972 Selye et al demonstrated that 
administration of high levels of LCA to rats induced severe cholestasis, which was reversed, and 
could be prevented by, administration o f a PXR agonist PCN (a catatoxic steroid) (Selye, 1972). 
Similar effects have been observed by the administration of rifampicin to patients suffering 
hepatic cholestasis, upon which symptoms are much relieved and in some cases the patients enter 
a remission (Cancado et al., 1998).
Subsequent to this, Staudinger and colleagues demonstrated that LCA and its principal 
metabolite in the rat 3 keto-LCA were effective ligands of PXR, activating PXR regidated genes. 
The use of a reporter gene assay with die promoter of CYP3A indicated that both LCA and 3 
keto-LCA wem the only bile acid agonists of PXR, with primary and tertiaiy bile acids having 
no effect (Staudinger et al., 2001b). LCA has now been demonstrated to activate seveml genes 
in a PXR dependent manner, including CYP3A, CYP7A1 and Oatp2 amongst others (Staudinger 
et ah, 2001b, Sonoda et al., 2002, Xie et al., 2001).
The implications of the works by Selye et al, Staudinger et al and others indicate that PXR is a 
central component of bile acid synthesis, metabolism and disposition (Kliewer et ah, 2002, 
Selye, 1972, Selye, 1971, Staudinger et ah, 2001a, Staudinger et ah, 2001b, Staudinger et ah, 
2003). The activation of PXR by bile acids, resulting in the regulation of metabolism and 
disposition pathways for bile, supports the argument that PXR acts in support of FXR as a bile 
acid biosensor (Kliewer and Willson, 2002).
To summarize, LCA has been chosen as an endogenous ligand of PXR which has been 
characterized in previous work to be efficacious at inducing expression of CYP3A1. LCA has 
been shown to be cross reactive with FXR (Rizzo et ah, 2005) and with VDR (Nehring et ah, 
2007) but to have greater selectivity for PXR. LCA is more specific for PXR but has some 
affinity and efficacy for FXR and VDR (Chawla et ah, 2001), LCA has been used in other gene
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array studies (discussed in section 5.1) as a ligand of PXR and so is appropriate for use in my 
study. The experiments and clinical obseiwations listed above, i.e. LCA levels rising to 5-15 pM 
in the livers of cholestatic patients and the use of between 10 and 100 pM LCA in previous 
experiments indicate that LCA at concentrations between 10 and 100 pM would be appropriate 
for my pilot study.
4.1.2 CDCA as a ligand for PXR and FXR
It has been shown conclusively that CDCA is not a good ligand of PXR in rats (Staudinger et al., 
2001b). However as a primary bile acid, synthesized in the liver in a reaction downstream of 
CYP7A1, it is the classical ligand of the bile acid sensor FXR (Chawla et al., 2001). CDCA has 
an EC50 for FXR activation between 10-50 pM, which is in keeping with endogenous levels of 
this bile acid in the liver, ranging from submicromolar to several hundred micromolar levels 
(Chawla et al., 2001, Chen et al., 2001, Gustafsson, 1999, Goodwin et al., 2000). CDCA was 
used in this study to investigate the potential involvement of FXR in genes shown to be regulated 
by LCA, should CDCA show an expression profile similar to that of LCA is can be presumed 
that LCA is activating FXR. To summarize; CDCA is used in my experiments as a positive 
control examining the contiibution of FXR activation of genes found to be regulated by LCA 
concentrations that have been selected as used in previous studies and should prove appropriate 
for this study. A dose range of 10-100 pM CDCA was chosen in keeping with the literature 
values of CDCA activation of FXR.
4.1.3 PCN as a PXR agonist
It was first observed by Selye that administration of so called ‘catatoxic’ steroids, such as PCN, 
reversed the LCA-induced hepatic cholestasis (Selye, 1972, Selye, 1971). Similai* effects have 
been observed in humans, where patients suffering hepatic cholestasis had their symptoms 
reduced by the macrolide antibiotic rifempicin, another classical PXR agonist (Staudinger et al., 
2001b). Further to the observations by Selye, PCN administration to rats was shown to increase 
the activity o f a batteiy of microsomal metabolizing enzymes in the liver (Kourounakis et al., 
1976), and PCN was shown to regulate a large number of genes, primarily involved in bile acid 
and xenobiotic metabolism and disposition. These genes include the hepatic efflux transporter 
Mrp2 (Kast et al., 2002), Oatp2 (Guo et al., 2002a, Guo et al., 2002b), CYP 7A1 (Einarsson and
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Gustafsson, 1973, Li et al., 1990) observations originally made in the early 1970’s (Eaton and 
Klaassen, 1979, Klaassen, 1974a, Klaassen, 1974b). PCN also induces the activation of several 
members of the CYP 3 A family across species; CYP 3 A ll in mice, CYP 3A1 in rats and CYP 
3A4 in humans, although the there is a distinct species difference in the efficacy o f this 
activation with human PXR being the least responsive (Xie et al., 2001). The induction o f the 
CYP 3 A sub-family was demonstrated to be dependent on the presence of PXR and hence to be 
through activation of this receptor (Xie et al., 2001, Staudinger et al., 2001b).
To summarize, PCN is a classical PXR ligand having been characterized first in the 1970s and 
later as a highly effective inducer of the PXR maiker gene CYP3A1 at the concentrations 
discussed above. There is little literature data on the specific binding values of PCN to PXR, 
however the use of PCN is typically between 1-10 pM in rat hepatocytes (Staudinger et al., 
2001b, Xie et al., 2001, Sporstol et al., 2005, Lehmann et al., 1998) mid so this range was used in 
this pilot study.
4.1.4 Target marker genes
In this pilot study it is necessaiy to look at the expression changes of a number of marker genes 
known to be regulated by either PXR, or one of the ligands discussed above. CYP7A1 and CYP 
8B1 are the rate limiting enzymes in tlie synthesis of the primary bile acids cholic acid and 
chenodeoxycholic acid firom cholesterol, and are negatively regulated by both PXR and FXR 
during periods of high bile acid concentration (Goodwin et al., 2000). These genes are well 
characterized as being regulated by both PXR and FXR and were examined in the current 
experiments to determine if LCA activation of PXR and FXR could be deteimined. CYP3A1 is 
the classical PXR activated gene in rats (Staudinger et al., 2001b) and is used in the current 
experiments to detennine the activation of PXR by the two ligands LCA and PCN. Fibrinogen p 
is a gene expressed in the liver and participates in the clotting cascade as a protein which forms 
the protein scaffold of a blood clot; fibrinogen p has been shown to be transcriptionally regulated 
by FXR (Anisfeld et al., 2005) and is used in this experiment to indicate FXR activation by LCA. 
There was no information regarding the regulation of fibrinogen p by PXR available at the start 
of this project, but the action of PCN on fibrinogen P transcript level will be used to examine 
this.
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4.1.5 TaqM an QRTPCR
QRTPCR (Quantitative Reverse Transcriptase Polymerase Chain Reaction) is a method of 
accurately qunatifying the tianscript levels of a specific gene. The first step involves the reverse 
transcriptase conversion of labile mRNA molecules to more stable CDNA. The second step is a 
controlled PCR amplification of the specific gene sequence that is the object of study (Plant, 
2003).
QRTPCR has both semi- and fully quantitative applications. It is possible to perfoim the 
amplification and measure the levels of gene in the sample, comparing one sample to others or to 
‘house keeping’ genes. A quantitative approach is to use species specific genomic DNA as a 
template for a standard curve. Using the calculation below it is possible to calculate the number 
of copies of a gene in a sample of genomic DNA of known quantity. These calculations are then 
used to make a standard curve typically starting with 10  ^or 10® copies (Plant, 2003).
TaqMan is a further development o f the above method. This particular method utilizes a labeled 
gene specific DNA probe labeled with a fluorescent reporter and quencher. While the probe is 
whole and intact the fluorescence emitted by the reporter is absorbed by the quencher (Plant,
2003). During amplification the probe is degraded by the DNAse function of Taq DNA 
polymerase which leads to the separation of the reporter form the quencher, allowing the probe 
to fluoresce. Typically Fluoresceine (FAM) and tetramethylrhodamine (TAMRA) are used as 
reporter and quencher respectively (Plant, 2003).
4.1.6 Summary
Ligand Nuclear receptor Genes expected to be affected
LCA PXR, FXR CYP8B1, 7A1, 3A1, and 
Fibiinogenp
PCN PXR CYP8B1,7A1 and 3 A1
CDCA FXR CYP8B1,7A1 and Fibrinogen p
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This chapter is a prelude to performing a gene aiTay analysis to test the hypothesis that different 
PXR ligands activate differing gene sets. To perform such a sensitive and complex experiment it 
is necessary to ensure that the dose ranges and cell responses are appropriate. The ligands LCA, 
PCN and CDCA have been selected to highlight PXR, FXR and joint activation of these 
receptors. The marker genes have been selected as they are marker genes o f PXR of FXR 
activation and are known to be regulated by one or both of the above receptors.
Aims:
• To identify appropriate dose ranges of PCN and LCA with regards to the expression of 
the genes chosen as marker genes.
• To confirm that cells in sandwich culture respond as expected with regards to the 
expression of the genes chosen as marker genes.
• To asses viability of gene an ay experimental plan.
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4.2 Results
4.2.1 CYP 7A1 and 8B1
Primaiy rat hepatocytes were cultured for 4 days and then tieated with the concentrations of 
LCA or PCN, treatments lasted for 72hours with media changes eveiy 24 hours. CYPs 7A1 and 
8B1 were investigated as markers o f activation of both PXR and FXR. Transcript levels of CYP 
7A1 and 8B1 were analyzed by Taqman QPCR of the cDNA from the cells treated witli LCA, 
PCN and CDCA. Levels of these transcripts in all cells, including DMSO control samples, were 
found to be between 10 and 80 copies which is almost below the sensitivity o f the Taqman assay. 
LCA, PCN and CDCA as ligands of PXR and FXR were expected to suppress the expression of 
these genes in cells, however, as the control expression levels were so low this was not possible 
to observe.
Figures 4.2.1 and 4.2.2 show the QPCR standard cui'ves for CYPs 7A1 and 8B1 respectively. 
The CT value or Cycle threshold is the point at which the fluorescence intensity reaches ten 
times the standard deviation of the background fluorescence, i.e. the cycle at which the reaction 
becomes detectable. Coupled with this the amplification must breach the level of the ROX 
which is a fluorescent component of the Taqman reaction mix which is used to standardize 
fluorescence levels in the samples. As can be seen the highest standard becomes detectable after 
cycle 22-23 while the lowest after 37-38. For reliable detection samples ideally become 
amplified between 10® and 10  ^samples in this case.
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CYP 7A1 standard curve
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Figure 4.2.1 QPCR standard curve for CYPs 7Al and 8B1.
The CT value or Cycle threshold is the point at which the fluorescence intensity reaches ten 
times the standard deviation of the background fluorescence, i.e. the cycle at which the 
reaction becomes detectable. This graph shows at which point in the cycling of the PCR 
each standard becomes detectable
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4.2.2 CYP 3A1
CYPS Al was investigated as a known marker for PXR activation, and it is not known that FXR 
regulates this gene. Transcript levels of CYP3A1 from primary rat hepatocytes in sandwich 
culture treated with a) LCA, b) PCN and c) CDCA are shown in figure 4.2.1. It can be seen that 
there is a significant (p=0.0076) up-regulation of CYP3A1 across the dose range of LCA. . In 
addition, PCN elicited a significant (*p=0.01) up-regulation CYP3A1 across the dose range 
tested, with 10 pM showing significant upregulation verses control (*p=0.01). In comparision to 
the effects observed with the two PXR agonist, the FXR-agnoist CDCA elicited no significant 
change in expression ofCYP3Al (Figure 4.2.1 c).
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Figure 4.2.1 Differential regulation of CYP3Al by LCA, PCN and CDCA.
Primary rat hepatocytes in sandwich culture were grown for 96 hours and treated 
for 72 hours with a) 0, 10, 20, 50, 80, and 100 pM LCA, b) 0, 1,2, 5, 8, and 10 pM 
PCN, and c) 0, 10, 20, 50, 80, and 100 pM CDCA. RNA was extracted and 
processed into cDNA for Taqman analysis which was used to analyze the expression 
of copies of CYP3A1 per 0.5 pg starting RNA. Data was analyzed using Graphpad 
Prism and chart bars are representative of the mean expression level (n=4) with error 
bars being SEM. Data analyzed by one way ANOVA with Bonferoni multiple 
comparisons correction. *p=0.01.
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4.2.3Fibrinogeii p
Fibrinogen (3 was investigated as it is regulated by FXR but is not known to be regulated by 
PXR. Transcript levels of Fibrinogen pwere analyzed by Taqman QPCR of samples from 
primary rat hepatocytes in sandwich culture treated with dose ranges of a)LCA, b)PCN and 
c)CDCA and are shown in fig 4.2.2. Figure 4.2.4 a) shows significant (p<0.0001) regulation of 
fibrinogen p by LCA, with 80 and 100 pM showing significant upregulation o f fibrinogen p 
(***p<0.0001). Figure 4.2.2 b) mid c) show no significant regulation of this gene by PCN or 
CDCA.
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Figure 4.2.2 Differential expression of Fibrinogen p by LCA, PCN and CDCA.
Experimental setup was as fig 4.2.1 and was analyzed as before. Data was analyzed using 
Graphpad Prism and chart bars are representative of the mean expression level (n=4) with error 
bars being SEM. Data analyzed by one way ANOVA with Bonferoni multiple comparisons 
correction. ***p<0.0001
4.2.4 Ketoconazole as a PXR antagonist
In addition to using CDCA, a FXR-agonist with no activity against PXR, ketoconazole was used 
in these experiments as an antagonist of PXR (Wang et al., 2007, Duret et al., 2006). The effect 
of ketoconazole on the expression of CYP3A, figure 4.2.5, shows the effect of a dose range of 
Ketoconazole on the expression of CYP3A1 induced by a) 80 pM CDCA and b) 8 pM PCN. 
Figure 4.2.5 a) 80pM CDCA has no significant effect on the expression of CYP3A1, hence
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ketoconazole has no significant effect in this case. Figure 4.2.5 b) 8pM PCN shows high levels 
of expression of CYP3A1 which is significantly (P=0.0001) reduced with increasing 
concentrations of ketoconazole, with 5, 10 and 15 pM ketoconazole showing significant 
reduction in expression verses 0 pM ketoconazole (8pM PCN) (*** p<0.0001, *p=0.01)
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Figure 4.23 Effect of Ketoconazole on the expression of CYP3A1.
Primary rat hepatocytes in sandwich culture were grown for 96 hours and treated for 72 hours 
with a) fixed concentration of 80 pM CDCA and concentrations of 0, 1, 2, 5, 10, and 15 pM of 
Ketoconazole and b) fixed concentration of 8 pM PCN with concentrations of 0, 1, 2, 5, 10 and 
15 pM Ketoconazole. RNA was extracted and processed into cDNA for analysis. Taqman 
QPCR was used to analyze the expression of CYP3A1 copies per 0.5 pg starting RNA. Data 
was analyzed using Graphpad Prizm chart bars are representative of the mean expression level 
with error bars being SEM. Data analyzed by one way ANOVA and Bonferroni multiple 
comparisons post hoc test. ***p<0.0001, *p=0.01.
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4.3 Discussion
The expression levels of CYP7A1 and 8B1 were analyzed as shown in section 4.2, but in these 
samples the transcript level was so low that no data analysis was possible. The literature 
suggests that both PXR and FXR suppress the expression of these enzymes in response to bile 
acid concentration increases (Staudinger et al., 2001b, Chiang, 1998, Chen et al., 2001, Li et al., 
1990, Gustafsson, 1999, Russell, 1999, Fomian et al., 1995, Seol et al., 1995, Stravitz et al., 
1993, Twisk et al., 1993, Crestani et al., 1994, Taniguchi et al., 1994). The previous 
demonsti'ations that PXR and FXR suppress the expression of CYP7A1 and CYP8B1 were 
performed in human cell lines via transfection and reporter gene assay (Chen et al., 2001, 
Taniguchi et al., 1994, Crestani et al., 1994), in the livers of rats fed bile acids (Li et al., 1990) or 
in monolayer rat hepatocyte cultures (Twisk et al., 1993, Stravitz et al., 1993). The data 
presented in this chapter suggests that the endogenous levels of CYP7A1 and 8B1 are 
considerably lower in the cultures used in the current study compared to previous studies.
Hepatocytes grown in sandwich culture have been demonstrated to be polarized and form 
functional cannaliculi, allowing them to hansport xenobiotics and bile acids (Liu et al., 1999a, 
LeCluyse et al., 1994, Hoffînaster et al., 2004, Liu et al., 1998, Liu et al., 1999b, Liu et al., 
1999c). As such these cells form an invaluable assay tool for the in vitro modeling of dmg 
transport. The formation of an intact billiary system in these cells lead to the conclusion that 
hepatocytes in sandwich culture were appropriate for these experiments (LeCluyse et al., 1994, 
Hoffinaster et a l, 2004, Liu et a l, 1998, Liu et a l, 1999a, Liu et a l, 1999b, Liu et a l, 1999c). 
Additionally, Bi et al demonstrated that the formation of cannaliculi and polarization of cells is a 
time dependent process (Bi et a l, 2006). It is possible that the 96-120 hour time period required 
for the formation of a billiaiy system in my cellular studies allowed the level of bile acids to 
increase to cholestatic levels; this would lead to the suppression of CYP7A1 and 8B1, through 
activation o f FXR and PXR.
The expression of CYP3A1 in response to LCA, PCN and CDCA are shown in figure 4.2.1 a, b, 
and c respectively. It is widely known that PXR activation leads to an increasing in expression 
of CYP3A1 (Xie et a l, 2001), but there is no reported information to date on the expression of 
CYP3A by FXR. The data in figure 4.2.3 shows significant upregulation of CYP3A1 by LCA
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and PCN but not by CDCA. This was to be expected as both PCN and LCA are ligands of PXR, 
whereas CDCA is not (Staudinger et al., 2001 b).
Fibrinogen (3 expression in response to LCN, PCN and CDCA treatment is shown in figure 4.2.2 
a, b and c respectively. Anisfeld et al demonstmted that fibrinogen (3 is transcriptionaly 
regulated by FXR (Anisfeld et al., 2005), whereas no information is available suggesting that 
fibrinogen p is transcriptional regulated by PXR. As LCA is a ligand of both PXR and FXR 
(Chawla et al., 2001, Staudinger et al., 2001b) it was decided to use fibrinogen p as a gene to 
check for FXR activation. As shown in figure 4.2.4 there is no significant regulation of 
fibrinogen p by PCN or CDCA, however LCA significantly upregulated this gene. PCN and 
CDCA can be viewed as the classical ligands of PXR and FXR respectively. The data suggests 
that PXR and FXR do not have any effect on the expression of fibrinogen p when activated by 
these ligands, which in the case of FXR is not consistent with the literature (Anisfeld et al., 
2005). It is possible that bile acids have accumulated within the cells due to their inability of the 
cells to export them. Primaiy bile acids are the ligands of FXR and tiieir high concentrations 
within a cholestatic cell would provide a competitive inhibition for LCA activation of FXR. 
Secondary bile acids represent only a small portion o f total bile load in hepatocytes (Einarsson et 
al., 2000, Johnson, 2005), hence FXR may still be sensitive to LCA despite the high 
concentration of primary bile acids. It is also possible that PXR has some transcriptional activity 
for this gene when activated by bile acids such as LCA or that LCA is acting through a 
mechanism tliat has not been considered and further experiments are required to understand this.
Figure 4.2.3 shows the effect of ketoconazole on the expression of CYP3A1 by a) a fixed 
concentration of 80 pM CDCA and b) a fixed concentration of 8 pM PCN. Ketoconazole is 
known to have an effect on PXR target genes, either indirectly as an antagonist of GR or through 
direct antagonism of PXR (Wang et al., 2007, Duret et al., 2006) and as such should reduce the 
expression level of CYP3A1. Fig 4.2.1 shows that, as previously demonstrated, CDCA has no 
effect on expression of CYP3A.In comparison, 8pM PCN elicits a high level of CYP3A 
transcripts, confirmed in figure 4.2.3 b). As ketoconazole leads to a significant reduction in the 
levels of CYP3A1, and is a known antagonist of PXR, this suggests that activation of CYP3A1 
by PCN is PXR-mediated.
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4.4 Summary
The primaiy purpose of this study was to establish appropriate marker genes for the activation of 
PXR and FXR by LCA and PCA, and to establish appropriate dose ranges for these compounds. 
From this study it was decided to use LCA at 0, 10, 20, 50, 80, and 100 pM and PCN at 0, 1, 2, 
5, 8 and 10 pM to treat primary rat hepatocytes in sandwich culture in the gene array experiment. 
It was also decided to use CYPs 7A1, 8B1, and 3A1 and fibrinogen p as marker genes as in this 
experiment.
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Chapter 5: Transcriptome analysis of primary rat 
hepatocytes following exposure to the PXR agonists PCN 
and LCA
5.1 Introduction
5.1.1 Gene array technology
Gene array, or DNA microarray, is a blanket term for a group of technologies that allow for the 
analysis of alterations in transcript transcript levels of a large number of genes in one sample. 
Gene arrays have evolved from the time consuming, and labour intensive northern blot which 
screened for one, or a limited number, of transcripts transcriptin any one sample. This ^^pe of 
gene arr ay transcriptional profiling is complex and generates a large amount of data for a large 
number of genes.
There are two main types of DNA microarray, cDNA and oligonucleotide arrays, both of which 
are nucleotide molecules hybridized onto a matrix material such as glass or membrane. cDNA 
arxays consist of cDNA targets spotted in a grid pattern on to the matrix material, the sample 
transcript is reverse transcribed into cDNA copies which are then hybridized to the chip. This 
particular type of chip suffers firom several shortcomings the most serious being that the variation 
in size, GC content and secondary folding of the cDNA molecules of the chip and of the sample 
leads to considerable differences in tlie efficiency of hybridization of sample cDNAs to the chip. 
Oligonucleotide arrays consist of a great number of pre-synthesized oligonucleotides which form 
approximately 25mer sections of gene sequences; these short oligonucleotides confer an high 
degree of specificity and uniformity to the army which is quite a significant advantage in 
reducing hybridization differences and anay variation. This particular type of array is utilized by 
Afftmetrix and is used in this project. Affymetrix chips consist of up to 500,000 distinct and 
individual oligonucleotides, and there are between 10 and 20 25mer sections per target transcript, 
such that there are 10-20 25mers per gene represented on the array.
With the complexity of the data generated in this type of experiment it is possible that inter-array 
variation and mismatch hybridization may be observed. Control for, and reduction of, such 
potential confovmding factors is extremely important and Affymetrix have approached these 
problems in three ways; first each 25mer oligo has a mismatch partner which has a base 
substitution mid sequence that acts as an hybridization control to indicate when mismatches 
occur. Second, each of the 25mer probes againat a single gene are distributed remote fiom each 
other across the chip, which prevents cross contamination and false detection of a change in the 
gene expression. Third, Affymetrix recommend that only gene chips from the same 
manufactured batch be used in a comparison as there is little variation within a batch but there 
can be considerable variation between batches.
5.1.2 Previous PXR microarray studies
The examination of PXR regulated genes has predominantly been on an individual basis, with 
the focus of research on drug metabolizing genes; both phase I, phase II and molecular' 
transporters (Bertilsson et al., 1998, Blumberg et al., 1998, Kliewer et al., 1998, Lehmann et al., 
1998, Zhang et al., 1999a, Gonzalez et al., 1993, Schuetz et al., 1986, Arlotto et al., 1987, 
Maglich et al., 2003, Maglich et al., 2002, Runge-MoiTis et al., 1999, Staudinger et al., 2001b). 
Whereas there are a few studies that have looked at PXR activation on a micro array basis (Goetz 
et al., 2006, Tully et al., 2006, Hartley et al., 2004, Slatter et al., 2006a, Rosenfeld et al., 2003, 
Ejiri et al., 2005b, Bjiii et al., 2005a, de Longueville et al., 2002) these have tended to use 
targeted arrays and hence focused on drug metabolism and distribution.
Author Significant notes
(de Longueville et al., 2002) Used a low density 'rathepatochip' containing  
59 g en es o f  interest including CYP3A1 but 
focusing on apoptosis gene, Sprague Dawley 
rats treated with phénobarbital and PCN w ere  
com pared vs control.
(Hartley e t  al., 2004) L-742694 and dexam ethasone w ere  
adm inistered to fem ale Sprague dawley rats 
and both hepatic and gastrointestinal gen e
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expression profiles w ere analysed with th e  
express intention o f looking for PXR activation, 
CYP3A1, U G T lal and Oatp2 w ere found to  be  
regulated. Concluded that regulation w as via 
different m echanism s in both tissues.
(Guzelian et a I., 2006) Used an unbiased array to  search for gene  
changed caused by PCN treatm ent o f Sprague- 
Dawley rats, a total o f 220 significant gene  
changes w ere found. Find that regulation of 
several areas o f m etabolism , cytosolic 
transport and redox balance w ere affected, 
conclude that PXR may regulate extensive  
pathways outside o f th e  ADME genom e.
(Slatter et al., 2006b) 75 human liver sam ples w ere used to analyse  
th e variation in the ADME genom e and 
com pared to that o f a 'contol' se t  o f 27 inbred 
rhesus monkey iivers. They identify clusters of 
g en es regulated by the major ADME nuclear 
receptors, including AhR, CAR and PXR based  
on th e  known gen es o f th e  CYPIA, CYP2A and 
CYP3A families. Not really able to  draw firm 
conclusions due to  com plexity of sam ple  
populations and th e  lack o f an adequate  
control.
(Slatter et al., 2006a) A 25000 oligonucleotide array w as used to  
analyse th e expression patterns in fem al 
Sprague dawley rats treated with on e o f a 
range of 26 different ligands for the com m on  
ADME regulating receptors AhR, CAR and PXR. 
A large num ber o f changes w ere found, over  
1000, and cluster analysis w as used to  
separate clusters belonging to  the three  
receptors based on the expression o f marker
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genes. Find that CAR and PXR are very difficult 
to  separate by cluster analysis while AhR is 
notably different.
(Goetz et al., 2006) Adult CD-I m ice w ere exposed to  one o f three  
oral d oses o f fluconazole, myclobutanil, 
propiconazole, or triadimefon. Use an 
unbiased oligonucleotide array to look for 
gen e expression changes and find that that 
m em bers o f the CyplA, 2A, 2B and 3A families 
are significantly altered. Conclude that CAR 
and PXR are highly activated by th ese  
com pounds, but that other pathways must 
also be activates as there is considerable 
alteration to th e size of the hepatocytes and 
liver.
(Tully et al., 2006) Much th e sam e as th e  work done by Goetz et 
al although in this case adult male Sprague- 
Dawley rats w ere of three oral d oses of 
fluconazole, myclobutanil, propiconazole, or 
triadim efon. These com pounds significantly 
regulated m em bers fo the Cyp2C and 3a 
families and other ADME gen es such as 
Udpgtr2. Commonality b etw een  com pounds 
suggests a central m echanism  which is 
suggested to be via PXR and CAR activation 
based on hierarchical cluster analysis.
(Rosenfeld et al., 2003) Perform microarray analysis focusing on the  
ADME g en eom e on sam ples from mice 
expressing a constitutively active form of PXR, 
VP-PXR. Find that a range o f both phase I and 
II enzym es are altered, as well as a num ber of 
transporters, all o f which have previously been
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dem onstrated as being regulated by PXR.
{Ejiri e t  ai., 2005a) Fisher 344 pregnant rates w ere dosed with 
PCN and Phénobarbital in order to asses fetal 
responses to  the PXR and CAR agonists. 
Found that both Cyp3a and 2b families w ere  
upregulated in the dams and fetus, also that 
the placenta show ed significantly expression  
increases of C yp3al in both phenobarb and 
PCN groups. PXR w as upregulated in the liver 
o f th e  dams.
(Ejiri e t al., 2005b) Identical in experim ental procedure to  Ejiri e t  
ai discussed above. This study focused on  
expression changes o f  the phase tw o  
m etabolic enzym es. A num ber of GSTs and 
UDPGTs w ere studied and in all cases there  
w ere m ore changes in th e  dams livers than 
th o se  o f th e fetus for both PCN and 
p h en ob arb .
Perhaps the most relevant array experiments in the literature are those of Slatter et al (Slatter et 
al., 2006a, Slatter et al., 2006b) and Guzelian et al (Guzelian et al., 2006). Slatter et al used a 
compendium of regulator's o f hepatic metabolism including LCA and PCN to assess the relative 
effects on only genes involved in dnrg metabolism and disposition; the major drawback to this 
study was that each compound and dose was performed with an n number of one removing any 
chance of statistical evaluation of the expression data. Guzelian et al used PCN treated rats to 
perform a broad range Affymetrix rat microarray experiment which does not focus only on the 
effects on genes known to be involved with drug metabolism but suggest that PXR has a more 
important wide ranging effect on cellular processes.
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5.1.3 Data Handling and Interpretation of Gene Array Data
Gene array analysis produces a volume and complexity of data such that commonly-used 
statistical analyses may be too simplistic, potentially resulting in eiToneous interpretations. 
Probability levels are arbitrary values designated as threshold chances below which a result is 
considered significant and above which not significant. A P-value o f 0.05 is the standard level 
set in most analyses and indicates a probability of 5 in 100, or 5%, that the result occurred by 
chance. In a sample of 100 genes 5 % or 5 genes will have occuired by chance, taken further in a 
sample of 50,000 genes 2500 will have been identified by chance. For this reason the standard 
mechanism of statistical validation of a result is inapplicable to tlie interpretation of high content 
biological approaches such as gene aiTays.
An alternative approach is the use of an arbitrary average fold change, above which a change is 
considered significant, below which is considered insignificant. Statistical approaches must 
accept a number of falsely identified changes. An average fold change (often 2 fold) threshold 
level will lead to identification of genes which have a broad variation in sample repeats pushing 
the fold change above the threshold, whereas small fold changes which are consistent over all 
sample repeats may be of tremendous biological importance and would be excluded, to try and 
avoid this problem raw gene array data was processed by a Statistical Analysis of MicroaiTays 
(SAM) approach, a statistical program developed for the analysis of high volume data (Efi-on, 
2007, Pan, 2002, Tusher et al., 2001). SAM calculates a statistical value which is related to a T 
statistic but which compensates for strength of gene expression and variation in response across 
the biological repeats. Each gene is given a score which is a function of the expression level of 
the gene and the standard deviation of the expression levels of the gene in the samples. Unlike a 
standard T test the threshold of significance is determined by the examiner such that the 
examiner chooses an acceptable number of false positives (presumably as low as possible to 
allow a good number of significant changes). Subsequently the program calculates a ‘delta’ 
value which gives the desired number of false positives; this ‘delta’ value is the threshold 
statistic that forms the basis for the analysis. This is unlike a normal P value as it compensates 
for the high volume of statistics. Once the statistical analysis the volume of data is still
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somewhat oveiwhelming and cannot be viewed without the aid of pathway analysis, as shown in 
chapter 6.
5.1.4 Gene array methodology
Primary rat hepatocytes from adult Sprague-Dawley rats were grown in sandwich culture for 96 
hours before treatment with doses of LCA (0,10, 50 and 100 pM) and PCN (0 ,1 ,5  and 10 pM), 
n=4. RNA was extracted and was processed before application to an Affymefrix Rat230 2.0 (Cat 
# 900507 http://www.affymetrix.com/products/arrays/specific/rat230_2.afïx) airays which were 
washed and stained with the Affymetrix fluidics stations 450 (Cat# 00-0079 
http://www.affymetiix.com/products/instruments/specifrc/fs450.af6c) . The levels of expression 
of 35,000+ genes was assessed with a Genechip scanner 3000 
(http ://www.affymetrix.com/prodiicts/instmments/specific/scanner_3000.affic) using the 
Microairay suit 5 software.
5.1.5 Summary
PXR biology is complex and may have implications extending beyond the narrow field of bile 
acid and xenobiotic metabolism and excretion, for which it is best known. Gene array analysis is 
the best method of identifying new aspects of PXR biology not limited to novel genes and 
cellular mechanisms, but also to identify differential regulation of these genes. Analysis of the 
genes expressed commonly between two ligands of the same receptor will indicate potential 
differences in mechanism of PXR activation.
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5.2 Results
5.2.1 Gene array Data Analysis
The raw gene anay data containing real term expression values and fold changes for each gene 
contained on the Rat230 2.0 array is found in appendix 1. This data is tabulated such that the 
expression level of each gene at each concentration of both PCN and LCA may be seen for all 
biological repeats (n=4). This data is unsorted and unfiltered and is a complete record of the 
gene array experiment, such a large volume of data is unintelligible and requires further data 
mining to derive biological significance.
To interpret the gene array results on must first decide what are significant expression changes 
within the raw data. To do this the data was analyzed by the SAM add-in for Excel. Figure 5.2.1 
shows the SAM plot of statistical calculations for all of the genes in a statistical comparison of 
all four 10 pM PCN biological repeats against all four DMSO control (also refened to as OpM) 
biological repeats. The false discovery rate (top left hand side) can be altered to reduce or 
increase the number of false positives this set rate is what determines the p value at which the 
expression change is considered significant. In this case, a false discoveiy rate of 5.85% gives 
710 significant changes and 41 false positives; this was considered an appropriate level for this 
data set.
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Figure 5.2.2 shows an example output from the SAM analysis for some significantly up­
regulated genes at 10 pM PCN treatment column headings are Score (T statistic value), 
numerator, denominator (T statistic functions), fold change and q value (false positive rate at 
which change is significant). Full details of all genes which are significantly regulated at each 
concentration of PCN and LCA, as determined by SAM analysis, may be found in appendix 2.
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Figure 5.2.2 Example of SAM analysis results for 10 pM PCN treatment
Gene array data was obtained as for figure 52.1 Resulting transcript levels were analysed 
using the SAM software suite, which results in tables of significantly altered genes in both a 
positive and negative direction. The above panel shows the heading categories of genes 
significantly upregulated by treatment o f primary rat hepatocytes with 10 pM PCN for 48 
hours.
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5.2.3 Initial analsysis of the Gene array data
Gene array data was obtained as described for fig 5.2.1. For interpretation of results and 
determination of significant changes the raw data was analyzed by the SAM program. Lists of 
significant genes for LCA and PCN treatments were assembles in Microsoft Excel and compared 
manually to search for genes common to both treatments. There were a total of approximately 
2100 significant gene changes (1840+330=2170) for PCN and approximately 1400 gene changes 
(1025+330=1452) for LCA, 330 of the gene changes were common for both treatments as 
represented by Venn Diagram (figure 5.2.3).
Figure 5.23 Simple Venn diagram of significantly regulated genes from all treatments.
Microarray data was obtained as described for fig 5.2.1. Raw data was analysed by SAM 
analysis and lists of significantly regulated genes were obtained as discussed in fig 5.2.1 and 
5.2.2. The data from SAM analysis of each dose of both LCA and PCN was collated in total 
and scanned for duplication before the total number of gene changes for each ligand treatment 
was counted.
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5.2.2 Validation of gene array data
It is important to note that the gene anay experiment was performed by dosing the cells for 48 
hours with concentrations of LCA and PCN, rather than previously performed in the pilot study 
which involved dosing for 72 hours. This change in protocol was on the advice of colleagues at 
AstraZeneca who helped me to organize and perform this complicated experiment. The papers 
referring to the development of sandwich culture as a technique do not directly look at cell 
viability and time in culture increases; however, work within AstraZeneca suggests that cells 
decline post development of cannaliculi, with a decline in cannalicular function following six to 
seven days in culture. (Bi et al., 2006). On this basis it was decided to undertake the analysis 
after 48 hours exposure, coixesponding to a total of six days in culture. In addition, due to the 
complex nature of the hybridizations undertaken during a gene anay analysis it is still possible to 
identify false positive; as evidenced by the FDR provided through the SAM. It is thus important 
to confirm at least some, biologically significant, changes using a fully quantitative teclmique, 
such as Taqman. For this puipose, the same target genes selected for the pilot study were 
analysed from the gene anay experiment by Taqman QPCR.
As discussed in section 4.3 the expression of CYPs 7A1 and 8B1 were too low for any 
meaningful analysis. Literature information suggests that PXR and FXR are capable of 
suppressing expression of these genes and as such it was expected that the expression would be 
higher in the control samples, decreasing as the concentrations of PCN and LCA increased. To 
examine the effect of a 24 hour reduction in total culture time on the expression of CYP 7A1 and 
8B1 their expression level was determined in the gene array samples. As observed in the pilot 
study the levels of these genes were too low for analysis.
Transcript levels for CYP3A1 were analysed by Taqman QPCR from primaiy rat hepatocytes 
gi’own in sandwich culture for 120 hours and treated for 48 hours with concentration ranges of a) 
LCA (0, 10, 20, 50, 80, and 100 pM) and b) PCN (0, 1, 2, 5, 8, and 10 pM), and are shown in 
figure 5.2.4. In a) it can be seen that LCA has no significant effect on transcript levels of 
CYP3A1, while in d) it can be seen that PCN has a significant effect on transcript levels of 
CYP3AI p<0.0001, with significant up-regulation seen at all doses.
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Figure 5.2.4 Gene array and Taqman analysis of the expression of CYP3A1.
Primary rat hepatocytes in sandwich culture were grown for 96 hours and treated for 48 hours 
with 0, 10, 20, 50, 80, and 100 pM LCA and 0, 1 ,2 , 5, 8, and 10 pM PCN. Expression of 
CYP3A1 was examined by gene array analysis, shown as fold change compared to control in 
a), followed by Taqman QPCR to analyze the expression per 0.5 pg starting RNA, shown as 
fold change compared to control in b) and as the real terms expression level in c) and d). Data 
was analyzed using GraphPadGraphPad PrismPrism chart bars are representative of the mean 
expression level with error bars being SEM. Data analyzed by one way ANOVA with 
significance displayed on the graphs, Column significance from control determined Bonferoni 
multiple comparisons correction, *** P<0.0001 * P<0.01.
Transcript levels of fibrinogen p are shown in figure 5.2.5, in primary rat hepatocytes grown in 
sandwich culture for 96 hours and treated for 48 hours with concentration ranges of a) LCA (0,
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10, 20, 50, 80, and 100 pM) and b) PCN (0, 1, 2, 5, 8, and 10 pM). Total RNA was extracted 
and processed into cDNA for Taqman analysis with raw data analyzed using GraphPad Prism. 
In a) it can be seen that LCA has a highly significant effect on the expression o f fibrinogen p 
p<0.001, while in b) it can be seen that PCN has no significant effect on the expression level of 
this gene.
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Figure 5.2.5 Gene array and Taqman analysis of the expression of Fibrinogen p.
Experimental was preformed as described for fig 5.2.1 with a) showing fold changes in 
expression of fibrinogen p, and b) Taqman QPCR fold changes in expression of fibrinogen P, 
c) and d) show the actual expression level in copy numbers per 0.5 pg of RNA. Data 
analyzed as described in fig 5.2.1 with one way ANOVA with significance displayed on the 
graphs, Column significance from control determined by Bonferoni multiple comparisons 
correction, ** P<0.001.
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5.3 Discussion
Do different ligands of PXR activate differential gene activation profiles? The hypothesis being 
tested within this thesis is that different ligands of the PXR will regulate a core set of genes and a 
set of genes unique to each ligand or groups of ligands. Taking all significant gene changes from 
all doses for both PCN and LCA treatments a Venn diagram (figure 5.2.3) was plotted showing 
genes regulated in a ligand specific manner by LCA or PCN, and in a common manner by both 
PCN and LCA. Viewing this information simply, it can be concluded that I have shown that an 
endogenous (LCA) and an exogenous (PCN) ligand of PXR activate ligand specific and common 
gene sets. In this simple analysis, I have proven our hypotliesis to be conect. This simplistic 
view does not take into account the fact that there aie many cellular mechanisms which can 
effect gene expression any of which may be responsible for some of the changes seen to be 
different between PCN and LCA.
As in the pilot study the expression levels o f CYP7A1 and 8B1 were too low for data 
interpretation. The literature would suggest that the levels of CYPs 7A1 and 8B1 in normal 
hepatocytes are at much higher levels than detected in my experiments and that the expression of 
these genes is suppressed by activation of FXR and PXR by bile acids, although these 
experiments were not performed under the same conditions and so would only indicate expected 
results rather than being conclusive (Staudinger et al., 2001b, Chiang, 1998, Chen et al., 2001, Li 
et al., 1990, Gustafsson, 1999, Russell, 1999, Forman et al., 1995, Seol et al., 1995, Hoffmaster 
et al., 2004).
As discussed in section 4.3 hepatocytes grown in sandwich culture become polarized and 
develop functionally exporting cannaliculi (Liu et al., 1999a, LeCluyse et al., 1994, Liu et al., 
1998, Liu et al., 1999b, Hoffmaster et al., 2004). The establishment o f the cannalicular excretion 
system is known to take several days and can be observed using a fluorescent metabolite of Mrp2 
called CDF. CDF is metabolized intracellularly into CDFDA a fluorescent metabolite, and is 
exported through Mrp2 into the cannaliculus (Bi et al., 2006). In section 4.3 it was suggested 
that the accumulation of primary bile acids during the time taken for the cannalicular* export 
mechanisms to establish lead to activation o f FXR and PXR and suppression o f CYP 7A1 
expression and is a potential.
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The levels of expression of CYP3A1 following 48 hour exposure to LCA and PCN are shown in 
figure 5.2.4. It can be noted that in fig 5.2.4 a) that the gene array showed a maximum fold 
change of a forty fold increase in expression o f CYP3A1 for PCN, whereas Taqman analysis of 
the same gene shows an 80 fold increase, as Taqman is fer more sensitive this is expected. 
CYP3A1 is a classical marker of PXR activation in hepatocytes (Xie et al., 2001, Staudinger et 
al., 2001b) and as such has been used as a check both in this experiment and in the pilot study as 
described in chapter 4 (figure 4.2.1). PCN is a classical agonist of rodent PXR (Selye, 1971, 
Selye, 1972) and had a highly significant (p<0.0001) effect on CYP3A1 expression indicating 
activation of PXR. LCA is known to be an agonist of PXR and appears to be exhibiting a 
significant transcriptional effect (p=0.0377) after 48 hours. As a positive control this indicated 
the PXR is being activated by both PCN and LCA.
Activation of FXR and PXR by bile acids is known to cause a suppression of the expression of 
the transporter proteins such as NTCP and OATPIBI (0ATP2), in hepatocytes (Rizzo et al., 
2005, Beilke et al., 2007, Staudinger et al., 2001b). These transporters are responsible for 
regulating the influx of polar molecules such as LCA into the cell, during times of cholestasis 
they are rapidly switched off as an hepatoprotective mechanism (Aii'ese et al., 1998, AiTese and 
Trauner, 2003, Xu et al., 2000). Slower influx of LCA into the cells due to a decrease in the 
transporter expression might mean that intracellular concentrations require more time to 
accumulate; this would require an experiment involving dosing the LCA with time points taken 
at 0 ,6 , 12,24,48 and 72 hours.
Fibrinogen (3 was used in the pilot study (figure 4.2.2 and discussed in section 4.3) as a marker of 
FXR activation (Anisfeld et al., 2005). It was demonstrated in chapter 4 that in this system 
CDCA did not activate fibrinogen (3, while LCA significantly increased expression (p<0.0001). 
The increase in expi^ession o f fibrinogen |3 caused by LCA was observed in the gene array results 
as well as in tire pilot study, with a) of figure 5.2.5 showing a significant increase (p<0.001) in 
expression of this gene. As marker of FXR activation it cannot be taken as conclusive evidence, 
however it can be said that the expression profile seen for LCA and PCN is similar to that seen in 
the pilot study.
LCA is known to activate FXR, VDR as well as PXR and although is it thought that LCA is 
more specific for PXR it is entirely possible that the effects seen are due to the activation of 
multiple receptors. It is a remote possibity that the genes found to be regulated by both PCN 
and LCA are the genes dependent on PXR activation and that genes regulated in a ligand specific 
manner are through activation of other transcriptional pathways. A more profound analysis of all 
the common and unique gene sets would provide further information regarding the involvement 
of any mechanisms other than PXR in the regulation of these genes although this is beyond the 
scope of this project and may be achieved by principal components analysis and pathway 
analysis.
5.4 Summary
In this context CYP3A1 and fibrinogen p are used as marker genes of PXR and FXR activation 
respectively. It can be seen that both LCA and PCN significantly regulate the expression of 
CYP3A1 indicating that they both activate PXR, while the data concerning fibrinogen p does not 
provide sufficient data to draw conclusions regarding FXR activation. Using the Venn diagram 
analysis it can be said that we have conclusively demonstrated that PCN and LCA share a core of 
commonly regulated genes, while simultaneously regulating independent gene sets. It could be 
ar gued that this is sufficient to answer the hypothesis question. Further, more indepth analsysis 
of the gene array data should enable us to put this information into context with the two ligands, 
and extrapolate functional pathway data as it si likely that PXR regulates other pathways outside 
of the ADME genome.
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Chapter 6: Analysis o f patterns of expression and 
functional gene changes caused by pregnenalone 16a 
carbonitrile and lithocholic acid in a rat genome gene 
array.
6.1 Introduction
6.1.1 Data Interpretation
Data interpretation of gene array data is challenging, as the size and complexity of the data set 
prohibit manual interpretation. There are several methods of handling data o f this volume, the 
easiest method being to filter the information using a simple program such as Microsoft Excel 
which allows selection of significant changes in gene expression of specific genes; as a simple 
method this does not allow identification of previously unknown patterns of expression and 
subsequent influence on biochemical pathways. The analysis of unfiltered, unbiased data can be 
undertaken in one of two main methods, namely hierarchical clustering or principal components 
analysis. Hierarchical clustering is a series o f computational clusterings and separations such 
that one cluster of genes may be entirely contained within another but with no overlap between 
clusters. This type of clustering bases its analysis on the physical separation of the points on a 
scatter plot of all gene changes from which a statistical score is calculated and assigned to each 
of the individual gene points. A threshold statistical value is calculated above which the physical 
separation of the points determines them as in separate cluster and below which determines them 
as part of the same cluster.
Principal components analysis does not bias the data by forcing a separation and as such will 
only find significant differences in a data set if  they are present, for this reason it was decided 
that we would use the latter principal component method to the interpret the gene array data. 
The object of a principal components analysis is to plot and separate the data in such a way that 
underlying patterns can be revealed in the data that cannot be determined from a simple XY plot
of the data. The analysis aligns the data along computed eigenvectors, these vectors representing 
significant patterns which drive separation of the data and may be representative of the 
unobservable mechanisms behind the data spread and distribution. Each data set can be 
separated into ‘n ’ dimensions and has more than the usual three dimensions that can be 
represented graphically and can have several eigenvectors each contributing o the patterns within 
the data. Each o f the eigenvectors is defined by a series of eigengenes which contribute to the 
separation of data along that particular vector. Each of these eigengenes is assigned an 
eigenvalue that is indicative of the degr ee to which the gene contributes to the separation of the 
data.
6.1.2 DAVID functional analysis
DAVID (Database for Annotation, Visualization and Integration Discovery, 
http ://david.abcc.ncifcrf.gov/ ) is software designed to categorize complex, high content genomic 
and proteomic data. The DAVID system gives a simplistic overview of functional pathways that 
are over represented within a list of gene changes. The pathway analysis is determined by 
categorical information regarding each gene and pathway contained within the GO (gene 
ontology) knowledge database, the data output is tabulated into GO functional terms. The GO 
knowledge database is an annotation tool of gene function and is constantly updated and it is the 
international standard for the annotation of genes (As defined by the Gene Ontology 
Consortium):The main GO terms are as follows; BP (Biological process); CC (Cellular 
Component); MF (Molecular Function); each term is sub-divided into five levels, representing a 
hierarchy of information detail, which will be discussed in more detail below.
The simplistic view afforded by DAVID analysis has the major advantage of providing a wealth 
of pathway information fi*om a list of genes within minutes, thereby providing the information 
required for identification of target pathways and hypothesis generation. The simplicity o f the 
system is also its disadvantage as this leads to potentially missed information and 
underestimation of the importance of some pathways, and that the coverage is not 1005 complete 
therefore missing some biological pathways. The categorization of genes into a pathway is 
hierarchical in line with the hierarchical nature of GO terms. The allocation of a gene into a 
paftiway by DAVID is absolute in that it is either entirely contained within the pathway, or it is
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not. The lack of information for some genes, due to either their ambiguous biological function, 
cellular localization or exact molecular function means that some genes will defy categorization.
GO terms are hierarchical and are clustered with levels spanning from 1 allowing the broadest 
gene list coverage with lowest specificity, to 5 which has the lowest gene list coverage but the 
h ip e s t specificity of categorization. In complex GO algorithms a gene may be associated with 
multiple GO terms at a base level, as the genes is classified further up the hierarchy a network of 
patterns and possible interactions develops and gives a very complex list of possible metabolic 
routes that can be influenced. DAVID analysis gives a simplified version which does not allow 
for the cross network o f path ways, giving a directed and reined output rather than a complex data 
set which requires flnther interpretation. This simplified version means that there is some 
information that may be excluded fiom the analysis and may lead to the importance o f some 
pathways being underestimated in comparison to others where networking o f genes is less 
important. That being said this form of analysis if  highly used in this type of analysis and has 
been shown to be far more effective than manual methods.
The identification of the pathways determined to be overrepresented relies heavily on the quality 
and quantity of information loaded into the program. The method of determining which genes 
are significantly regulated has ramifications in the number and robustness of the pathway data 
that the program produces. The use of statistical algoritlims to determine the significance of 
genes is discussed in section 5.1, the corrections which are applied to accoimt for the multiple 
testing necessary to run thousands of comparisons can be overly conservative, such as the 
Bonferoni multiple comparisons correction, giving an incomplete picture. Studies using SAM 
analysis (Section 5.1) have successfully generated DAVID data that proved robust when tested 
statistically.
The DAVID program accumulates the list of categorized data by placing genes into the various 
GO terms depending on fire categorical data of the GO database. Once this is done the software 
estimates the level of representation of the pathway by calculating the hypergeometric 
distribution o f the data within the pathway, essentially calculating a probability that the number 
of genes contained within a given GO term may have occurred by random chance. To do this 
DAVID employs the Fisher exact test which compares the number of genes found to be
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contained in the pathway with the total number of genes that could be contained within the 
pathway and the total number of genes analyzed. The resulting probability value is a function of 
the level of representation of that pathway in the data set, this smaller the p value file greater the 
degr ee of oveirepresentation and the greater the importance of the pathway. Below is shown the 
formula for calculating the hypergeometric distribution/probability, and a simple example of its 
use:
h(X;N,nJk)=[kCx] [N-kCn-x]/[NCn]
Where:
N is the total number of genes, k is the total number of genes that may be contained in the GO 
term, n is the number of genes in the sample, x is the number of genes that have been identified 
as being in the GO term, kCxis the total number of combinations of k genes taken x at a time and 
is expressed by C= k!/x!(k-x)!, h(X;N, n, k) is the hypergeometric distribution.
IN a deck of 52 cards 26 are red 26 are black, and a selection of 5 cards yields 2 red cards and 
three black cards. To calculate the hypergeometric probability of drawing 2 red cards from 5 one 
uses the following:
N= 52 (the total number of cards in the deck), k=26 (the total number o f red cards), n=5 (number 
of cards chosen form the deck), and x=2 (number of cards chosen that are red).
h(2; 52, 5 ,26)=[26!/2!(26-2)!][26!/3!(26-3)!]/[52!/5!(52-5)!]
=[325][2600]/[2598960]
=0.325 or 32.5%
Should 5 of the five cards chosen have been red:
h(4; 52, 5 ,26)=[26!/4!(26-4)!][26!/l !(26-l)!]/[52!/5!(52-5)!]
=[14959][26]/[2598960]
=0.149 01*14.9%
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As demonstrated the smaller the number the greater the level of ovenepresentation.
6.1.3 Summary
Gene array data in its raw form is meaningless as tire number of data points makes statistical 
analysis in its simplest form impossible. Application of the SAM program enables us to simplify 
the data set and run further analysis which highlights any patterns of gene expression held within 
the data. PCA is one method of analyzing the significantly regulated data which highlights 
underlying patterns and should highlight the most significant commonalties and differences 
between LCA and PCN. Pathway analysis, such as DAVID, will enable us to indicate which 
pathways are the most heavily influenced by PXR and will be of interest in the future 
understanding of PXR biology.
6.2: Results
Gene expression data was obtained as described for fig 5,2.1 and is shown in fiill in appendix 
one. For the interpretation of results and determination of significant changes the raw data was 
analyzed by the SAM program, with all significantly changed genes shown in appendix 2. 
Significantly regulated genes were collated and input into MVSP the principal components 
analysis of the collated data is represented in figure 6.2.1. The data clearly separates along two 
Eigen vectors, with Eigen vector 1 defined mostly by PCN treatments, and Eigen vector 2 being 
defined mostly by LCA treatments.
6.2.1 Principal components analysis
Genes found to be significantly regulated by SAM analysis were collated and input into MVSP 
(multivariate statistical program) principal components analysis indicated clear separation of the 
data along two different Eigen vectors (figure 6.2.1). Figure 6.2.2 is a list of Eigen genes, which 
contribute to the separation of the data along Eigen vector one. The left hand column is the name 
of the Eigen gene and the right hand column is the Eigen value which is the degree to which the 
gene contributes to separation along Eigen vector one. Eigen genes contributing to separation of 
the data along Eigen vector two are seen in fig 6.2.3 and are displayed as described above.
Confirmation of the expression levels of eigengenes identified by MVSP analysis of the 
significant genes from the gene array data is necessary to further validate the gene array and 
better understand the dose dependency and perhaps further highlight biological importance.
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Eigen gene Eigen value
hvmosin. beta 10 0.534
glutathione S-transferase, mu 2 H I glutathione S-transferase. mu 2 0.297
alutathlone-S-transferase. aloha tvoe2 0.236
rhrombosDondln 1 ///Thrombosoondln 1 0.22
nIutathlone-S-transferase. aloha tvoe2 0.215
iver UDP-alucuronosvltransferase. ohenobarbital-induclbleform 0.197
UDP-glucuronosvltransferase 2 family, member 5 0.185
Transcribed locus///Transcribed locus 0.156
LIDP glvcosvitransferase 2 family, member 3 0.145
shemoklne fC-C motif) llaand 2 0.142
3VtochromeP450. family 2. subfamily c. DolvoeotideTO 0,122
alutathlone S-transferase. aloha 4 0.12
aldehyde dehvdroaenase family 1. subfamily A4 0.114
ATP-binding cassette, sub-family G (CFTR/MRP), member 2 0.105
2D164 antigen -0.116
Jesmoplakin -0.121
sukarvotiotranslation Initiation fôctor 5 -0.127
/cltaae-deDendentanlon channel 3 -0.125
ntegrin linked kinase -0.137
RT1 class 1. CEI 2 -0.137
solute carrier family 25 (mitochondrial carrier: adenine nucleotide translocator), member 3 -0.294
Table 6.2.1 Genes driving separation along Eigen vector 1 (Fig 6.2.1).
Gene array data was obtained as described in fig 5.2.1 and was analysed for significance as in fig 5.2.1 
and 5.2.2, significant data was analyzed by principal components analysis by the MVSP program. 
Analysis separated the data along Eigenvectors as seen in figure 6.2.1. The data separation is driven by 
Eigengenes, which are genes contributing to the spread of data along the Eigen vectors. The left hand 
column contains the names of the Eigengenes, the right hand column contains the Eigenvalues which 
relate to the contribution of each eigengenes to the separation along eigenvector 1.
173
Eiaen Gene Eiaen Value
attv acid bindina protein 5, epidermal -0.196
wpothetloal protein LOC679258 -0.357
Tietallothionein 1a 0.46
similar to Metailothionem-2 (MT-2) (Metallothionein-ll) (MT-II) 0.344
Transcribed locus -0.189
Table 6.2.2 Genes driving separation along Eigen vector 2 (Fig 6.2.1).
As in figure 6.2.2 MVSP of genes found to be significantly regulate by SAM revealed two Eigenvectors. 
Fig 6.2.3 contains the gene found to be significantly contributing to the separation along eigenvector (as 
seen in fig 6.2.1). The left hand column contains the names of the Eigengenes, the right hand column 
contains the Eigenvalues which relate to the contribution of each eigengene to the separation along 
eigenvector 2.
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6.2.2 Validation of Eigengene gene array responses by Taqman QPCR
To validate the gene array data it is necessary to utilize a second technique to assess the 
expression level of the selected genes. It is not possible to validate all genes on the array, and so 
only those identified as being important through the PCA were analysed. The gene array and 
was performed fi’om Sprague Dawley isolated rat hepatocytes in sandwich culture treated with 0, 
10, 50,100 pM LCA and 0 ,1 ,5 ,1 0  pM PCN, treatementwas for 48 hours. It is possible that the 
variation in the response seen in the gene airay is artifactual due to hybridization error, which is 
the chief reason for confinning the expression changes in the same RNA samples by Taqman. 
Comparing fire Taqman responses of the selected genes to the response of the selected genes in 
the gene anay will give some indication o f the reproducibility of the response.
Figure 6.2.3 shows the transcript levels of MRP2 in the gene array and post Taqman analysis, 
and is derived fiom primary rat hepatocytes grown in sandwich culture for 96 hours and treated 
for 48 hours with concentration ranges of a) LCA (0,10,20,50, 80, and 100 pM) and b) PCN (0, 
1, 2, 5, 8, and 10 pM). Total RNA was extracted and processed into cDNA for Taqman analysis 
with raw data analyzed using GraphPad Prism. In c) it can be seen that LCA has a significant 
effect on expression of this gene (p<0.01), while in d) it can be seen that PCN has a highly 
significant effect on expression of this gene (p<0.0001) with significant effects seen at all doses.
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Figure 6.2 J  Gene array and Taqman QPCR analysis of the expression MRP2.
Primary rat hepatocytes in sandwich culture were grown for 96 hours and treated for 48 with 
0, 10, 20, 50, 80, and 100 pM LCA and d) 0, 1, 2, 5, 8, and 10 pM PCN. Fold change 
compared to DMSO control from the gene array data is shown in a) while fold change in 
comparison to DMSO control form Taqman analysis of the gene array samples are shown in 
b). RNA extracted and processed into cDNA for analysis by Taqman QPCR for the expression 
of Mrp2 per 0.1 pg starting RNA for LCA treatment c) and PCN d). Data analyzed by one 
way ANOVA and where significant with Bonferoni multiple comparisons correction using the 
GraphPad prism program, error bars represent the mean ±SEM fix>m 4 replicate samples,
***p=0.001** p<0.01
Transcript levels of Gst p2 in samples from the gene array are shown in figure 6.2.4, with the 
experimental protocol performed as for figure 6.2.2. In c) it can be seen that LCA has no
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significant effect on the expression level of Gst p2, while in d) it can be seen that PCN has a 
significant effect on the expression level o f this gene (p<0.01), with significant effects observed 
at all doses, although no clear dose response relationship is evident.
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Figure 6.2.4 Gene array and Taqman QPCR analysis of the expression of Gst p2 in gene 
array samples.
Experimental was performed as in fig 6.2.2. Fold change compared to DMSO control from 
the gene array data is shown in a) while fold change in comparison to DMSO control form 
Taqman analysis of the gene array samples are shown in b). RNA extracted and processed into 
cDNA for analysis by Taqman QPCR for the expression of Mrp2 per 0.1 pg starting RNA for 
LCA treatment c) and PCN d). Data analyzed by one way ANOVA and where significant 
with Bonferoni multiple comparisons correction using the GraphPad Prism program, error bars 
represent the mean ±SEM from 4 replicate samples. *p<0.01.
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Transcript levels of Gst A2 from the gene army samples are shown in figure 6.2.5, with 
experimental protocol peifoimed as described for fig 6.2.3. It can be seen from c) that LCA has 
a highly significant effect on the expression of Gst A2 (p<0.0001), with significant effects seen 
at 80 and 100 pM, suggesting a dose response relationship. It can be seen in d) that PCN has a 
significant effect on the expression of Gst A2 (p<0.001) with significant effects seen at all doses; 
in this case the response appears to have reached the plateau of the dose response, as no 
significant increase is observed with increasing dose.
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Figure 6.2.5 Gene array and Taqman QPCR analysis of the expression of Gst A2 in gene 
array samples.
Experimental was performed as in fig 6.2.2. Fold change compared to DMSO control from the 
gene array data is shown in a) while fold change in comparison to DMSO control form 
Taqman analysis of the gene array samples are shown in b). RNA extracted and processed into 
cDNA for analysis by Taqman QPCR for the expression of Mrp2 per 0.1 pg starting RNA for 
LCA treatment c) and PCN d). Data analyzed by one way ANOVA and where significant 
with Bonferoni multiple comparisons correction using the GraphPad Prism program, error bars 
represent the mean ±SEM from 4 replicate samples. *** p<0.0001 ** p<0.001 *p<0.01.
Transcript levels of Udpgt in gene array samples as shown in figure 6.2.6, with experimental 
performed as described for fig 6.2.3. It can be seen in a) that LCA has an highly significant 
effect on the expression of Udpgt (p<0.0001), with significant effects seen and 100, 80 and 50
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pM. It can be seen from b) that PCN has an highly significant effect on the expression of Udpgt 
(p<0.0001), with significant effects seen at all doses. Whereas a clear dose-dependent 
relationship can be seen for LCA, no such relationship is evident with PCN, with even the lowest 
dose used causing a large increase in transcript levels.
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Figure 6.2.6 Gene array and Taqman QPCR analysis of the expression of Udpgt in gene array 
samples.
Experimental was performed as in fig 6.2.3. Fold change compared to DMSO control from the gene 
array data is shown in a) while fold change in comparison to DMSO control form Taqman analysis 
of the gene array samples are shown in b). RNA extracted and processed into cDNA for analysis by 
Taqman QPCR for the expression of Mrp2 per 0.1 jig starting RNA for LCA treatment c) and PCN 
d). Data analyzed by one way ANOVA and where significant with Bonferoni multiple 
comparisons correction using the GraphPad Prism program, error bars represent the mean ±SEM 
from 4 replicate samples *** p<0.0001 ** p<0.001.
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Transcript levels of M tl in gene aiTay samples as shown in figure 6.2.7, with experimental 
performed as described for fig 6.2.3. It can be seen fiom a) that LCA has a highly significant 
effect on the expression of Mtl (p< 0.0001), with significant effects obseived at 100 pM, 
suggesting a dose-dependent relationship. It can be seen from b) that PCN has no significant 
effect on the expression of Mtl at any dose used.
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Figure 6.2.7 Gene array and Taqman QPCR analysis of the expression of Mtl in gene 
array samples.
Experimental was performed as in fig 6.2.3. Fold change compared to DMSO control fi-om the 
gene array data is shown in a) while fold change in comparison to DMSO control form 
Taqman analysis of the gene array samples are shown in b). RNA extracted and processed into 
cDNA for analysis by Taqman QPCR for the expression of Mrp2 per 0.1 pg starting RNA for 
LCA treatment c) and PCN d). Data analyzed by one way ANOVA and where significant 
with Bonferoni multiple comparisons correction using the GraphPad Prism program, error bars 
represent the mean ±SEM fiom 4 replicate samples. *** p<0.0001.
Transcript levels of Mt2 in gene array samples as shown in figure 6.2.8, with experimental 
performed as described for fig 6.2.3. It can be seen from a) that LCA has a highly significant
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effect on the expression of Mt2 (p<0.0001), with significant effects observed at 100 pM, 
suggestive of a dose-dependent response. It can be seen fi-om b) that PCN has a significant effect 
on the expression (p<0.0), although this is due to a single significant point (5 pM) and hence the 
biological significance of this is not clear.
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Figure 6.2.8 Gene array and Taqman QPCR analysis of the expression of M tl in gene 
array samples
Experimental was performed as in fig 6.2.3. Fold change compared to DMSO control from the 
gene array data is shown in a) while fold change in comparison to DMSO control form 
Taqman analysis of the gene array samples are shown in b). RNA extracted and processed into 
cDNA for analysis by Taqman QPCR for the expression of Mrp2 per 0.1 pg starting RNA for 
LCA treatment c) and PCN d). Data analyzed by one way ANOVA and where significant 
with Bonferoni multiple comparisons correction using the GraphPad Prism program, error bars 
represent the mean ±SEM fi-om 4 replicate samples. **p=0.001, *p=0.01.
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Transcript levels of Fabp5 in gene array samples as shown in figure 6.2.9, with experimental 
performed as described for fig 6.2.3. It can be seen firom a) that LCA has an highly significant 
effect on the expression of Fabp5 (p<0.0001), with significant repression of transcript levels 
observed at all doses over 20 pM. It can be seen in b) that PCN has an highly significant effect 
on the expression of Fabp5 (p<0.0001), with significant decreases observed at all doses.
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Figure 62.9 Gene array and Taqman QPCR analysis of the expression of FabpS in gene 
array samples.
Experimental was performed as in fig 6.2.3. Fold change compared to DMSO control fi-om the 
gene array data is shown in a) while fold change in comparison to DMSO control form 
Taqman analysis of the gene array samples are shown in b). RNA extracted and processed into 
cDNA for analysis by Taqman QPCR for the expression of Mrp2 per 0.1 pg starting RNA for 
LCA treatment c) and PCN d). Data analyzed by one way ANOVA and where significant 
with Bonferoni multiple comparisons correction using the GraphPad Prism program, error bars 
represent the mean ±SEM fi-om 4 replicate samples. *** p<0.0001, ** p<0.001.
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6.2.3 DAVID functional pathway analysis
Gene anay experiments such as the one described in this chapter and in chapter 5 consist o f a 
wealth of potentially interesting information. The complexity of the experiment itself can 
obscure large segments of this data as the techniques used to refine the lists of thousands of 
genes into lists of significant changes inevitably yield a smaller, but still prohibitively large data 
set. As discussed in section 6.1 DAVID analysis is a pathway analysis system which has been 
commonly used to perform a “surface value” pathway interpretation of this type of data set.
Figirre 6.2.10 gives representations of the total number of GO terms found to be overrepresented 
by DAVID analysis. Commonly regulated GO pathways are shown in blue, those regulated by 
PCN are shown in pink and those by PCN are shown in green. The total GO terms can be 
separated into biological processes, molecular firnction and cellular component GO terms. These 
terms are flrrther represented in figures 6.2.11, 6.2.12 and 6.2.13.
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Figure 6.2.11 shows the total level 5 BP GO terms identified by DAVID analysis as containing 
genes regulated significant in the gene aiTay, as for 6.2.10 blue represents the commonly 
regulated pathways, pink those unique to PCN and green those unique to LCA. Below the Venn 
diagram are tables of the top 5 most significantly overrepresented pathways indicating that these 
contain the greatest number of genes which are found significantly regulated in the gene array 
data.
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Level 5 biological process terms
vesicle-m ediated
transport
establishm ent o f cellular 
localization
intracellular transport
Golgi vesicle transport
protein transport
m acrom olecule biosynthesis
protein biosynthesis
ribosom e biogenesis and 
assem bly
cellular protein m etabolism
am ino acid m etabolism
nitrogen com pound  
catabolism
am ine catabolism
amino acid m etabolism
apoptosis
negative regulation o f  
programmed cell death
Figure 6.2.11 Identification of Level 5 BP GO terms form array results.
Significant genes identified by SAM analysis were entered into a DAVID analysis as seen in figure
6.2.9. BP terms are the bioclogical processes associated with the genes overrepresented in PCN 
regulated (pink), LCA regulates (green) and regulated by both (Blue). Displayed are the top 5 most 
significantly overrepresented biological process for each group.
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Figure 6.2.12 shows the total level 5 MF GO terms identified by DAVID analysis as containing 
genes regulated significant in the gene array, as for 6.2.10 blue represents the commonly 
regulated pathways, pink those unique to PCN and green those unique to LCA. Below the Venn 
diagram are tables of the top 5, for PCN and LCA, and one most significantly overrepresented 
pathways indicating that these contain the greatest number of genes which are found 
significantly regulated in the gene array data.
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Level 5 Molecular Function terms
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NADH dehydrogenase  
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Figure 6.2.12 Identification of Level 5 MF GO terms form array results.
Significant genes identified by SAM analysis were entered into a DAVID analysis as seen in figure
6.2.9. MF terms are the molecular functions associated with the genes overrepresented in PCN 
regulated (pink), LCA regulates (green) and regulated by both (Blue). Displayed are the most 
significantly overrepresented molecular functions for each group (Top 5 where possible).
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Figure 6.2.13 shows the total level 5 CC GO terms identified by DAVID analysis as containing 
genes regulated significant in the gene anay, as for 6.2.10 blue represents the commonly 
regulated pathways, pink those unique to PCN and green those unique to LCA. Below the Venn 
diagram are tables of the top 5 most significantly ovenepresented pathways indicating that these 
contain the greatest number of genes which are found significantly regulated in the gene anay 
data.
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Figure 6.2.13 Identification of Level 5 CC GO terms form array results.
Significant genes identified by SAM analysis were entered into a DAVID analysis as seen in figure
6.2.9. CC terms are the Cellular components associated with the genes overrepresented in PCN 
regulated (pink), LCA regulates (green) and regulated by both (Blue). Displayed are the top 5 most 
significantly overrepresented cellular components for each group.
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6.3 Discussion
6.3.1 Microarray analysis
Collation o f all the gene expression data for PCN and LCA treatments and input into
MVSP enabled a principal components analysis of the data as a whole. Figure 6.2.1
shows a very clear separation o f the data along two Eigen vectors. The PCN !
treatment data separates predominantly along Eigen vector one with some separation ;Ialong Vector 2 at low and high doses. LCA data separates predominantly along axis ]
two with some separation along axis one at low and high doses. Such a firm I
separation of PCN and LCA treatments along the two different vectors suggest that |
there is a defined mechanistic difference between the two treatments. 1
It should be highlighted that both treatments separate along both axes, to greater or 
lesser extents. This highlights that there is a linking commonality between the 
regulation of the two eigenvector sets. This is a fundamental observation and that 
there are differences and similarities between the two eigenvectors agrees with the 
Venn diagram observations in fig 5.2.3 where there a number o f unique and common 
genes.
When analyzed closely the eigengenes which are highlighted are part o f the jointly 
regulated data set. It is evident that the mechanism driving the PCA to separate the 
data is made stronger by the increasing dose. PCA analysis o f the entire data set has 
gave rise to the generation o f lists o f Eigen genes, or those genes contributing 
significantly to the separation o f the data. Eigen genes for Eigen vectors one and two 
are listed in figures 6.2.2 and 6.2.3 respectively. Investigation into the changing 
patterns of expression of these eigengenes may serve to highlight the mechanism 
which drives the PCN separation o f the data.
6.3.2 Validation o f Eigengene expression profile
Microarrays are not 100% quantitative due to the complex nature of the 
hybridizations that occur and it is common to validate important genes using a 
secondary technique such as Taqman QPCR. The genes selected for this 
confirmatoi-y study are drawn jfrom the lists of Eigen Genes generated by principal 
components analysis o f all genes significantly regulated at all doses o f PCN and LCA.
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Mrp2 is an ATP binding cassette transporter protein found on the cannalicular 
membrane o f hepatocytes and has previously been demonstrated to be regulated by 
PXR (Kast et al., 2002, Borst and Elferink, 2002). Figure 6.2.3 shows the changes in 
expression o f Mip2 in the gene array. Mip2 was significantly upregulated by LCA 
(P<0.01) and by PCN (P<0.0001).
The glutathione-s-transferases (Gst) are a lai’ge family o f multisubunit enzymes 
catalyzing the nucleophillic conjugation o f glutathione to a host o f organic xenobiotic 
and endogenous compounds (Marmervik et al., 1985). PCA analysis o f all significant 
gene changes at all concentrations o f PCN and LCA identified Gst p2 and Gst A2, 
which contributed significantly to the difference between Eigen vector. Gst \x2 has 
been previously demonstrated as being regulated by PXR (Ding et al., 1986), and 
micro army evidence fiom other studies supports this conclusion (Hartley et al., 2004, 
Rosenfeld et al., 2003, Ejiri et al., 2005b), as does the data firom my current 
experiments. Figure 6.2.4 shows the changes in expression o f Gst p2 in the gene 
anay. In the gene array study LCA (fig 6.2.4 c) appears to have no significant effect 
on expression of Gst |.i2. A possible explanation is that the expression of import 
proteins necessary to import LCA into the cell have not reached their maximal level 
as the billiary system develops over time in sandwich culture (Bi et al., 2006) 
therefore limiting access to the dosed compounds.
PCN (figs 6.2.4 d) has significant effects on the expression of Gst p2 in both the gene 
array and pilot studies (P<0.01) with significant effects observed at most 
concentrations. This is in agreement with the evidence suggesting Gst \x2 is regulated 
by PXR (Ding et al., 1986, Hartley et al., 2004, Rosenfeld et al., 2003, Ejiri et al., 
2005b). The differences seen in PCN and LCA activation could be due to a ligand 
specific alteration in PXR specificity for its target genes, as discussed previously for 
Mrp2. It is possible that with more time points it would be possible to assess the 
contribution of the transporter levels on the access o f the compounds (LeCluyse et al., 
1994, Hoffinaster et al., 2004, Liu et al., 1998, Liu et al., 1999a, Liu et al., 1999b, Liu 
et al., 1999c).
Figures 6.2.5 shows the change in expression o f Gst A2 in the gene array respectively. 
LCA (6.2.8 c) shows significant upregulation o f Gst A2 in the gene array (p<0.0001) 
with significant effects observed at 80 and 100 pM. PCN (6.2.5 d) has a significant
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transcriptional regulation o f expression o f Gst A2 in the gene array (p<0.001) with 
significant effects observed at all concentrations.
The glucuronosyl transferases (Udpgts) are a family o f intracellular, membrane 
associated enzymes which catalyse the transfer o f a glucuronic acid moiety firom UDP 
glucuronic acid to a range o f organic lipophillic compounds, including xenobiotics 
and endogenous compounds such as billirubin (Mackenzie, 1986a, Mackenzie, 
1986b). The pheonobarbital inducible Udpgt was first cloned and isolate in 1986 
(Mackenzie, 1986a, Mackenzie, 1986b) and is regulated by PXR in several previous 
gene array studies using PXR ligands (Hartley et al., 2004, Ejiri et al., 2005b). PCA 
analysis o f all significantly regulated genes fi*om all concentrations o f both PCN and 
LCA revealed that Udpgt is a significant contributor to separation of data along Eigen 
vector one. Figure 6.2.6 shows the expression change for Udpgt in both the gene 
array. LCA (figs 6.2.6 c) significantly regulates the expression o f Udpgt in the gene 
array (p<0.0001) with significant effects observed at 100, 80 and 50 pM. PCN (figs 
6.2.6 d) significantly regulates the expression of Udpgt in both the gene array 
(p<0.0001) with significant effects observed at most concentrations. The regulation 
o f Udpgt by both LCA and PCN suggests that PXR is responsible for the regirlation of 
this gene, an observation in agreement with the literature (Hartley et al., 2004, Ejiri et 
al., 2005b).
The metallothioneins are a family o f zinc containing proteins which are greatly up- 
regulated during times of oxidative stress and help to prevent the peroxidation of 
membrane lipids by fi*ee radicals (Andersen et al., 1987). hr common with their 
requirement to respond to a wide number o f cellular insults, the regulation of these 
genes is by no means simple and may be influenced by a number of pathways 
(Andersen et al., 1987), including regulation by the oestrogen receptor (ER) (Harris et 
al., 2001, Miller et al., 2003, Hua et al., 2003) with feedback between the two proteins 
in the form o f a zinc exchange fi*om the métallothionein to the zinc finger domain of 
the ER (Cano-Gauci and Sarkar, 1996). PCA analysis of all significantly regulated 
genes by all doses of PCN and LCA identified both metallothionein la  (M tl a) and 2 
(Mt2) as significant contributors to the spread of data along Eigen vector 2, along 
which LCA treatment separated in a dose dependent manner. Figure 6.2.7 show tire 
changes in expression o f M tl a in the gene anay, 6.2.8 show the changes in expression
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of Mt2 in the gene anay and pilot studies respectively. In the gene anay study LCA 
(figs 6.2.7&S c) shows a significant regulation of M tl a (p<0.0001) and Mt2 
(p<0.0001). PCN (figs 6.2.7 &8 d) only demonstrated a significant effect on Mt2 
expression in the gene anay study (p<0.01).
As stated above, the regulation o f metallothionein expression is complex, and PXR, 
like ER (Zilliacus et al., 1994), may its expression, in common with several other 
nuclear receptors. The fact that regulation is seen by LCA in all experiments and by 
PCN of Mt2 suggests that this is due to activation of PXR. LCA is clearly a more 
potent activator o f these genes in both pilot and gene array studies. PCN is a 
significant regulator of MT2 in the gene anay study. The interplay and zinc donation 
by metallothionein to the zinc finger domain o f the receptor (Cano-Gauci and Sarkar, 
1996) may represent a new aspect of PXR biology.
Despite the evidence to support PXR involvement in the expression o f M tl a and Mt2, 
it cannot be proven definitively from this data and may be due to secondary 
mechanisms regarding the metabolism of the dosed compounds. Further 
experimentation and in silico and in vitro analysis of the promoter regions of M tl a 
and Mt2 would shed some light on the ability of PXR to regulate expression of these 
latter genes.
Fatty acid binding protein 5 (FabpS) is a low molecular weight transporter of 
insoluble fatty acids and hydrophobic compounds throughout the cytoplasm of cells 
and is a member o f a large family o f proteins o f similar function (Watanabe et al., 
1994, Wen et al., 1995, Krieg et al., 1993, Dickinson Zimmer et al., 2004). The 
primary functions o f these proteins is the transport and metabolism of fatty acids 
within the cell (Watanabe et al., 1994). FabpS has been genetically characterized in 
several rat tissues including the retina, kidney, liver, lung, and lens (Wen et al., 1995), 
but its specific function, and the pathways in which it is involved, are unknown and 
literature regarding this particular protein is sparse. PCA analysis o f all significant 
gene changes at all concentrations o f PCN and LCA found FabpS to be a significant 
contributor to separation of data along Eigen vector 2. Figure 6.2.9 shows the 
changes in expression of FabpS in the gene arTay and pilot studies respectively. 
Unlike all other genes mialyzed in my work, this gene was transcriptionally repressed 
in a significant manner by both LCA (fig 6.2.1 c, P<0.0001) and PCN (fig 6.2.9 d,
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P<0.0001) with significant effects observed at most concentrations. Variation in inter 
sample data means that the pilot study reveals no significance in regulation.
The negative regulation of FabpS by PXR in this manner may be a defensive 
mechanism to prevent retention o f the hydrophobic bile acids within the cell and 
perhaps diverting them into metabolic and excretory pathways. It is not possible to 
draw detailed conclusions fiom this data, other than simply stating that in the gene 
anay samples both PCN and LCA show significant transcriptional effects. As with 
M tl and 2, in vitro and in silico analysis o f the promoter region of FabpS will shed 
more light on the PXR dependency of expression this gene.
It is evident fiom these QPCR analyses that the genes which are drivers for separation 
along axis one are all upregulated and are all predominantly regulated by PXR. The 
genes along eigenvector 2 all show much more variation in their regulation, with 
FABPS being downregulated and all genes responding approximately equally to PCN 
and LCA. The mechanism behind this difference is difficult to determine, it may be 
due to the potency o f PCN for PXR making the vector once changes so heavily 
favored for PCN. The fact that LCA regulates almost all o f the genes, and that LCA 
favors vector two genes suggests that the differences are due to ligand specific 
selection of target gene rather than an issue o f potency.
6.3.3 DAVID analysis of significant genes
DAVID analysis o f the significant genes is useflil to identify and highlight functional 
changes produced by PCN and LCA. Figures 6.2.10-13 show the distribution of GO 
pathways which which aie significantly regulated by PCN and LCA treatments. 
Figure 6.2.10 shows the total number o f GO terms which are altered but both PCN 
and LCA (blue), PCN alone (pink) and LCA (green). This total is made up of BP, 
MF and CC terms as shown below the Venn diagram of the total, and in more detail 
in figures 6.2.11-13. The smaller number o f pathways which commonly regulated by 
PXR activation represents those pathways which are essential to the PXR response, 
with those pathways regulated by each ligand independently are representative of the 
ligand specific response.
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Fig 6.2.11 shows the total number o f biological processes which are regulated 
commonly and on a ligand specific basis. Biological processes are the biological 
metabolic pathways which are altered by the change in gene expression caused by 
PXR activation by PCA and LCA. The tables o f the top 5 significantly 
overrepresented patliways are presented below the Venn diagram and correspond in 
colour to the Venn diagram. The most significant core BP regulated by both LCA 
and PCN are pathways responsible for protein production and ribosome assembly 
which would be core needs to cells requiring an increase in the expression of other 
proteins. Those regulated by PCN are involved in subcellular tr afficking o f proteins 
and movement through the golgi body, possibly suggesting that PCN induces a 
change in the function o f the proteome as one o f its major fimctions. The most 
significant pathways regulated by LCA are much more involved in the metabolism of 
amine groups and amino acid sysnthesis, which may reflect a change in the 
metabolism of the cell or in the speed with which amino acids are synthesised for 
protein production.
Molecular function terms represent the overrepresentation of genes which have an 
associated metabolic function. The only molecular function term which was 
significantly overrepresented was that o f aminoacyl tRNA ligase activity which I
indicates that several genes with this function are regulated, suggesting that PXR ;
controls the processes which form the peptide bonds. The MF which are most 
significantly regulated significantly by PCN and LCA alone aie concerned with 
mitochondrial metabolism, ATP syntetase function, transfer and NADH 
metabolism. It is interesting that these processes are required to increase the ability of 
the cell to respond to an insult and to its environment.
Cellular component terms indicate the oveipresented cellular compartments and 
organelles. The commonly regulated genes are most significantly assoicted with the 
nucleus, nucleolus and transcription afctor complex, suggesting that PXR treatment 
regulates large number of genes which affect the levels o f the proteins required for 
tianscription. PCN and LCA both regulate genes heavily associated with the 
mitochondrion and with the golgi and nucleus, possibly suggesting that both PCN and 
LCA alter the cellular metabolism to adjust to the insult and environment.
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The work into establishing a function for the overrepresented pathways, functions and 
cellular components is only just started. To further understand these it’s important to 
verify the expression changes o f the genes associated with these pathways. It is also 
be important to assess tlie functionality o f these changes which may be done using 
siRJSTA to knock down levels o f these genes, to assess the functionality o f the PXR 
response the level o f cell death, metablolic rate and transcription o f marker genes 
such as CYP3 A1.
6.3.4 Conclusions
PGA analysis is a highly effective mechanism for highlighting the differences 
between groups o f related data. Wlien scrutinized closely it can be seen that the genes 
identified as separating data along Eigen vector one and two in figure 6.2.1 are 
regulated by both PCN and LCA in the Venn diagram (fig 6.2.3) analysis. Wlien 
considering the nature o f a PGA where there is expected to be a core o f commonly 
regulated data within the data sets, it is logical to presume that the separation will 
naturally be based on differences in these commonalities. PGA separates data in ways 
that highlight underlying factors that cannot be directly obsei-ved first hand. The two 
Eigen vectors seen in fig 6.2.1 separate PGN and LG A treatments with PGN being 
defined by Eigen vector one and LG A by Eigen vector two, although there is some 
cross separation on both vectors. If  the vectors separate the data based only on ligand 
specific gene regulation there would be no component of vector one on LGA 
tieatment, likewise no component o f vector two on PGN, but this is not the case. 
These considerations point towards a ligand specific differential regulation of these 
genes in a PXR dependent manner.
One o f the objectives of my experiments was to determine and analyze the ligand 
specific and common transcriptional effects. By separating the data in this way, I 
have analyzed in detail the differential regulation of commonly affected genes and 
this may be an important contribution towards furtheiing the understanding o f PXR 
biology. Analysis o f the ligand specific effects will be of equal interest and may 
indicate some previously unknown aspects o f PXR biology this is outside the scope of 
this report.
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Chapter 7: General Discussion
7.1 Nuclear receptor regulation: How do they work?
Exposure to a range of compounds throughout life has driven the body to adapt to 
detoxify and remove many of the compounds from the body and are the processes of 
adsoiption, distribution, metabolism and excretion (ADME) (Plant, 2003, Gibson et 
ah, 2006, Gibson, 2001). Absorbtion of compounds from the environment is typically 
through the routes of ingestion or inhalation and there are a number o f transport 
proteins that specialise in regulating compound access through these routes into the 
blood. Once in the blood the compound is distributed to the tissues in the body and is 
taken up by the liver where it can be metabolized (Gibson, 2001, Plant, 2003). Drug 
metabolism in the liver is a two stage process designed to increase the hydrophilicity 
o f the compound. Phase 1 metabolism involves cytochrome P450 enzymes which 
hydroxylate the compound leading to an increase in the solubility or to better access 
for the phase II enzymes. The Phase II enzymes are responsible for the addition of 
large hydrophilic groups usually glucuronic acid, glutathione and sulphate, the 
addition o f which greatly increase the solubility of the parent compound allowing for 
excretion via glomemlar filtration in the kidney (Plant, 2003, Gibson et al., 2006, 
Gibson, 2001). The excretion o f compounds fiom the body may follow one o f two 
routes, the more soluble compounds may be absorbed back into the blood and 
removed by glomerular filtration via the kidneys, more insoluble compounds will not 
be released back into the blood but will be excreted into the billiary system for release 
with the faeces (Gibson et al., 2006, Gibson, 2001, Plant, 2003).
The nuclear receptors are a family o f ligand dependent transcription factors which 
share a core o f related structures including the DBD, LBD A Fl, AF2 and hinge 
regions (Giguere, 1999). The DBD consist o f two zinc finger motifs (Giguere, 1999) 
which intercalate with the minor grove o f the DNA when ligand is bound to the LBD 
(Gigitere, 1999). The LBD of each receptor is the site of greatest sequence variation 
(Wurtz et al., 1996a, Wagner et al., 1995) PXR has one o f the largest and most 
flexible LBDs of all receptors (Gampe et al., 2000) which is able to stretch to 
accommodate a broad spectrum of ligands, while repositioning several key amino 
acid residues to form transient interactions with the ligand (Xu et al., 2002, Nolte et
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al., 1998). The binding o f the ligand alters the entire structure of the receptor and 
enables binding o f co-regulator proteins (Renaud and Moras, 2000, Xu et al., 2002).
Nuclear receptors regulate the expression o f target genes through the recruitment of 
protein complexes which act as a core upon which the transcriptional proteins can be 
rectuited and alter the chromatin structure through histone modification and 
remodeling o f the nucleosomes (Felsenfeld and Groudine, 2003). Histone 
modification (méthylation, acétylation, phsophrylation ect) alters the nucleosome 
structure and the ability to bind the DNA changing the density of the DNA wrapped 
around the histone and the accessibility for transcriptional proteins (Kinyamu and 
Archer, 2004, Fischle et al., 2003, Strahl and Allis, 2000). These modification and 
remodeling complexes have been formd to associate with several o f the steroid 
hormone receptors and orphan nuclear receptors, including ER, TR, GR, FXR and 
RAR (discussed in section 1.14) (Kinyamu and Archer, 2004).
7.2 PXR co-regulators: How close are we?
There is little information regarding the co-regulator complexes o f PXR in the 
literature, and likewise the broader spectrum of the genes that are regulated by PXR is 
relatively unconsidered in comparison with its regulation of the ADME genes. Co­
regulator proteins that interact with PXR were identified in this project by 
immunoprécipitation fiom Huh7 total cell lysate. Identities o f the proteins were 
confirmed by ESIMS with the help of Dr Lucas Bowler of the University o f Sussex; 
importantly, the reported pro tins were identified and are fiom two, independent, 
experiments, increasing the confidence in the identified interactions, and had some 
literature basis for a functional interaction at some point in the life cycle o f PXR. To 
verify the interactions between the identified proteins and PXR the half GFP 
interaction assay developed by the Regan laboratoiy of Yale University (Maglieiy and 
Regan, 2006, Maglieiy et al., 2005, Wilson et al., 2004). This method has been 
demonstrated to perform well for many proteins but did not provide reliable results in 
this case with the RXR PXR control interaction (Maglieiy and Regan, 2006, Maglieiy 
et al., 2005, Wilson et al., 2004). PXR is unusually stiuctured with a ligand binding 
domain much longer than most other nuclear receptors, due to an extended p sheet in 
the middle of the binding site that is lined with amino acid residues which have 
hydrophobic side chains (Kliewer et al., 1998).
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The literature regarding the PXR interacting proteins is sparse with the existing 
studies having identified the co-activators, SRCl, SRC2, RIP 140, SUGl, GRIPl, the 
ACTR and DRIP205 (Kliewer et al., 1998, Masuyama et al., 2000, Masuyama et al., 
2001, Synold et al., 2001, Takeshita et al., 2001, Takeshita et al., 2002, Zhou et al., 
2004). The co-repressors NCoR and SMRT have also been linked to PXR activity 
(Zhou et al., 2004, Takeshita et al., 2002). These studies have utilised a range of 
techniques including yeast two hybrid (Kliewer et al., 1998, Masuyama et al., 2000, 
Masuyama et al., 2001) and constructs of the PXR LBD or PXR (Synold et al., 2001, 
Takeshita et al., 2001, Takeshita et al., 2002, Wentworth et al., 2000).
Author Use o f  antibody and findings
Rotli et al (Rotli et al., 2008) Used chromatin immunoprécipitation (chip) to 
demonstrate an interplay between PXR and a no 
competitive inhibitor o f PXR co-activator binding.
Iwazaki et al(Iwazaki et al., 2008) Used chip to deomonstrate an interaction between 
PXR and the co-activator SR C l.
Igaraski et al(Igaiaslii et al., 2007) Demonstrates using chip tliat vitamin K activates 
PGR and recruits the p300 co-activator to PXR.
Liii et al (Liu et al., 2008) Uses chip to demonstrate preferential binding o f  
PXR to tlie procimal enhancer o f  the CYP3A4 
gene.
Kodama et al (Kodama et al., 2007) GST pull downs and ip usd to deomonstiate PXR 
binding to the cAMP response element binding 
protein to smpress the glucose-6-phosphatase 
gene.
Sec et al (Sec et al., 2007) Uses chip to demonstrate that there is no effect o f  
aging on the ability o f  PXR to bind DNA.
Li etal(L ietal.,2007) Uses chip to demonstrate PXR binding SRCl and 
activation o f  the CYP27A1 gene.
Itoli et al(Itoh et al., 2006) Demonstrates suing chip PXR binging the 
CYP2A6 promoter and recruiting the peroxisome
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proliferator receptor gamma co-activator 1 alpha.
Gu et al(Gu et al., 2006) Shows NF-kappaB as an inhibitory agent 
disrupting PXR-RXR dimérisation using chip.
Li et al(Li and Chiang, 2006) Uses chip to deomonstrate recruitment o f HNF4a 
and SRCl to the CYP3A4 promoter and shows 
PXR suppression o f  SHP expression.
Squires et al (Squires et al., 2004) Uses ip to demonstrate binding o f  PXR to the CAR 
cytosolic retention protein (CCRP), uses HSP90 
antibody.
Li et al (Li and Chiang, 2005) Uses co-ip to show PXR in complex with HNF4a 
and the peroxisome proliferator receoptor gamma 
co-activator 1 alpha.
Song et al (Song et al., 2004) Uses chip to show preferential binding o f PXR to 
the proximal CYP3A4 promoter
Table 7.1 Review of previous PXR immunoprécipitation literature.
Table shows author and significant findings including methods used. Also seen in
chapter 3 as table 3.3.1.
Reviewing the literature o f previous works which have used an antibody based 
method to isolate PXR fi"om cells. As can be seen chip is one of the most common 
methods used, along with ip and co-ip. The use o f a total cell lysate rather than a 
nuclear protein extract gives the potential to identify proteins associating with PXR at 
any stage within the cell. This project is the first to use a more generalised search o f 
the whole cell proteome coupled with an ip methodology to identify members o f the 
PXR co-regualtor complex. This has both its advantages and disadvantages as the 
lack of proteins so far identified to interact with PXR may be due to the relative 
abundance within the cell o f proteins which complex with PXR, i,e, the cytosolic 
binding partners may be greater in quantity than those for nuclear binding. A total 
cell lysate also contains many proteins which bind to PXR thoughout the various 
stages o f processing and synthesis. These proteins are those responsible for 
trafficking PXR throughout the cell and through the synthesis process and are much 
more likely to be isolated from a sample o f this nature. Such an approach is
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particularly important as it is becoming increasingly clear that cellular localization o f 
nuclear receptors may represent an important input into their functionality; for 
example, GR, VDR and CAR appear to be tethered in the cytoplasm when unliganded 
(Yudt and Cidlowski, 2001, Yasmin et al., 2005, Kobayashi et al., 2003), whereas 
PPARa appears to be mainly nuclear (Escher and Wahli, 2000). This difference in 
localisation may impact on the interaction of the nuclear receptor with DNA, in both 
unliganded and ligand-activated state, and thus affect gene expression, although the 
exact relationship o f nuclear receptor localisation to gene activation is not yet clear. 
The evidence for PXR localisation is more equivocal, with evidence for both nuclear 
and cytoplasmic localizations presented (Squires et al., 2004, Saradhi et al., 2005, 
Koyano et al., 2004, Kawana et al., 2003); within this laboratory we have shown that 
in the absence o f exogenous ligand PXR exists 25:75 (cytoplasmic:nuclear) in Huh7 
cells (E.Wiedemann, peraoMfl/ communication).
7.3 Gene expression: What role does PXR play?
The ADME processes are carefiilly regulated at the transcriptional level and the 
breakdown of any one part o f this chain o f events can lead to very serious 
complications. Nuclear receptors as a family are heavily involved in the regulation of 
the expression levels o f the ADME genes, with particular emphasis being on the 
receptors CAR, FXR and PXR (Gibson et al., 2006). PXR in particular is shown to 
regulate the expression o f genes in all parts o f the ADME pathway and is responsible 
for the metabolism of 60% of prescription compounds by the up-regulation o f the 
enzyme CYP3A4 in man (Plant and Gibson, 2003, Cholerton et al., 1992).
Do different ligands of PXR activate differential gene activation profiles? The 
hypothesis behind this thesis is that different ligands o f the PXR will regulate a set of 
core genes and a set o f genes unique to each ligand or groups o f ligands. Analysis of 
all significant gene changes from all doses for both PCN and LCA treatments and 
their expression as a Venn diagram (figure 5.2.3) shows genes regulated in a ligand 
specific manner by LCA or PCN, and in a common manner by both PCN and LCA. 
From this simplest interpretation of the data is it may be concluded that an
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endogenous (LCA) and an exogenous (PCN) ligand o f PXR activate ligand specific 
and common gene sets.
Gene arrays generate a vast amount o f data, and when analyzing this data it is very 
easy to get mired in the minutiae and the tiny details, losing sight o f the big picture. 
The in depth analysis should be, as far as possible, unbiased so that all o f the 
transcriptional changes can be seen as equally valid; a principal components analysis 
was used to identify patterns and differences in the gene expression patterns in this 
case. Principal components analysis is a highly effective mechanism for highlighting 
the differences between groups o f related data (Yang, 2008, Yang et al., 2008). When 
scrutinized closely the data sets presented fiom the PCN and LCA treatments separate 
effectively along two eigenvectors and it can be seen that the genes identified as 
separating data along Eigen vector one and two (figure 6.2.1) are regulated by both 
PCN and LCA in the Venn diagram (fig 6.2.3) analysis. PCA analysis of data sets 
where there is a core o f commonly regulated data, the separation will naturally 
separate based on differences in these commonalities. PCA separates data in ways 
that may highlight underlying factors that cannot be directly observed first hand. The 
two Eigen vectors seen in fig 6.2.1 separate PCN and LCA treatments witli PCN 
being defined by Eigen vector one and LCA by Eigen vector two, although there is 
some cross separation on both vectors. When scrutinized closely the separation is not 
perfect in that there is some component o f vector two separation in the PCN data and 
vector one separation in LCA data. DAVID analysis highlights many pathways which 
are overrepresented within the data sets presented in chapters 5 and 6 show a great 
many pathways regulated by both PCN and LCA, as well a number o f interesting 
pathways which are regulated by each ligand independently. Perhaps the most 
interesting pathways will be those which are not associated with the ADME genome. 
Further investigation is needed to firlly understand how these pathways contribute to 
the cellular changes when PXR is activated
It is important to bring the gene array work presented here into context with the other 
literature on the subject. As can be seen fi*om table 7.2, where I have reviewed the 
pertinent literature on PXR gene aiTays, these other studies have been much more 
focused towards establishing the gene expression patterns o f a single ligand, gioup of 
specific ligands of interest, or groups o f genes of interest. Our primary objective was
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to compare tlie gene expression profiles o f two ligands o f PXR with a view to 
determining alternative areas o f cell biology which are regulated by PXR in ligand 
dependent and independent ways. Perhaps the most relevant of the works shown 
below is that o f Guzelian et al (Guzelian et al., 2006) who uses an unbiased 
oligonuceotide array to analyze the gene expression profile of PCN in Sprague- 
Dawley rats. Some o f the most significantly regulated genes found in the work 
presented such as Mip2 and Gstp2 & u2 are all found to be significantly regulated by 
Guzelian et al (Guzelian et al., 2006) along with some 220 other genes. Perhaps the 
most pertinent conclusion o f the work by Guzelian et al is that PCN treatment, and 
presumably PXR activation, leads to the regulation o f a great many genes and 
pathways outside of the traditional ADME geneome to which PXR is attached 
(Guzelian et al., 2006).
Slatter et al (Slatter et al., 2006a) also demonstrated interesting results in their 
treatment of Sprague-Dawley rats with 26 different known regulators o f the ADME 
genome, including LCA and PCN. Although not taking into consideration those gene 
changes which were not one fo the known ADME genes the work shows clear ligand 
activation differences within the treatment groups between the AhR, CAR and PXR. 
Should fiirther extrapolation of the results be possible it may be possible to 
deominstrate that the different ligands o f PXR all cluster together regulating a core 
set o f genes which are always altered when PXR is activated, and unique sets of genes 
specific to individual or groups o f ligands, this is speculation and this analysis was not 
performed by Slatter et al (Slatter et al., 2006a). This work did however coiToborate 
the changes seen in several o f the important genes highlighted in the aiTay presented 
in this thesis, including Mrp2 and Gstp2 & a2 (Slatter et al., 2006a).
The works by Slatter et al and Guzelian et al are both of tremendous interest and 
should be held as comparable to the study presented in chapters 4, 5 and 6. There are 
significant differences between the way in which these two studies were established 
and analysed and the work presented in this thesis. Guzelian et al use only PCN to 
analyse the gene expression profile o f PXR, and used only one dose of 100 mg/kg 
given over 8 hours to live rats, n of five (Guzelian et al., 2006). Without lessening the 
value o f this work the study takes no accounting of dose or the effects o f secondary 
metabolites fiom other tissues in their analysis, and the exposure time of 8 hours goes
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some way to explain the limited number of gene changes they detected (220 total 
significant changes). Slatter et al used an n of one in each dose group but used three 
doses o f all 26 compounds (Slatter et al., 2006a). The study allows for dose 
dependent effects o f the compounds but with an n of one has no way o f correcting for 
inter-animal and inter-experimental variation. The second array published by Slatter 
et al is based on the analysis o f the ADME genome form a collection of 75 human 
liver samples and as such is not particularly relevant to the work presented in this 
thesis (Slatter et al., 2006b). I would like to say, however, that the work approaches 
the issue in a complex manner confounded by the use of a collection o f 26 liver 
samples from inbred laboratoiy rhesus monkeys as a control, I do not see that much 
information can come from this particular study.
The studies by Ejiri et al are o f relevance as they are based on an attempt to dissect 
the relative potency of PCN and phenobarbial on both adult (mother) and fetal liver 
expression of phase I and phase II enzymes (Ejiri et al., 2005b, Ejiri et al., 2005a). 
PCN was administered to 3 pregnant female Fisher 344 rats at 50 mg/kg. This once 
dose does not account for dose dependent variation nor is it as high as used in other 
studies (Guzelian et al., 2006, Ejiri et al., 2005a, Ejiri et al., 2005b). Rats were treated 
for three days to ensure that the maximum change in expression is recorded (Ejiri et 
al., 2005a, Ejiri et al., 2005b). The complication o f pregnancy for the female rats 
makes drawing compaiisons to the data presented difficult in this case, although many 
o f the phase I and phase II compounds shown in these studies were also changes in 
the presented array (Ejiri et al., 2005a, Ejiri et al., 2005b).
De Longueville et al dosed female Sprague-Dawley rats with 100 mg/kg PCN or 
Phénobarbital for 4 days, the paper is vague on the number o f animals in each 
treatment group which makes interpretation of the results difficult (de Longueville et 
al., 2002). An oligonucleotide array containing 59 genes was used to check the 
expression changes in 8 housekeeping genes, apaotosis genes including Bcl2, ADME 
genes including Cyp2A, 2B, 3A, 4A and Udpgrtl and stress factors such as 
fibronectin (de Longueville et al., 2002). In general this is a good study looking at 
the expression levels o f a small number o f genes and is presented almost as a prelude, 
or preliminary data set, to a bigger study which is not yet published.
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Hartley et al used female Sprague-Dawley rats dosed with 50 mg/kg L-742694 and 
dexamethasone with an n o f three in each group, with expression changes measured in 
the gastrointestinal tract and liver. 25000 gene rat oligonucleotide arrays were 
screened for expression changes in tlie ADME genome represented (Hartley et al., 
2004). This work showed regulation of many o f the important genes found regulated 
in this array, including Mrp2 and Gstp2 & a2 (Hartley et al., 2004). The exact aim of 
this work is unclear and it is presented with some work on changing expression levels 
o f particular genes in HepG2 cells which is o f seemingly no relevance.
Goetz et al and Tully et al performed similar array experiments in GDI mice and 
Sprague-Dawley rats respectively (Tully et al., 2006, Goetz et al., 2006). Both 
species were treated for 14 days with fluconazole, myclobutanil, propiconazole, or 
tiiadimefon with an n o f six. These arrays identified that CyplA, 2A, 2B and 3A 
families were significantly altered and found in clustering analysis cluster 
corresponding to CAR and PXR activation (Tully et al., 2006, Goetz et al., 2006). 
These two studies are designed to dissect effects on the liver o f the dmgs used and as 
such are not of particular relevance to tlie work presented here. It is possible to see 
that Cyp3a is consistently upregulated suggesting PXR activity but this is not a 
surprising result.
Rosenfeld et al present work performed on mice expressing a constitutive form o f 
human PXR (VP-hPXR) and performed a gene array whereby the total RNA from 
two individual mice in the PXR null control and the VP-hPXR were pooled making 
an effective n o f one (Rosenfeld et al., 2003). The array work itself was performed on 
a self made gene chip and an average fold change o f 1.3 above background was 
considered significant (Rosenfeld et al., 2003). This work very much focuses on the 
expression changes brought about by human PXR in a mouse system and on the 
ADME genome (Rosenfeld et al., 2003). This work also uses an average gene change 
firom a biological n o f one, using technical repeats in the place of legitimate biological 
repeats, to draw conclusions over what is a significant change (Rosenfeld et al., 
2003). This work is interesting in that it demonstrates that human PXR can act 
within a mouse system, and that the same genes are upregulated by human PXR as 
mouse PXR, however, it does not attempt to answer the same questions as the work 
presented in this thesis.
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Author Significant notes
(de Longueville et al., 2002) U sed a low  density ‘rathepatochip’ containing 
59 genes o f  interest including CYP3A1 but 
focusing on apoptosis gene, Sprague D aw ley  
rats treated with phénobarbital and PCN were 
compared vs control.
(Hartley et al., 2004) L -742694 and dexamethasone were 
administered to fem ale Sprague dawley rats 
and both hepatic and gastrointestinal gene 
expression profiles were analysed with the 
express intention o f  looking for PXR  
activation, CY P3A 1, U G T la l and Oatp2 
were found to be regulated. Concluded that 
regulation was via different mechanisms in 
both tissues.
(Guzelian et al., 2006) U sed  an unbiased anay to search for gene 
changed caused by PCN treatment o f  
Sprague-Dawley rats, a total o f  220  
significant gene changes were found. Find  
that regulation o f  several areas o f  
metabolism, cytosolic transport and redox 
balance were affected, conclude that PXR  
may regulate extensive pathways outside o f  
the ADM E genom e.
(Slatter et al., 2006b) 75 human liver samples were used to analyse 
the variation in the A D M E genome and 
compared to that o f  a ‘contoP set o f  27 inbred 
rhesus m onkey livers. They identify clusters 
o f  genes regulated by the major ADM E  
nuclear receptors, including AhR, CAR and 
PX R  based on the known genes o f  the 
C Y PIA , C Y P2A  and C Y P3A  families. N ot 
really able to draw firm conclusions due to 
com plexity o f  sample populations and the 
lack o f  an adequate control.
(Slatter et al., 2006a) A  25000 oligonucleotide anay was used to 
analyse the expression patterns in femal 
Sprague dawley rats treated with one o f  a 
range o f  26 different ligands for the com mon  
ADM E regulating receptors AhR, CAR and
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PXR. A large number of changes were 
found, over 1000, and cluster analysis was 
used to separate clusters belonging to the 
three receptors based on the expression of 
marker genes. Find that CAR and PXR are 
very difficult to separate by cluster analysis 
while AhR is notably different.
(Goetz et al., 2006) Adult CD-I mice were exposed to one of 
three oral doses of fluconazole, myclobutanil, 
propiconazole, or triadimefon. Use an 
unbiased oligonucleotide array to look for 
gene expression changes and find that that 
members of the CyplA, 2A, 2B and 3A 
families are significantly altered. Conclude 
that CAR and PXR are highly activated by 
these compounds, but that other pathways 
must also be activates as there is considerable 
alteration to the size of the hepatocytes and 
liver.
(Tully et al., 2006) Much the same as the work done by Goetz et 
al although in this case adult male Sprague- 
Dawley rats were of three oral doses of 
fluconazole, myclobutanil, propiconazole, or 
tiiadimefon. These compounds significantly 
regulated members fo the Cyp2C and 3a 
families and other ADME genes such as 
Udpgtr2. Commonality between compounds 
suggests a central mechanism which is 
suggested to be via PXR and CAR activation 
based on hierarchical cluster analysis.
(Rosenfeld et al., 2003) Perform microarray analysis focusing on the 
ADME geneome on samples from mice 
expressing a constitutively active form of 
PXR, VP-PXR. Find that a range of both 
phase I and II enzymes are altered, as well as 
a number of transporters, all of which have 
previously been demonstrated as being 
regulated by PXR.
(Ejiri et al., 2005a) Fisher 344 pregnant rates were dosed with 
PCN and Phénobarbital in order to asses fetal
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responses to the PXR and CAR agonists. 
Found that both Cyp3a and 2b families were 
upregulated in the dams and fetus, also that 
the placenta showed significantly expression 
increases of Cyp3al in both phenobarb and 
PCN groups. PXR was upregulated in the 
liver of the dams.
(Ejiri et al., 2005b) Identical in experimental procedure to Ejiri et 
al discussed above. This study focused on 
expression changes of the phase two 
metabolic enzymes. A number of GSTs and 
UDPGTs were studied and in all cases there 
were more changes in the dams livers than 
those of the fetus for both PCN and 
phenobarb.
Table 1 2  Literature review
A review o f available literature o f gene anay studies specific to PXR, PXR ligands of 
concluding that PXR was a significant player contiibuting to the expression changes shown.
Based on the literature presented in table 7.2 it is possible to conclude that the gene 
array presented in this thesis, designed to directly compare the expression profiles of 
two ligands o f the same receptor, is the first o f its kind for PXR. The results indicate 
that both PCN and LCA regulate unique and common gene sets which may, or may 
not, be due to a difference in the co-regulator complexes recmited. The indications 
are that PXR has wide ranging effects not limited to the ADME genome which is in 
agreement with the works of Guzelian et al and Slatter et al (Slatter et al., 2006a, 
Guzelian et al., 2006), and it is investigation into the involvement of PXR in 
regulating these alternative pathways which will be the major breakthroughs in the 
future.
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A) Different ligands 
bind to PXR
B) Co-regulators are 
recruited, somewhat 
different for each ligand
C) Each ligand leads to the 
regulation of a core set of 
genes and a set of genes 
unique to It.
Figure 7.1 A model of the regulation of PXR and its regulated gene sets.
The hypothesis that has formed the basis of this PhD is that different ligand recmit different 
co-regulator proteins which then lead to differential gene expression. We have demonstrated 
differential gene expression, although have not been able to reliably isolate PXR co-regulator 
proteins.
Thus far the analysis o f the data from this experiment has yielded some potentially 
very interesting new aspects to PXR biology. I am confident that the results 
contained within this document and any future results that can be mined from the data 
will provide some significant new areas of research within the nuclear receptor field.
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8 Future directions
There are several commonly used methods which could potentially provide more 
practical approaches to identifying the proteins which interact with PXR. The use of 
transient transfection reagents is a common method to over express a limited number 
o f genes within a mammalian cell, as a starting point for examingin interactions of 
cellular components with these cells.. However, the non specific over expression of 
proteins in cells can lead to false protein-protein interactions and hence such results 
must be treated with a degree o f caution; they may however have utility for 
confirming results generated with an alternate technique. The use o f primaiy human 
liver tissue could also be considered for such analysis, as it is known that expression 
o f many genes are much higher that that found in cancer cell lines, however, the 
availability o f primary human tissue is limited and expensive and not fit for the 
purposes method development.
The addition of poly histidine and glutathione tags involves the cloning o f a gene, for 
instance PXR, into an expression plasmid containing the DNA sequence which 
extends the protein by 6 histidine residues or by addition GST molecule (Mikhailov et 
al., 2008, Poh et al., 2008, Kamil and Coen, 2007). His tagged proteins can fold 
noimally and can form a large number o f biologically relevant complexes with other 
cellular proteins; which can be isolated by binding the poly his tail to nickel beads 
(Mikhailov et al., 2008, Poh et al., 2008). A GST tag is a much larger molecule as 
glutathione S-transferases are large kd protein and so tagged proteins find it much 
harder to fold noimally (Kamil and Coen, 2007). Any complexes which form are 
isolated by binding to glutathiolated sepharose beads (Kamil and Coen, 2007). O f the 
two methods discussed above His tagging is more commonly used to isolate proteins 
fi"om complex mixtures as the tag is much smaller and does not disrupt the protein 
structure and function. The work presented here has led to further work by E. 
Weidermann a PhD student also working on the regulation o f PXR.
A newer methodology known as tandem affinity purification has proven extremely 
useful in the isolation and identification o f protein complexes (Kamil and Coen, 
2007). As with his and GST tagged proteins a plasmid constmct is made with the 
gene o f interest attached to a two part molecular tag which is cleaved to leave the
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final tag and the protein of interest. The gene constmct is attached to a protein A 
domain which allows purification o f the protein complexes by binding to IgG 
sepharose the second purification domain is a cahnodulin binding domain allowing a 
second purification step by binding to calmodulin sepharose(Kamil and Coen, 2007). 
These two motifs are separated by a tobacco etch vims (TEV) cleavage domain 
allowing separation of the initial protein A purification domain and the secondaiy 
calmodulin domain. The two step purification allows for two stages o f washing and 
greater stringency than a one step his tag or antibody method. This method was given 
serious consideration and a cloning strategy was planned but due to time constraints it 
was not possible to proceed.
Once the identities have been made it is necessaiy to confiim them, as suggested in 
chapter 3 an adaptation of the half GFP method whereby the essential elements are 
cloned into a mammalian vector such as pCDNA3 under the control o f the CMV 
promoter. This would enable expression in mammalian cells, the lysis o f which could 
be tested for fluorescence. While this is a quick approach to the problem it does 
eliminate the possibility of missing some transient interactions, or proteins which 
have been identified which bind to a member of the co-activator complex rather than 
to PXR itself. To establish a functional association of the identified proteins transient 
transfection of PXR and the protein to be studied into a cell line such as H4-II-E-C3 
(Pollard and McGivan, 2000), followed by treatment with PCN to check for increases 
in marker genes such as CYP3A1. Alternatively a reporter constmct such as 
luciferase can be co-transfected in with PXR and the level of luciferase activity to 
compare to a control level. These will show if  the presence o f the protein identified 
alters the efficacy o f PXR.
The gene array work here is very much a first o f its kind, gene array technology has a 
unique ability to give insights into genome wide expression changes in response to 
compounds. This almost overly generalized approach has its advantages and 
disadvantages, the first point in both categories being the volume of data. The 
expression changes o f over 30,000 genes are difficult to analyse as a whole and as 
such are easily biased towards a point o f view. The important work for the future is 
to further the investigation into the alternate pathways which have nee affected by 
PXR activation. Confiimation o f PXR activity at the gene promoter can be performed
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învîtro and însilico. Insilîco promoter analysis is a little complex as the promoter of a 
gene is not always a defined area within the genome; to search for the promoter 
region o f the gene in question a program called Vista
(http://genome.lbl.gov/vista/index.shtmD can be used to compare the DNA sequence 
o f the lOkb immediately before the start o f the gene in question for three species o f 
different stages of evolution, for instance human, rat and zebra fish. The search will 
identify areas o f the DNA where the sequence is conserved, which is the most likely 
location o f the gene promoter. Use of a second program Transfac 
(http://www.genomatix.de/cgi-
bin/sessions/iogm.pl?s=7e73bdf46dc2£2f9359ca648fD6669db) will look for nuclear 
receptor binding sites within the promoter sequence, which should reveal the PXR 
binding sites. A lack o f binding sites found insilico for a particular gene does not 
mean that PXR cannot bind and a simple luciferase assay, using tlie promoter for the 
gene to control expression o f the luciferase, with PXR cotransfected will demonstrate 
the inducibility o f the promoter by PXR.
I personally feel it is necessary not to step out of the big picture, there is potential to 
generate masses o f data based in the work presented here. Using this gene array as a 
foundation we could map the effects o f PXR within the cell to give us a more 
complete understanding of what happens when a drug is administered. A human gene 
array following the same concept and experimental design can be used to draw a 
complete map o f the functions o f PXR within the human liver. Comparison of these 
maps would be of tremendous use for the pharmaceutical industry when interpreting 
the data form toxicology studies in rats, as it is possible that not all fimctions are the 
same between the two species. These maps may also lead to the development of new 
therapeutic targets for diseases to which PXR has not yet been linked.
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